Hepatits C: Generalization of trials to clinical practice by Berden, F.A.C.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/173275
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
HEPATITIS C
GENERALIZATION OF 
TRIALS TO 
CLINICAL PRACTICE
F l o o r B e r d e n
UITNODIGING
Voor het bijwonen van de 
openbare verdediging
van mijn proefschrift
HEPATITIS C
GENERALIZATION OF TRIALS
TO CLINICAL PRACTICE
op vrijdag 30 juni 2017
om 10.30 uur precies
in de Aula van de Radboud 
Universiteit,
Comeniuslaan 2 
te Nijmegen.
U bent van harte welkom 
op de receptie na aﬂoop 
van de promotie.
Floor Berden
Stevertsemolen 44
5612 DV Eindhoven
06 13 45 30 40 
ﬂoor.berden@radboudumc.nl
Paranimfen
Romy Keijsers
romy.keijsers@gmail.com
Maud Heldens
maudheldens@gmail.com
H
E
P
A
TITIS
 C
        G
E
N
E
R
A
LIZ
A
TIO
N
 O
F TR
IA
LS TO
 C
LIN
IC
A
L P
R
A
C
TIC
E
                         
 F  L O O R    B E R D E N
Hepatitis C: Generalization of 
Trials to Clinical Practice
Floor Berden
The work presented in this thesis was carried out at the department of 
Gastroenterology and Hepatology of Radboudumc, within the Radboud Institute for 
Health Sciences. 
Cover and chapter design: Kris Berden, based on a painting of Will Berden-Wilms
Lay-out:    Britt Berden en Floor Berden
Printing:   Gildeprint, the Netherlands
ISBN: 978-94-6233-643-8
The production of this thesis was financially supported by Radboud University 
Nijmegen and Nederlandse Vereniging voor Gastro-Enterologie (NVGE).
Copyright © 2017, Floor Anne Corina Berden
All rights reserved. No part of this publication may be reproduced or transmitted 
in any form by any means, without permission of the author of from the publisher 
holding the copyright of the published articles.
Hepatitis C: Generalization of 
Trials to Clinical Practice
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J. H. J. M. van Krieken, 
volgens besluit van het college van decanen
in het openbaar te verdedigen op vrijdag 30 juni 2017
om 10.30 uur precies
door
Floor Anne Corina Berden
geboren op 16 januari 1986 
te Horst
Promotor
Prof. dr. J.P.H. Drenth
Copromotor
Dr. W. Kievit
Manuscriptcommissie
Prof. dr. R. van Crevel  
Prof. dr. G.A.P.J.M. Rongen
Prof. dr. H.J. Metselaar (Erasmus MC Rotterdam)
Paranimfen
Romy R.M.C. Keijsers
Maud W.H.E. Heldens

Contents
Chapter 1  General introduction     8
Chapter 2 Limited generalizability of registration trials in  20
  hepatitis C: a nationwide cohort study
  PLoS One, 2016
Chapter 3 High risk of infection during triple therapy with  46
  first-generation protease inhibitors: a nationwide 
  cohort study
  Journal of Gastrointestinal and Liver Diseases, 2016
Chapter 4 Bleeding episodes during interferon-based triple  62
  therapy in hepatitis C: a nationwide cohort study
  Submitted.
Chapter 5 The gap between registration trials and real world  78
  in hepatitis C is closing
  Digestive and Liver Disease, 2017
Chapter 6 The majority of hepatitis C patients treated   82
  with direct-acting antivirals are at risk for relevant 
  drug-drug interactions. 
  United European Gastroenterology Journal, 2016
Chapter 7 Identification of the best direct-acting antiviral  100
  regimen for patients with hepatitis C virus 
  genotype 3 infection: a systematic review and 
  network meta-analysis
  Clinical Gastroenterology and Hepatology, 2017
Chapter 8 Dutch guidance for the treatment of chronic   142 
  hepatitis C virus infection in a new therapeutic era
  Netherlands Journal of Medicine, 2014
Chapter 9 General discussion      166
  Adapted from Nederlands Tijdschrift voor 
  Geneeskunde, 2016
Chapter 10 Summary & Samenvatting    176
  Summary      178
  Samenvatting      184
  
Appendices about the author      190
  Dankwoord      192
  Curriculum vitae      196
  List of Publications     197
  RIHS PhD portfolio     198
1
General introduction
General introduction
1
10
Hepatitis C
The hepatitis C virus (HCV) is a hepatotropic RNA virus causing infectious hepatitis. 
The disease, formerly called non-A-non-B-hepatitis, was known for centuries, but 
was discovered only decades ago in 1989 when researchers isolated HCV RNA from 
chimpanzee plasma.1, 2 Worldwide about 130- 150 million patients are infected with 
HCV, in the Netherlands the number of patients is estimated to be around 19,200.3, 4 
There are seven different HCV genotypes identified, and each genotype has an unique 
geographic distribution. Genotype 1 is most prevalent (50%), followed by genotype 3 
(30%), both globally and in the Netherlands.5, 6 Hepatitis C is a blood-borne disease 
and highest prevalence of disease is found in certain risk groups: people who inject 
drugs (PWID), haemophilia patients who received blood products prior to screening 
of transfusions (1992), HIV-infected patients, and men who have sex with men (MSM).7 
Once a person is HCV infected, there is 20-25% chance of spontaneous viral clearance, 
but the majority of patients will become chronically infected.8 Often these patients 
are diagnosed accidentally or through screening activities, because an acute and 
chronic HCV infection causes no or only mild symptoms, such as malaise, fatigue and 
exceptionally jaundice.9 Patients with chronic hepatitis C can develop fibrosis (scarring 
of the liver) over the years due to constant liver inflammation, which can progress to 
cirrhosis. This development is undesirable because cirrhosis can decompensate with 
ensuing complications such as variceal bleeding, hepatic encephalopathy and ascites. 
In addition cirrhotic patients have a 1-4% annually risk of developing hepatocellular 
carcinoma (Figure 1).10 Furthermore HCV may cause extrahepatic manifestations, such as 
mixed cryoglobulinemia, B-cell non-Hodgkin lymphoma, diabetes, and atherosclerosis 
resulting in morbidity and even mortality.11
Figure 1. Natural course of disease of hepatitis C virus infection.
Figure adapted from Lauer et al. NEJM 2001; HCC = hepatocellular carcinoma
Treatment of hepatitis C
The primary goal of HCV therapy is to cure the patient by eradicating HCV to prevent 
cirrhosis and spread of the virus. Both clinical trials and clinical practice use sustained
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virological response (SVR) as a surrogate biomarker for cure. SVR is an objective 
parameter and defined as undetectable HCV RNA 12 or 24 weeks after cessation of 
treatment.12 Achievement of SVR has been associated with reduced liver-related and 
all-cause mortality.13
For years, therapy consisted of (peg-)interferon (pegIFN) and ribavirin (RBV). PegIFN 
was injected subcutaneously once weekly and depending on genotype given for 24 
or 48 weeks. The disadvantage of pegIFN was the moderate chance for SVR (66-80% 
in genotype 2 and 3, 45% in genotype 1 and 4) and relatively high risk of (severe) 
toxicity. The most common adverse events are: flu-like symptoms, anemia, neutropenia, 
thrombocytopenia, depression, and fatigue. The addition of RBV, an oral guanosine 
analog, has improved the SVR rate, but also intensified toxicity, mainly by inducing 
abdominal complaints, hemolytic anemia and rash.14
The advent of direct acting antivirals (DAAs) in 2012 changed the therapeutic 
outlook enormously. All-oral interferon-free treatments were available and improved 
effectiveness, safety and quality of life of HCV patients.15 Currently there are 3 classes of 
DAAs developed which target the virus directly at three different proteins of the virus. 
Each class contains several DAAs. Figure 2 shows the HCV RNA structure of the virus, 
with the targets of the DAAs and the various DAAs in each class:14, 16
• NS3/4A protease inhibitors (name: -previr)
NS3/4A protease inhibitors target the NS3/4A serine protease which is responsible 
for production of new virions. First-generation protease inhibitors, telaprevir and 
boceprevir, were approved in 2011 and were added to pegIFN and RBV. These 
agents improved efficacy significantly in clinical trials, however also caused 
severe toxicity, such as anemia, infections, and rash. In 2013 simeprevir has been 
approved, a second generation protease inhibitor with a more favorable safety 
profile. There are two other agents approved in this class: paritaprevir with ritonavir 
and grazoprevir, both are combined with other DAAs in one pill. Protease inhibitors 
are mainly effective against genotype 1 and 4.
• NS5A inhibitors (name: -asvir)
NS5A inhibitors target the non-structural 5A protein and inhibit viral assembly 
and replication. Currently, there are four NS5A inhibitors approved by regulatory 
authorities: daclatasvir, ledipasvir, velpatasvir, and ombitasvir. All but the latter are 
combined with sofosbuvir.
• NS5B polymerase inhibitors (name: -buvir)
The NS5B polymerase inhibitors are involved in the HCV RNA replicative machinery. 
Currently, sofosbuvir is the most important NS5B polymerase inhibitor because it 
can be combined with both protease inhibitors as NS5A inhibitors, it possesses a 
high barrier for resistance and a high effectiveness against all genotypes. Another 
NS5B inhibitor is dasabuvir, this agent is developed together with paritaprevir/
ritonavir and ombitasvir.
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The latest generation DAAs have a high efficacy, on average >90% in genotype 1, 2, and 
4. Genotype 3 remains somewhat more difficult to cure.17 Further the DAAs have low 
toxicity, compared to pegIFN and RBV. The main side effects of DAAs are fatigue, nausea, 
headache and insomnia. In case ribavirin is added, patients may develop (hemolytic) 
anemia, diarrhea, and loss of appetite.18 Treatment discontinuation due to adverse 
events occurs around 1-2% of treatments. There is a comparable low risk of serious 
adverse events in all DAAs.19, 20 A remaining issue in current clinical practice is the risk 
of drug-drug interactions of DAAs with concomitant medication that the HCV patient is 
using for other conditions. DAAs are substrate and inhibitor of several cytochrome P450 
(CYP) enzymes and drug transporters which increases the risk of interactions. This can 
result in loss of efficacy or increased toxicity of both the DAA and the co-medication.21
Figure 2. Classes of approved direct acting antiviral (DAA) agents which target the virus.
 
DAAs target the non-structural (NS) proteins of the HCV RNA in order to eradicate the virus. There 
are 3 classes: 1) Protease inhibitors target the NS3/4A serine protease, 2) NS5A inhibitors target 
the NS5A protein and 3) NS5B inhibitors target the NS5B polymerase inhibitor. Several DAAs are 
developed within the classes. Agents marked by a, b, c, d are all developed as one combination.
Approval and registration of new drugs
Research into new drugs is mainly done by pharmaceutical companies and pass over 
2 stages (pre-clinical and clinical). Pre-clinical studies are done to assess biological 
activity. The clinical studies are executed in humans in 3 phases (Figure 3). Phase 1 trials 
aim to determine drug dose and side effects and are performed in healthy volunteers. 
Phase 2 trials aim to assess the most effective dose, while monitoring adverse events 
in patients. Phase 3 trials, ideally randomized clinical trials (RCTs), are designed to 
confirm efficacy in various populations of patients (representative for the whole disease 
spectrum within clinical practice). These phase 3 trials are often used for registration by 
regulatory authorities such as U.S. Food and Drug Administration (FDA) and European 
Medicines Agency (EMA). FDA or EMA then checks if the drug is safe and effective, and 
if benefits outweigh the risks.22, 23 After approval, phase 4 (post-marketing) surveillance 
can be conducted and some countries will assess the cost-effectiveness of the drug for 
reimbursement. In the Netherlands this is done by ZIN (ZorgInstituut Nederland), ZIN 
compares the therapeutic value of the new drug to standard of care, and evaluates the 
budget impact and cost-effectiveness of the new drug.24
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Figure 3. Schematic visualization of population included in clinical trials
This figure shows which part of the population is included in different phases of drug development: 
1 (phase 1 trial), 2 (phase 2 trial), 3 (phase 3 trial), and 4 (phase 4 data). The size represents the size 
of the trial. Light grey represents trials before registration and dark grey after registration; it is clear 
that not the whole disease spectrum is included in phase 1-2-3 research.
Generalizability of registration trials
Ideally, phase 3 registration trials include patients that resemble the clinical practice 
population, however designing the perfect trial with both a high internal and high 
external validity is difficult. Generalizability or external validity of registration trials 
appeared to be limited in some disease areas (e.g. psoriasis, rheumatic arthritis, 
inflammatory bowel disease) which hampers direct use of the data in clinical practice.25, 
26 Often, trials use strict eligibility criteria in order to increase internal validity and to 
select easy-to-treat patients with the highest chance of efficacy and limited risk of 
toxicity. While in clinical practice the difficult-to-treat patients receive treatment.27 This 
can be called a development paradox which can result in limited generalizability of 
outcomes of registration trials. Still, physicians, guideline developers and policy makers 
do need to choose or recommend specific regimens for a variety of patients.
Some essential components in the translation of registration trials to clinical practice 
are: generalizability of trials and use of an adequate comparator. There are some ways 
to assess generalizability of trials: a) to examine eligibility criteria and assess whether 
the trial population was sufficiently representative, b) to use data from observational 
cohorts, when no direct evidence is available for the population, and c) to use relative 
effects found in RCTs and apply this to the population to estimate the absolute effect.28 
The latter can be done with statistical techniques such as network meta-analysis 
and Bayesian statistics. Apart from generalizability, the comparative arm in studies is 
important for physicians and guideline developers. Ideally a standard of care option 
should be included in the trials to adequately assess comparative effectiveness.
Patients with disease
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Moderate disease
Severe disease
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Concerns about registration trials in hepatitis C
In HCV the development paradox was clear in the case of first-generation protease 
inhibitors: registration trials showed improved efficacy with tolerable toxicity in easy-
to-treat patients, while the first real world cohorts demonstrated high risk of serious 
adverse events and even mortality in patients with cirrhosis.29, 30 Here, the registration 
trials included standard of care (PegIFN and RBV) as the comparative arm. For trials 
with newer DAAs there were two reasons which made inclusion of the standard of 
care complex: 1) the field developed at such a rapid pace that the standard of care at 
initiation of the trial was different from the time of introduction to the market; 2) the 
DAAs are developed by many pharmaceutical companies, and head-to-head trials are 
not part of their portfolio. The design of many registration trials in hepatitis C appears 
suboptimal, for example the ALLY-3 trial was a single arm trial including 152 easy-to-
treat HCV genotype 3 patients with only 21% cirrhotics, who received sofosbuvir with 
daclatasvir for 12 weeks.31 This trial led to the FDA approval of sofosbuvir with daclatasvir 
for 12 weeks in all HCV genotype 3 patients and illustrates the development paradox.32
Outline and aims of this thesis
The therapeutic landscape in HCV treatment has changed and is still changing. Many 
registration trials that have been executed used strict eligibility criteria, resulting in a 
gap between trials and clinical practice. The main aim of this thesis was to improve 
translation of results from clinical trials with direct acting antivirals in chronic hepatitis 
C to clinical practice. We will study two steps of translation of trials in hepatitis C: 
generalizability of trials and interpretation of evidence in clinical practice.
Generalizability of trials to clinical practice
In chapter 2 we answered the research question: What is the effectiveness and safety of 
real world patients who are eligible vs. ineligible for registration trials? We hypothesized 
that a high proportion of HCV patients treated in clinical practice would not be eligible 
for trials and that characteristics for ineligibility were risk factors for treatment failure. 
To investigate this hypothesis we retrospectively collected data in a nationwide registry 
of all patients treated with first-generation protease inhibitors combined with pegIFN 
and RBV. In addition we aimed to identify the criteria that impact trial eligibility and to 
assess the risk of these criteria on effectiveness and safety.
Based on the data of this registry we performed two studies on specific adverse events 
(infections and bleeding episodes) in clinical practice. It is thought that neutropenia and 
thrombocytopenia, two important side effects of pegIFN, increase the risk of infections 
and bleeding episodes respectively. In that case, strict dose reduction of pegIFN is 
recommended, which may lead to reduced effectiveness.33, 34
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The rational to perform studies with first-generation protease inhibitors combined with 
pegIFN and RBV were clear: (i) there is data that protease inhibitors increase the risk 
of severe infection29, 35, and (ii) a meta-analysis demonstrated more thrombocytopenia 
with protease inhibitors which might lead to more bleeding episodes.36 In chapter 
3 we answered the research question: What is the prevalence and what are the risk 
factors for infections during triple therapy with first-generation protease inhibitors? 
We hypothesized that these drugs result in a high risk of infections, but without a 
relation to neutropenia. In chapter 4 we answered the research question: What are 
the prevalence and risk factors for bleeding episodes during triple therapy with first-
generation protease inhibitors? Here the hypothesis was that protease inhibitors are 
associated with thrombocytopenia but not with bleeding episodes.
Over time new DAAs were trialed and approved by regulatory authorities (FDA and 
EMA). The new generation DAAs are administered without pegIFN, which contributed 
to the better safety profile of these drugs. We hypothesized that this led to less strict 
eligibility criteria in the registration trials of these new DAA regimens, probably resulting 
in a better generalizability. In chapter 5 we tried to find an answer to the research 
question: does the eligibility rate of clinical practice patients for DAA trials improve over 
time? Here we focused on the most important eligibility criteria identified in chapter 
2. We studied these criteria in all registration trials of new DAAs and collected cross- 
sectional data of all HCV infected patients in two hospitals (tertiary and regional center). 
We determined the eligibility rate of this cohort on the selected criteria.
As toxicity decreased and efficacy increased with the new generation DAAs not all 
issues in clinical practice were solved. As shown in chapter 2 prohibited concomitant 
medication was one of the most frequent reasons for exclusion from a trial. The rational 
here is that DAAs inhibit/induce and can be substrates of drug-metabolizing enzymes 
and drug transporters, so DAAs have the potential to cause drug-drug interactions.21 In 
chapter 6 we answered the following research question: What concomitant medication 
do HCV patients use, and what is the predicted risk on drug-drug interactions with 
DAAs for hepatitis C? We hypothesized that use of concomitant medication is diverse 
and that many patients use concomitant medication with risk of interaction. For this 
study we used baseline data of the registry of patients treated with first-generation 
protease inhibitors.
Interpretation of evidence in clinical practice
It is difficult to interpret evidence from trials into clinical practice in the presence of 
a development paradox and lack of head-to-head trials. A way to deal with this lack 
of head-to-head trials is by using the technique of network meta-analysis (NMA) with 
Bayesian statistics. A NMA is able to compare more than 2 treatments. By combining 
direct and indirect evidence using Bayesian statistics NMA is able to estimate outcomes 
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such as mean SVR rate per DAA regimen.37, 38 In chapter 7 we performed a systematic 
review and NMA to answer the research question: What is the most effective DAA 
regimen for HCV genotype 3 patients and what is the role of ribavirin here? Genotype 
3 turned out to be the most difficult genotype to cure during the drug development 
phase and head-to-head trials of DAA regimens were scarce, therefore the technique 
of NMA was suitable to indirectly compare efficacy of various DAA regimens in this 
genotype.
The ultimate translation of evidence is done in guideline development. Guidelines 
provide an overview and take multiple factors of both trials and practice into account, 
such as efficacy, safety, settings, costs/reimbursement, and availability. With this 
information guideline developers attempt to steer physicians in clinical practice to 
improve and standardize care. The need for a guideline for the treatment of hepatitis C 
in the Netherlands was high, because the last guideline dated from 2013, included only 
first-generation protease inhibitors and was already outdated soon after publication.33 
However, the latter was the reason why a formal guideline was not suitable for 
hepatitis C in the past years. In chapter 8 we developed a guidance for the treatment 
of hepatitis C which served as a dynamic document. The first version was published 
and based on a systematic review of sofosbuvir combined with (pegIFN and) RBV. We 
formulated recommendations based on the GRADE method.39 Later we established a 
guidance committee of five associations: NVMDL (Netherlands Association of Hepato-
gastroenterologists), NVH (Netherlands Association of Hepatology), NIV (Netherlands 
Association of Internal Medicine), NVHB (Dutch Association of HIV- treating physicians), 
NVZA (Netherlands Association of Hospital Pharmacists) and produced an online 
guidance which was updated every 3-6 months (www.hcvrichtsnoer.nl). This online 
guidance is based on international guidelines, a practical and suitable way to provide 
the most updated information to Dutch physicians in clinical practice.
Finally, in chapter 9 we describe a general discussion on the generalization and 
interpretation of evidence from trials to clinical practice in hepatitis C, including 
alternatives for this problem.
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Abstract
Background
Approval of drugs in chronic hepatitis C is supported by registration trials. These trials 
might have limited generalizability through use of strict eligibility criteria. We compared 
effectiveness and safety of real world hepatitis C patients eligible and ineligible for 
registration trials.
Methods
We performed a nationwide, multicenter, retrospective cohort study of chronic hepatitis 
C patients treated in real world. We applied a combined set of inclusion and exclusion 
criteria of registration trials to our cohort to determine eligibility. We compared 
effectiveness and safety in eligible vs. ineligible patients, and performed sensitivity 
analyses with strict criteria. Further, we used log binomial regression to assess relative 
risks of criteria on outcomes.
Results
In this cohort (n=467) 47% of patients would have been ineligible for registration trials. 
Main exclusion criteria were related to hepatic decompensation and co-morbidity 
(cardiac disease, anemia, malignancy and neutropenia), and were associated with an 
increased risk for serious adverse events (RR 1.45-2.31). Ineligible patients developed 
significantly more serious adverse events than eligible patients (27% vs. 11%, p< 0.001). 
Effectiveness was decreased if strict criteria were used.
Conclusions
Nearly half of real world hepatitis C patients would have been excluded from registration 
trials, and these patients are at increased risk to develop serious adverse events. Hepatic 
decompensation and co-morbidity were important exclusion criteria, and were related 
to toxicity. Therefore, new drugs should also be studied in these patients, to genuinely 
assess benefits and risk of therapy in the real world population.
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Introduction
Regulatory approval of drugs and the development of guidelines are supported by 
evidence generated by registration trials. These trials aim for high internal validity 
through use of strict eligibility criteria, although this may jeopardize generalizability.1,2 
Some studies suggest that many real world patients would be excluded from registration 
trials and that drugs tested through these trials are less effective or less well tolerated 
in these patients.3-5
The treatment arsenal for chronic hepatitis C patients (CHC) has increased enormously 
with the introduction of Direct Acting Antivirals (DAAs). DAAs were approved by 
regulatory authorities for use in clinical practice, with evidence coming from registration 
trials having strict criteria.6 Indeed, real world cohorts contain large number of treated 
CHC patients who would be excluded from registration trials.7-10 A lack of generalizability 
is only an issue when ineligible patients have worse outcomes, but this is not known 
for CHC. We hypothesize that CHC patients ineligible for trials, but who are treated 
in clinical practice have characteristics that are risk factors for treatment failure and 
toxicity.
Therefore, we aim to compare effectiveness and safety in real world CHC patients who 
are eligible or ineligible for registration trials. Our secondary aim is to identify criteria 
that impact trial eligibility and assess the risk of these criteria on outcomes.
Materials and Methods
Population and design
We conducted a nationwide, multicenter, retrospective real world cohort study of CHC 
patients in the Netherlands. We chose genotype 1 patients treated between 2011 and 
2015 with telaprevir or boceprevir with peg-interferon and ribavirin as an example 
cohort. We identified CHC patients using up-to-date local databases. Treatment 
indication, choice of therapy, drug dosing and duration were at the discretion of the 
physician, following national guidelines.11 Patients co-infected with HIV or hepatitis B 
virus (HBV) were excluded.
Formal evaluation was waived by the institute review board committee on research 
involving human subjects Arnhem-Nijmegen given the retrospective character of 
our study. However, approval in participating centers was obtained according to 
local regulations. The study was conducted in accordance with good clinical practice 
guidelines and the code of conduct for medical research (www.federa.org). We obtained 
oral informed consent or collected data anonymously in accordance with the code of 
conduct for medical research. No identifying patient data was collected, and all patient 
data was anonymously entered in the database.
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Identification of registration trials and general set of eligibility criteria
We identified registration trials of telaprevir and boceprevir in CHC patients through a 
systematic search (S1 Table). We extracted eligibility criteria from published protocols, 
and used the least stringent criteria of all studies to develop a general criteria set (Table 
1). We applied the general set to our real world population to determine eligibility. If 
variables were missing, we assumed the patient would be eligible for that criterion.
Data acquisition and definitions
We extracted demographics, CHC characteristics, and laboratory values from the 
patient’s medical records on a pre-designed case report form. Baseline variables were 
collected at the start of treatment not exceeding one year prior to treatment. Baseline 
concomitant medication was collected prior to possible medication switch for expected 
interactions. Data was collected until 24 weeks after cessation of treatment. We 
collected whether patients had a history of or current decompensated liver disease, this 
was defined as a history or signs of ascites, variceal bleed or hepatic encephalopathy. 
Effectiveness was defined as sustained virological response (SVR): undetectable hepatitis 
C virus RNA 12 or 24 weeks after cessation of treatment. Safety data included adverse 
events (AEs) and serious adverse events (SAEs). AEs were defined as any event that 
required 1) dose reduction of peg-interferon or ribavirin, 2) prescription of medication 
or 3) referral. We used the FDA definition for SAEs.12 We categorized AEs and SAEs by 
common terminology criteria for adverse events (CTCAE version 4.0).13 We recorded data 
anonymously in an Access database (Microsoft Access 2007).
Outcomes and analysis
The primary outcomes were SVR and (S)AE rates, which were compared between 
patients eligible and ineligible for registration trials. Furthermore, we identified 
criteria that affected eligibility and were associated with the outcomes. Analyses were 
performed on an intention to treat population, where telaprevir and boceprevir treated 
patients were pooled. To check validity of pooling, we compared baseline characteristics 
and treatment outcomes between telaprevir and boceprevir patients.14
SVR rates, and (S)AE rates were analyzed with chi-square (or Fisher exact if counts <5), 
and Mann-Whitney U test (median number of (S)AEs). For analyses on SVR, we separated 
patients into two groups based on expected similar effectiveness: 1) treatment-naive 
and relapse patients, and 2) patients with a prior non-response, viral breakthrough or 
early discontinuation15; for safety outcomes this distinction was not made. We used 
frequency counts to identify most important eligibility criteria. To study the association 
of criteria and outcomes, we performed log binomial regression (relative risk) or poisson 
regression.16 To explore the validity of our generated set of the least stringent criteria 
from the protocols, we performed three sensitivity analyses: a) with most stringent 
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Criterion
Subject ≥ 18 years
HCV RNA detectable
Weight between 40-125 kg 
Ultrasound with no signs of HCC
HCV with > 1 subtype or genotype
Hemoglobin <12 g/dL (females) or <13 g/dL (males) 
Absolute neutrophil count <1.2 x109/L
Platelet count <90 x109/L
Serum albumin < 3.3 g/dL
Total bilirubin > 1.8 xULN†
INR ≥ 1.5
TSH > 1.2 xULN or 0.8 xLLN†
ALT 10 xULN†
AST 10 xULN†
-  Hemoglobinopathy present (thallassemia major,        
    sickle-cell disease) 
-  Significant cardiac disease presenta
-  Creatinine clearance ≤ 50 ml/min
Presence of auto-immune diseaseb
History of chronic pulmonary disease with 
impairment (COPD gold III or IV, interstitial lung 
disease, pulmonary fibrosis or sarcoidosis) 
Current or history of ascites, encephalopathy or 
bleeding varices
Presence of another liver disease
Active malignant disease or malignant disease in past 
5 years (except basal cell carcinoma)
History of acute pancreatitis in past 5 years
Presence of retinopathy
Presence of a seizure disorder requiring medication
Patient with a history of an organ transplant
Presence of severe psychiatric diseasec
Use of systemic corticosteroids
Hemophilia present
CNS disorder presentd
History of malabsorption disorder
Subject with indwelling venous catheter
Prohibited comedication listed in protocols
Variable    
 
Inclusion
Age
Hepatitis C virus (HCV) RNA 
Weight
Hepatocellular Carcinoma (HCC)
Exclusion
Genotype HCV
Hemoglobin
Neutrophil count
Platelet count
Albumin
Bilirubin
International Normalized Ratio (INR) 
Thyroid Stimulating Hormone (TSH) 
Alanine aminotransferase (ALT) 
Aspartate aminotransferase (AST) 
Contra-indication to peginterferon or 
ribavirin 
- Hemoglobinopathy
- Cardiac disease
- Renal insufficiency
Auto-immune disease 
Pulmonary disease
Current or history of decompensated  
liver disease
Other liver disease
Malignancy
Pancreatitis 
Retinopathy
Seizure 
Transplantation 
Psychiatric comorbidity 
Corticosteroids 
Hemophilia
Central nervous system (CNS) disorder 
Malabsorption
Indwelling cathether
Comedication
Table 1. Set of general eligibility criteria
a Significant cardiac disease was defined as: current or history of unstable cardiac disease (angina, congestive heart 
failure, recent myocardial infarction, pulmonary hypertension, complex congenital heart disease, cardiomyopathy, 
and/or significant arrhythmia)
b Auto-immune disease was defined as: immunologically mediated disease (inflammatory bowel disease, celiac 
disease, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, auto-immune 
hemolytic anemia, scleroderma, sarcoidosis, severe psoriasis, or auto-immune hepatitis)
c Psychiatric comorbidity was defined as: severe depression or hospitalization for depression, schizophrenia, bipolar 
illness, severe anxiety or personality disorder, a period of disability or impairment due to a psychiatric disease within 
the past 5 years
d CNS disorder was defined as: CNS trauma requiring intubation, intracranial pressure monitoring, brain meningeal/
skull surgery, or resulting in seizure, coma, neurologic deficits, abnormal brain imaging, cerebrospinal fluid leak, prior 
brain hemorrhage and/or intracranial aneurysms, or history of stroke or transient ischemic attack
† ULN = upper limit of normal; LLN = lower limit of normal
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criteria (S2 Table), b) with strictest exclusion of co-morbidity, and c) with the most 
important factor for exclusion eliminated from the criteria set. All analyses were two-
sided with a significance level of p <0.05, and performed in SPSS (IBM SPSS Statistics 
20).
Results
Population
We identified 489 treated patients from 45 centers, and we excluded 22 patients 
(Figure 1). Centers treated a median of 8 patients (range 1-53). Overall, the majority of 
patients (60%) was treatment naive, 52% had advanced fibrosis or cirrhosis and 5% had 
a history of decompensated liver disease. Baseline characteristics are shown in Table 2. 
We pooled telaprevir (n=265) and boceprevir (n=202) data, as there were no significant 
differences in characteristics and treatment outcomes between these patients (S3 and 
S4 Tables).
Figure 1. Study flowchart
The flowchart shows both enrollment of patients in all centers and assessment of eligibility for 
registration trials in this study. 
 Nationwide 47 hepatitis treatment centers
 Exclusion of centers:
 - 1 center: no treated patients
 - 1 center: tardily assessment      
   of study protocol
 Datacollection in 45 centers (8 academic)
 489 patients identified
 22 patients excluded:
 - 5 no consent
 - 6 treatment not finished at   
   time of data collection
 - 4 treatment in another   
   center
 - 3 missing files
 - 2 peginterferon/ribavirine 
   instead of triple therapy
 - 2 HBV co-infected    
 467 patients received at least one dose of telaprevir (n=265) or boceprevir (n=202)
 Eligible (n=247)
 Systematic search for registration trials
 Ineligible (n=220)
 Extraction of eligibility criteria of protocols
 Generate set of least stringent criteria
 Application of set of criteria on patients to 
determine eligibiliy for registration trials
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Table 2. Baseline characteristics
a Race: available in 360 patients; b Previous response: available in 454 patients; c Metavir score: available in 308 
patients; d Lab values >10% missings in: neutrophil count, albumin; e CP-score (assumed no ascites and hepatic 
encephalopathy at start of treatment): available in 223 patients
Registration trials and outcomes eligible vs. ineligible
Our search yielded eight trials of telaprevir and boceprevir17-24, and five registration 
trials were included (S1 Table).22-24 On the basis of the general criteria (Table 1), 47% of 
patients treated in real world practice would be excluded from registration trials. We 
than compared the eligible to ineligible population with respect to safety parameters. 
We found that ineligible patients had significantly more SAEs compared to eligible 
patients (27% vs. 11%, p<0.001) (Figure 2). A total of 37 SAEs occurred in 28 eligible 
patients (1 patient died due to an accident), compared to 103 SAEs which occurred 
in 60 ineligible patients (7 patients died) (S5 Table). Also, after excluding patients with 
a history of decompensated liver disease (n=24) from the analysis, ineligible patients 
had significantly higher SAE rates (24% vs. 11%, p<0.001). Further, ineligible patients
had a higher median number of AEs and SAEs (p=0.039 and p<0.001 respectively, S6 Table). 
The incidence of some typical hepatic or therapy related (S)AEs (anemia, thrombopenia 
Characteristic
Age, y – mean (range) 
Male sex – n (%)
White race – n (%)a
HCV genotype – n (%) 
   Genotype 1 indeterminate 
   Genotype 1a
   Genotype 1b
Previous responseb
   Naive
   Relapse
   Nonresponse
   Viral breakthrough
   Early discontinuation
Current or history of decompensated 
liver disease – n (%)
Metavir score F3-4c
Laboratory valuesd
Hemoglobin g/dL – mean (SD)
Leucocyte count x109/L – mean (SD)         
Neutrophil count x109/L – mean (SD) 
Platelet count x109/L – mean (range) 
Albumin g/dL – mean (range)
Total bilirubin g/dL – median (IQR)
Child Pugh (CP) scoree
A – n (%)
B – n (%)
C – n (%)
Overall 
(n= 467)
51 (19-77) 
319 (68) 
321 (89)
86 (18) 
226 (48) 
155 (33)
273 (60) 
76 (17) 
78 (17) 
16 (4) 
11 (2) 
24 (5)
161 (52)
9.1 (0.9)
6.7 (2.2)
3.5 (1.5)
192 (24-764) 
4.1 (2.4-5.1) 
10.0 (7-14)
212 (95)
11 (5)
0 (0)
Eligible 
(n= 247)
50 (22-77) 
170 (69) 
173 (91)
49 (20) 
122 (49) 
76 (31)
142 (59) 
45 (19) 
41 (17) 
9 (4)
5 (2) 
0 (0)
66 (42)
9.2 (0.8)
7.0 (2.1)
3.6 (1.5)
207 (90-388) 
4.3 (3.3-5.1)
9 (7-13)
107 (100)
0 (0)
0 (0)
Ineligible 
(n=220)
52 (19-70) 
149 (68) 
148 (88)
37 (17) 
104 (47) 
79 (36)
131 (62) 
31 (15) 
37 (18) 
7 (3)
6 (3) 
24 (11)
95 (63)
9.0 (1.0)
6.4 (2.2)
3.3 (1.5)
175 (24-764) 
4.0 (2.4-5.1) 
11 (8-16)
105 (91)
11 (10)
0 (0)
p-value
0.07 
0.80 
0.08 
0.23
0.81
<0.001 
<0.001
0.02 
0.003 
0.22 
<0.001 
<0.001 
<0.001
0.001
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and hepatobiliary events) were significantly higher in the ineligible patients (Figure 3). 
We found (non-significant) lower SVR rates in ineligible patients. Two sensitivity analyses 
detected lower SVR rates in ineligible patients (treatment naive – relapse group): when 
applying most strict criteria (81% vs. 67%, p= 0.01) or when most stringent exclusion of 
patients with co-morbidity was done (76% vs. 65%, p= 0.02). We observed no difference 
in SVR in the third sensitivity analysis, where we excluded concomitant medication 
from the criteria set (Figure 4). No significant differences in effectiveness were found in 
the non-responder group (S1 Figure).
Figure 2. Safety in real world patients who would be eligible and ineligible for registration trials
The bars represent the proportion of patients who experienced a serious adverse event or adverse 
event in patients eligible or ineligible for registration trials
Figure 3. Incidence of specific (serious) adverse events in eligible and ineligible patients
The bars represent the incidence of various categories of (serious) adverse events between patients 
eligible and ineligible for registration trials. The asterix (*) marks significant differences between 
eligible and ineligible patients.
Dermatological events
Gastrointestinal events
Anemia
Psychiatric events
Leucopenia
Thrombopenia
Hepatobiliary events
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Criteria for ineligibility
Most important criteria for ineligibility were related to co-morbidity and signs or history 
of hepatic decompensation. In 220 ineligible patients, main reason for exclusion was 
the use of prohibited concomitant medication (n=65), followed by anemia (n=25), 
psychiatric co-morbidity (n=24), and current or history of decompensated liver disease 
(n=24). Median number of exclusion criteria within a patient was 1 (range 1-6). 
Univariable analysis showed most important criteria associated with lack of SVR, i.e. 
current or history of decompensated liver disease (RR 0.66), platelet count (RR 0.58), 
albumin (RR 0.49), bilirubin (RR 0.58) and neutrophil count (RR 0.55). Similar criteria 
were associated with a higher risk on an SAE: a history of decompensated liver disease 
(RR 1.81), platelet count (RR 1.45), albumin (RR 2.03), bilirubin (RR 1.89), hemoglobin 
(RR 1.72), malignancy (RR 2.31) and presence of cardiac disease (RR 1.97). Outcomes of 
these analyses are depicted in Table 3.
Figure 4. Effectiveness in real world treatment naive and relapse patients who would be eligible 
and ineligible for registration trials
Primary and sensitivity analyses on effectiveness of therapy in eligible vs. ineligible treatment naive 
and relapse patients (n=348). The bars represent the proportion of patients who reached a sustained 
virological response (SVR) within the groups. For sensitivity analyses different criteria sets are used to 
determine eligibility of patients, hence different numbers of patients in both groups.
Discussion
This study sheds doubt on the generalizability of registration trials to the real world 
CHC population. In our study, one of the key findings is that nearly half of treated 
CHC patients would be ineligible for registration trials. Most important exclusion 
criteria relate to signs or history of hepatic decompensation and co-morbidity (cardiac 
disease, anemia, malignancy and neutropenia). Patients meeting those exclusion
Primary analysis Sensitivity analyses
p=0.12 p=0.06p=0.02p=0.01
Eligible
Ineligible
100
80
60
40
20
0
SV
R
 (%
)
   General              Strict        Strict co-     Prohibited 
 criteria set             criteria     morbidity    comedication
n=       186  162                         85   263      167  181     214  134
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Table 3. Top criteria which impact trial eligibility
* Poisson regression when log binomial regression did not converge; † ULN = upper limit of normal; LLN = lower limit 
of normal
criteria developed more SAEs (RR between 1.45 and 2.31) and were less likely to reach 
SVR (RR between 0.49 and 0.66), especially when strict criteria were used. Vice versa, 
eligible patients had SVR and SAE rates comparable to published trials.17-21 Altogether, 
this indicates that results from registration trials are only generalizable to the real world 
patients who fulfill the eligibility criteria. Translating results originating from registration 
trials to patients that would be ineligible should be done with caution.
The difference between registration trials and real world reflects a ‘development 
paradox’. Drugs are developed through a phase II-III program that targets easy-to-treat 
patients, while in the real world difficult-to-treat patients are prioritized for treatment.1, 
25, 26 The sequence of drug development starting with easy-to-treat patients seems 
appropriate, but the final hurdle to perform trials that specifically target difficult-to-
treat patients is often sidestepped or delayed until after market authorization. 
As a result, this population who has a clear treatment indication is exposed to DAAs in 
the real world, without proper data on efficacy and toxicity.27 This results in an increased 
proportion of adverse events, dropouts and hence lower effectiveness.28 Our results 
support the ‘development paradox’ and provide reasons why real world outcomes do 
differ from registration trials.
Criterion
Prohibited comedication listed in protocols 
Hemoglobin <12 g/dL (females) or <13 g/
dL (males)
Presence of severe psychiatric disease
Current or history of ascites, 
encephalopathy or bleeding varices
Platelet count <90 x109/L
Presence of hemophilia
Serum albumin <3.3 g/dL
Total bilirubin >1,8 xULN†
TSH >1.2 xULN or <0.8 xLLN†
Active malignant disease or malignant 
disease in past 5 years (except basal cell 
carcinoma) 
Central nervous system disorder present 
Significant cardiac disease present
Presence of auto-immune disease 
Absolute neutrophil count <1.2 x109/L 
Ultrasound with no signs of HCC 
Creatinine clearance ≤50 ml/min
AST 10 xULN†
Presence of another liver disease
n
65
25
24
24
23
23
22
16
14
14
13
12
11
9
6
5
5
5
% of 
ineligible
patients
30
11
11
11
11
11
10
7
6
6
6
6
5
4
3
2
2
2
RR on SVR
(95% CI)
0.99 (0.70-1.39) 
0.69 (0.46-1.02)
1.27 (0.67-2.40)
0.66 (0.44-0.97)
0.58 (0.41-0.82) 
1.42 (0.71-2.85) 
0.49 (0.36-0.68) 
0.58 (0.39-0.86) 
0.71 (0.41-1.22) 
1.02 (0.50-2.09)
0.78 (0.43-1.43) 
1.46 (0.54-3.91) 
1.34 (0.51-3.55) 
0.55 (0.34-0.90) 
0.74 (0.33-1.66) 
0.63 (0.30-1.30) 
0.61 (0.29-1.26) 
0.60 (0.29-1.24)
RR on SAE
(95% CI)
1.17 (1.00-1.38) 
1.72 (1.14-2.60)
1.03 (0.84-1.72)
1.81 (1.17-2.81)
1.45 (1.01-2.08) 
4.51 (0.66-30.93)* 
2.03 (1.23-3.37) 
1.89 (1.08-3.29) 
1.34 (0.36-4.90)* 
2.31 (1.14-4.66)
1.18 (0.82-1.70) 
1.97 (1.01-3.86) 
1.50 (0.87-2.58) 
1.62 (0.25-10.43)* 
1.64 (0.74-3.65) 
2.05 (0.70-6.01) 
1.01 (0.65-1.57)
-
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Our data on limited generalizability of registration trials accords with the literature. An 
increased likelihood for SAEs in patients with a history of decompensated cirrhosis who 
would have been excluded from registration trials was reported in a large CHC
cohort (n=2084).9 Some 30-47% of compensated cirrhotic patients treated with first-
generation protease inhibitors would be ineligible for registration trials, and this study 
showed unexpected high SAE rates in that population.7
In addition, a study on ledipasvir/sofosbuvir in advanced liver disease patients, published 
after FDA and EMA approval, reported much higher SAE rates (23%) compared to 
registration trials (3%).29 For another CHC regimen, paritaprevir/ritonavir, ombitasvir and 
dasabuvir, the FDA label changed within one year following approval based on review 
of adverse events. This regimen is now contra-indicated in patients with Child-Pugh B 
cirrhosis.30 It is likely that this could have been prevented if these patients had been 
trialed prior to approval of the regimen. There is literature that suggests that serious 
adverse events might be related to disease course instead of therapy.31 Nonetheless, 
timely controlled studies in CHC patients with decompensated liver disease are 
necessary to accurately gauge risk-benefit balance for these individual patients.
Here, we used the first-generation protease inhibitor treated patients as an example 
cohort. We believe that our results are also applicable to new generation DAAs, because 
eligibility criteria of registration trials are comparable to the set used in the current 
study (S7 Table).31-37 Indeed, a Canadian HIV/HCV cohort, found that up to 94% of 
patients from that cohort would be ineligible for registration trials with new generation 
DAAs.10 Furthermore a real world cohort showed that liver decompensation and SAEs 
during sofosbuvir containing regimens were associated with lower baseline albumin 
and higher total bilirubin, which are general exclusion criteria.38 As toxicity of new 
generation DAAs decreases, the difference between trials and real world might become 
smaller, however with the high ineligibility rate of real world patients, generalization of 
results remains difficult.
Limited generalizability of registration trials is also seen in other liver diseases such 
as hepatocellular carcinoma (HCC) and HBV infection. For example, sorafenib was 
approved for HCC treatment, on the basis of studies that excluded Child-Pugh B and 
C cirrhotic patients.39, 40 A real world cohort reported significantly decreased overall 
survival with sorafenib in Child-Pugh B compared to Child-Pugh A cirrhotics.41 Likewise, 
post-marketing studies in entecavir for chronic HBV infection show lower proportions of 
ALT normalization than was shown in registration trials.42
Our study comes with strengths and limitations. Strengths of this study are the 
nationwide and multicenter character, resulting in a large and representative real 
world cohort. Limitations of this study are the retrospective character that resulted in 
(some) missing values. We handled this conservatively, by classifying the missing value 
as eligible for that criterion. Furthermore, chart review may result in reporting bias, but
we used strict definitions to reduce this. Another limitation is that patients received
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first-generation protease inhibitors, peginterferon and ribavirin, which may increase the 
potential for toxicity. However, we think that our results are also valid for new generation 
DAAs.
In conclusion, nearly half of CHC patients treated in real world practice would be 
ineligible for registration trials. In these patients we found impaired safety and 
effectiveness related to specific eligibility criteria (hepatic decompensation and co-
morbidity). Prior to regulatory approval, new drugs should also be studied in the difficult-
to-treat population, including patients with hepatic decompensation and co-morbidity, 
to genuinely assess the benefits and risks of treatment in the real world population.
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Supporting Information
S1 Table. Search strategy
This is the flowchart of the systematic search for registration trials with telaprevir and boceprevir.
FDA Telaprevir label (Reference ID: 3397093), clinical studies:
 - Treatment naive adults: trial 108 (ADVANCE), trial 111 (ILLUMINATE), trial C211 
   (OPTIMIZE)
 - Treatment experienced adults: trial C216 (REALIZE)
FDA Boceprevir label (Revised 05/2011), clinical studies:
 - Treatment naive adults: SPRINT-2
 - Treatment experienced adults: RESPOND-2
Pubmed database
Clinical trials.gov
Results
31 results: 
Inclusion:
- NCT01241760 – OPTIMIZE
- NCT00703118 – REALIZE
- NCT00627926 - ADVANCE
25 results 
Inclusion:
- NCT00910624 - PROVIDE
- NCT00845065
- NCT00705432 - SPRINT-2
- NCT00708500 - RESPOND-2
Search
Telaprevir AND phase 3
Limits:
- clinical trial
- date: 1-1-2000 until    
  1-1-2014
Boceprevir AND phase 
3
Limits:
- clinical trial
- date: 1-1-2000 until 
  1-1-2014
No
#1
#2
Exclusion
Exclusion on title and 
abstract: 27
Exclusion on full text: 1 
(Japan)
Exclusion on title and 
abstract: 21
 Search #1 Telaprevir OR VX 950: 93 studies
 Additional criteria: phase 3: 26 hits
 Search #2 Boceprevir: 54 studies
 Additional criteria: phase 3: 17 hits
 Exclusion of studies:
 - Roll over: 1
 - HIV coinfection: 3
 - HCC: 1
 - Post-livertransplantation: 1
 - Another regime: 8
 - Other peg-interferon: 5
 - Subgroups: 1 (IL28B CC)
 - Russian: 1
 - Early access: 1
 Exclusion of studies:
 - No phase 3: 
 - HIV coinfection: 2
 - Another regime: 2
 - Subgroups: 5 (menopausal 
   women, pediatric, EPO vs. dose 
   reduction, IL28B CC, 
   eltrombopag
 - Asia: 2
 - Russia: 1
 - Other genotype: 2
 4 trials selected:
 - NCT01241760 - OPTIMIZE
 - NCT00703118 - REALIZE
 - NCT00627926 - ADVANCE
 - NCT00758043 - ILLUMINATE
 3 trials selected:
 - NCT00705432 - SPRINT-2
 - NCT00708500 - RESPOND-2
 - NCT00845065
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Conclusion search in FDA label, clinical trials.gov and pubmed:
S2 Table. Set of least and most stringent combined inclusion and exclusion criteria 
of registration trials
This table shows the least stringent and most stringent criteria of different registration trials per 
variable. The least stringent criteria set was used for primary analyses and the most stringent criteria 
set for a sensitivity analysis.
Inclusion
Exclusion
Telaprevir 
- NCT00703118 – REALIZE
- NCT00627926 – ADVANCE
- NCT00758043 - ILLUMINATE
- NCT01241760 – OPTIMIZE: no 
  full eligibility criteria available
Boceprevir
- NCT00705432 - SPRINT-2
- NCT00708500 - RESPOND-2
- NCT00910624 – PROVIDE: 
  roll over of SPRINT-1, SPRINT-2 and 
  RESPOND-2, so identical inclusion criteria
- NCT00845065 (identical inclusion criteria   
  RESPOND-2)
Variable
Inclusion
Age
HCV RNA
Weight
Hepatocellular 
carcinoma (HCC)
Exclusion
Genotype 
Treatment history
Hemoglobin (Hb)
Neutrophil count 
Platelet count 
Renal insufficiency 
Albumin
Bilirubin
Glucose
Protrombin Time (PT)/
INR 
TSH
ALT
AST
Contra-indication to 
peginterferon/ribavirin
- Hemoglobinopathy
- Cardiac disease1
- Renal insufficiency
Auto-immune disease2 
COPD
Least stringent criteria
Subject ≥ 18 years
HCV RNA detectable
Between 40-125 kg
Ultrasound with no signs of HCC
HCV with > 1 subtype or genotype 
Ignore this criterion
Hb <12 g/dL (females) or <13 g/dL 
(males)
Absolute neutrophil count <1.2x109/L
Platelet count <90 x109/L
Creatinine clearance ≤ 50 ml/min 
Serum albumin < 3.3 g/dL
total bilirubin > 1.8 xULN†
Ignore this criterion
INR ≥ 1.5
TSH > 1.2 xULN or < 0.8 xLLN† 
ALT 10 xULN†
AST 10 xULN†
Hemoglobinopathy present 
Significant cardiac disease present 
See renal insufficiency
Presence of auto-immune disease 
COPD gold III or IV
Most stringent criteria
Subject 18-70 years
HCV RNA ≥ 10.000
Between 40-125 kg
Ultrasound with no signs of HCC
HCV with > 1 subtype or genotype 
Exclusion of nullresponders, 
viral breakthrough and early 
discontinuation 
Hb <12 g/dL (females) or <13 g/dL 
(males)
Absolute neutrophil count <1.5x109/L 
Platelet count <100 x109/L
Creatinine > ULN†
Serum albumin < LLN†
total bilirubin > 1.6 xULN †
Serum glucose ≥ 140 mg/dL (nonDM) 
PT > 10% ULN†
TSH above or below normal range 
ALT 10 xULN†
AST 10 xULN†
Hemoglobinopathy present* 
Significant cardiac disease present*
See renal insufficiency*
Presence of auto-immune disease* 
COPD gold I-IV and unknown gold 
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1 Significant cardiac disease was defined as: current or history of unstable cardiac disease (angina, congestive heart 
failure, recent myocardial infarction, pulmonary hypertension, complex congenital heart disease, cardiomyopathy, 
and/or significant arrhythmia)
2 Auto-immune disease was defined as: immunologically mediated disease (inflammatory bowel disease, celiac 
disease, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, auto-immune 
hemolytic anemia, scleroderma, sarcoidosis, severe psoriasis, or auto-immune hepatitis)
3 Psychiatric comorbidity was defined as: severe depression or hospitalization for depression, schizophrenia, bipolar 
illness, severe anxiety or personality disorder, a period of disability or impairment due to a psychiatric disease within 
the past 5 years
4 CNS disorder was defined as: CNS trauma requiring intubation, intracranial pressure monitoring, brain meningeal/
skull surgery, or resulting in seizure, coma, neurologic deficits, abnormal brain imaging, CSF leak, prior brain 
hemorrhage and/or intracranial aneurysms, or history of stroke or transient ischemic attack (TIA)
† ULN = upper limit of normal; LLN = lower limit of normal
* plus exclusion of cases with insufficient information about specific co-morbidity
Variable (continued)
Exclusion (continued)
Current or history of 
decompensated liver 
disease 
Other liver disease 
Malignancy
Pancreatitis 
Retinopathy 
Seizure 
Transplantation
Psychiatric 
comorbidity3 
Corticosteroids use 
Alcohol or drugs use 
Hemophilia
Central Nervous System 
disorder/Stroke/TIA4 
Malabsorption
Indwelling cathether
Comedication
Least stringent criteria (continued)
History of ascites, encephalopathy or 
bleeding varices 
Other liver disease
Active malignant or malignant 
disease in past 5 years (except basal 
cell carcinoma) 
Acute pancreatitis in past 5 years 
Retinopathy present
Seizure disorder requiring 
medication 
Patient with a history of an organ 
transplant
Severe psychiatric disease
Use of systemic corticosteroids 
Ignore this criterion 
Hemophilia
CNS disorder present
History of malabsorption disorder
Subject with indwelling venous 
catheter
Comedication literally on prohibited
medication list of protocol
Most stringent criteria (continued)
History of ascites, encephalopathy or 
bleeding varices*
Other liver disease*
Active malignant or malignant 
disease in past 5 years (except basal 
cell carcinoma)* 
History of acute or chronic 
pancreatitis 
Retinopathy present*
History of seizure disorder
Patient with a history of an organ 
transplant*
Moderate and severe psychiatric 
disease 
Use of systemic corticosteroids*
Alcohol use > 2 IE/day or drugs use 
Hemophilia*
CNS disorder present*
History of malabsorption disorder*
Subject with indwelling venous 
catheter*
Comedication in the same 
anatomical therapeutic code (ATC)-
group as prohibited medication list 
of protocol
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S3 Table. Baseline characteristics telaprevir and boceprevir treated patients
Table including baseline characteristics of patients treated with telaprevir and boceprevir, these 
patients are pooled in the primary analysis.
a Race: available in 360 patients; b Previous response: available in 454 patients (257 TPR, 197 BOC); c Metavir score: 
available in 308 patients (184 TPR, 124 BOC); d Lab values >10% missings in: neutrophil count, albumin.
Characteristic
Age, y – mean (range) 
Male sex – n (%) 
White race – n (%)a 
HCV genotype – n (%)
   Genotype 1 indeterminate       
   Genotype 1a
   Genotype 1b
Previous responseb 
   Naive
   Relapse 
   Nonresponse
   Viral breakthrough 
   Early discontinuation
Decompensated liver disease – n (%) 
Metavir score F3-4c
Laboratory valuesd
Haemoglobin g/dl – mean (SD) 
Leucocyte count x109/L – mean (SD) 
Neutrophil count x109/L – mean (SD) 
Platelet count x109/L – mean (range) 
Albumin g/dL – mean (range)
Total bilirubin g/dl – median (IQR)
Telaprevir 
(n=265)
51 (19-71) 
174 (66) 
186 (89)
31 (20) 
121 (46) 
91 (34)
152 (59) 
40 (15) 
47 (18) 
11 (4)
7 (3) 
12 (5) 
96 (52)
9.1 (0.9)
6.8 (2.1)
3.5 (1.6)
195 (51 – 764) 
4.2 (2.4-5.1)
10 (7-14)
Boceprevir 
(n=202)
51 (22-77) 
145 (72) 
135 (90)
33 (16) 
105 (52) 
64 (32)
121 (61) 
36 (18) 
31 (16) 
5 (3)
4 (2) 
12 (6) 
65 (52)
9.2 (0.9)
6.7 (2.2)
3.4 (1.5)
188 (24 – 387) 
4.1 (2.4-4.9)
9.9 (7-14)
p-value 
(TPR/BOC)
0.84
0.16
0.43
0.35
0.70
0.49
0.97
0.29
0.74
0.66
0.31
0.06
0.82
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S4 Table. Effectiveness and safety of telaprevir compared to boceprevir
Table showing effectiveness and safety results of telaprevir vs. boceprevir, these patients are pooled 
in the primary analysis.
* analysis with Fisher exact as frequency counts <5
SVR on previous response, n (%)
  Naive (TPR n=152, BOC n=121)
  Relapse (TPR n=40, BOC n=36)
  Non response (TPR n=47, BOC n=31) 
  Viral breakthrough (TPR n=11, BOC n=5) 
  Early discontinuation (TPR n=7, BOC n=4) 
  Unknown (TPR n=8, BOC n=5)
SVR on previous response, n (%)
  Naive and Relapse (n=349)     
  Nonresponse, viral breakthrough, early     
  discontinuation (n=118)
SAE on previous response, n (%)
  Naive (TPR n=152, BOC n=121)
  Relapse (TPR n=40, BOC n=36)
  Non response (TPR n=47, BOC n=31) 
  Viral breakthrough (TPR n=11, BOC n=5)      
  Early discontinuation (TPR n=7, BOC n=4)  
  Unknown (TPR n=8, BOC n=5)
Mean sum AE on previous response (±SD)
  Naive (TPR n=152, BOC n=121)
  Relapse (TPR n=40, BOC n=36)
  Non response (TPR n=47, BOC n=31) 
  Viral breakthrough (TPR n=11, BOC n=5)      
 Early discontinuation (TPR n=7, BOC n=4)     
  Unknown (TPR n=8, BOC n=5)
Mean sum SAE on previous response (±SD)
  Naive (TPR n=152, BOC n=121)
  Relapse (TPR n=40, BOC n=36)
  Non response (TPR n=47, BOC n=31) 
  Viral breakthrough (TPR n=11, BOC n=5)  
  Early discontinuation (TPR n=7, BOC n=4)   
  Unknown (TPR n=8, BOC n=5)
TPR (n=265)
107 (70) 
27 (69) 
20 (43) 
4 (36)
5 (71) 
5 (63)
135 (70) 
34 (47)
33 (22) 
9 (23) 
9 (19) 
1 (9)
1 (14) 
3 (38)
3.0±2.2 
2.7±1.8 
3.0±2.5 
1.9±2.1 
2.7±0.8 
3.0±1.5
0.3±0.7 
0.3±0.5 
0.2±.05 
0.3±0.9 
0.1±0.4 
0.6±0.9
BOC (n=202)  p-value
84 (69)   0.86 
26 (72)   0.78 
13 (42)   0.96 
1 (20)   1.00* 
1 (25)   0.24* 
3 (60)   1.00*
110 (70)   0.96 
18 (40)   0.49
18 (15)   0.15 
4 (11)   0.19 
5 (16)   0.73 
3 (60)  0.06* 
1 (25)   1.00* 
1 (20)   1.00*
2.8±2.3   0.63 
3.4±2.2   0.10 
2.7±2.9   0.82 
3.6±3.2   0.36 
2.8±1.0   0.58 
3.2±2.1   0.83
0.25±0.7   0.09 
0.17±0.5   0.27 
0.48±1.5   0.02 
1.00±1.0   0.41 
0.25±0.5   0.45 
0.40±0.9   0.59
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S5 Table. Serious adverse events categories
Table with categories of serious adverse events in eligible vs. ineligible patients
1  Percentage is noted between brackets in whole table 
2 One eligible patient died due to an accident
3 Seven ineligible patients died, causes: hepatic encephalopathy, decompensated liver disease and CVA, sepsis and 
  CVA, CVA, renal insufficiency, endocarditis, and one patient died of unknown cause
Category1  
 
Hepatobiliary
Anemia
Respiratory
Gastrointestinal
Circulatory
Psychiatric
General
Central nervous system
Endocrine
Musculoskeletal
Skin
Ear Nose Throat
Renal
Leucopenia
Pancytopenia
Nutritional
Reproductive system
Eye disorder
Eligible2  
(37 SAEs)  
 
  
   
1 (2.7) 
4 (10.8)  
9 (24.3)  
5 (13.5)  
0 (0.0)  
3 (8.1)  
3 (8.1)  
0 (0.0)
1 (2.7) 
1 (2.7) 
4 (10.8)  
1 (2.7)  
2 (5.4)   
0 (0.0)  
1 (2.7)  
0 (0.0)  
1 (2.7)  
1 (2.7) 
Ineligible3  
(103 SAEs) 
23 (22.3) 
15 (14.6) 
13 (12.6) 
9 (8.7)
8 (7.8) 
6 (5.8) 
6 (5.8) 
5 (4.9) 
4 (3.9) 
4 (3.9) 
3 (2.9) 
3 (2.9) 
2 (1.9) 
1 (1.0) 
0 (0.0) 
1 (1.0) 
0 (0.0) 
0 (0.0)
Number of 
ineligible
patients   
(n=60)
15 (25.0) 
14 (23.3) 
10 (16.7) 
7 (11.7) 
8 (13.3) 
5 (8.3)
6 (10.0) 
4 (6.7) 
3 (5.0) 
3 (5.0) 
3 (5.0) 
2 (3.3) 
2 (3.3) 
1 (1.7) 
0 (0.0) 
1 (1.7) 
0 (0.0) 
0 (0.0)
p-value 
(Fisher exact)
0.017
0.247
0.257
0.738
0.051
0.706
1.00
0.302
1.00
1.00
0.378
1.00
0.589
1.00
0.318
1.00
0.318
0.318
Number of 
eligible
patients   
(n=28)
1 (3.6)
3 (10.7) 
8 (28.6)
4 (14.3)
0 (0.0)
3 (10.7)
3 (10.7) 
0 (0.0)
1 (3.6)
1 (3.6)
3 (10.7)
1 (3.6)
2 (7.1) 
0 (0.0)
1 (3.6)
0 (0.0)
1 (3.6)
1 (3.6)
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S6 Table. Sensitivity analyses
Table showing outcomes of sensitivity analyses: analysis with most stringent criteria, analysis with 
strict exclusion of patients with co-morbidity, analysis without prohibited comedication as exclusion 
criterion
* analysis performed with Mann-Whitney U test
TN= Treatment Naive; NR= Non responder; SAE= Serious Adverse Event; SVR= Sustained Virological Response; AE = 
Adverse Event
Sensitivity analysis
Primary analysis
Sensitivity analysis: 
most strict analysis
Sensitivity 
analysis: more 
strict exclusion of 
patients with 
co-morbidity
Sensitivity analysis: 
comedication 
not included in 
analysis
No of patients – n (%)
SVR (TN/relapse, n=348) – n (%) 
SVR (NR/other, n=118) – n (%) 
SAE – n (%)
Sum of SAEs – median (IQR) 
AE – n (%)
Sum of AEs – median (IQR)
No of patients – n (%)
SVR (TN/relapse, n=348) – n (%)
SVR (NR/other, n=118) – n (%) 
SAE – n (%)
Sum of SAEs – median (IQR) 
AE – n (%)
Sum of AEs – median (IQR)
No of patients – n (%)
SVR (TN/relapse, n=348) – n (%) 
SVR (NR/other, n=118) – n (%) 
SAE – n (%)
Sum of SAEs – median (IQR) 
AE – n (%)
Sum of AEs – median (IQR)
No of patients – n (%)
SVR (TN/relapse, n=348) – n (%) 
SVR (NR/other, n=118) – n (%) 
SAE – n (%)
Sum of SAEs – median (IQR) 
AE – n (%)
Sum of AEs – median (IQR)
Eligible 
– n (%)
247 (53) 
137/186 (74) 
29/60 (48) 
28 (11)
0 (0-0)
211 (85)
2 (1-4)
102 (22) 
69/85 (81)
7/16 (44) 
12 (12)
0 (0-0) 
84 (82)
2 (1-4)
222 (48)
127/167 (76) 
26/54 (48) 
23 (10)
0 (0-0)
188 (85) 
2 (1-4)
289 (62)
158/214 (75) 
34/74 (46) 
38 (13)
0 (0-0)
253 (88) 
2 (1-4)
Ineligible 
– n (%)
220 (47) 
107/162 (66) 
23/58 (40) 
60 (27)
0 (0-1) 
199 (91) 
3 (1-5)
365 (78)
175/263 (67)
45/102 (44)
76 (21)
0 (0-0)
326 (89)
3 (1-4)
245 (52)
117/181 (65) 
26/64 (41) 
65 (27) 
0 (0-1) 
222 (91) 
3 (1-5)
178 (38)
86/134 (64)
18/44 (41)
50 (28)
0 (0-1)
157 (88)
3 (1-5)
p-value
0.12 
0.34 
<0.001 
0.001* 
0.097 
0.039*
0.01
0.98
0.04
0.034*
0.06
0.018*
0.02
0.41
<0.001
<0.001*
0.05
0.001*
0.06
0.59
<0.001
<0.001*
0.83
0.030*
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S7 Table. Exclusion criteria of registration trials in new generation DAAs
Table with exclusion criteria of new generation DAAs in comparison to our general criteria set
 † ULN = upper limit of normal; LLN = lower limit of normal; DAA = Direct-Acting Antiviral
General exclusion 
criteria set of our 
study
Decompensated liver 
disease
Platelets < 90 x109/L
Total bili > 1.8 xULN†
Serum albumin < 3.3 
g/dL
Significant cardiac 
disease
Hb <12 g/dL (females) 
or <13 g/dL (males)
Active or recent 
malignancy
Absolute neutrophil
count <1.2 x109/L
ION-1, ION-II
Clinical hepatic 
decompensation
Platelets < 50 
x109/L
Direct bili > 1.5 
xULN†
Serum albumin  
< 3.0 g/dL
Significant 
cardiac disease
Hb <11 g/dL 
(females) and 
<12 g/dL (males)
Active or recent 
malignancy
n/a
ION-III
 
Presence of 
cirrhosis
Platelets < 90 
x109/L
Direct bili > ULN†
Serum albumin  
< 3.0 g/dL
Significant 
cardiac disease
Hb <11 g/dL 
(females) and 
<12 g/dL (males)
Active or recent 
malignancy
n/a
Sapphire I, 
Pearl III, Pearl 
IV, Saphire II, 
Pearl II
Presence of 
cirrhosis
Platelets < 120 
x109/L
Indirect bili >1.5 
ULN and direct 
bili > ULN†
Serum albumin 
< LLN†
Significant 
cardiac disease
Hb < LLN†
Active or recent 
malignancy
Absolute 
neutrophil count 
<1.5 x109/L
Turquoise II 
(compensated 
cirrhotics)
Child Pugh-B, 
and -C cirrhosis
Platelets < 60 
x109/L
Total bili ≥ 3.0 
mg/dL
Serum albumin  
< 2.8 g/dL
Significant 
cardiac disease
Hb < LLN†
Active or recent 
malignancy
Absolute 
neutrophil count 
<1.5 x109/L
Paritaprevir/ritonavir, ombitasvir, 
dasabuvir
Ledipasvir/sofosbuvir
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S1 Figure. Effectiveness in real world treatment nonresponder and other patients 
who would be eligible and ineligible for registration trials
Primary and sensitivity analyses on effectiveness of therapy in eligible vs. ineligible nonresponder or 
other patients (n=118). For sensitivity analyses different criteria sets are used to determine eligibility 
of patients, hence different numbers of patients in groups.
Primary analysis Sensitivity analyses
p=0.34 p=0.59p=0.41p=0.98
Eligible
Ineligible
100
80
60
40
20
0
SV
R
 (%
)
   General             Strict           Strict co-     Prohibited 
 criteria set            criteria        morbidity    comedication
n=        60    58        16   102       54    64        74   44 
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Abstract
Background and Aims
Peginterferon (pegIFN) remains the backbone of therapy for chronic hepatitis C (CHC) 
in economically constrained regions. However, pegIFN may cause neutropenia and 
addition of a protease inhibitor can increase the likelihood of neutropenia. The aims 
of this study were to assess the occurrence of clinically relevant infections during first-
generation protease inhibitor based therapy and its risk factors as well as the relation to 
treatment-induced neutropenia.
Methods
This multicenter (n=45) retrospective cohort study included CHC patients treated in 
the Netherlands. Based on absolute neutrophil count, categories of neutropenia 
were defined: severe (<500/μL), moderate (500-750/μL) and mild (750-1500/μL). 
Likewise, infections were classified as severe (intravenous antibiotics/hospitalization) 
and moderate (anti-infective treatment). We assessed risk factors for infections using 
multivariable regression analysis with correction for multiple measurements.
Results
We included 467 CHC patients, 319 (68%) were male and 111 (24%) had cirrhosis. A 
total of 185 clinically relevant infections (34 severe) occurred in 145 patients (31%). 
During treatment 310 patients experienced neutropenia (34 severe). Multivariable 
analysis identified female sex (OR 1.7, 95%CI 1.2-2.5), COPD (OR 2.7, 95%CI 1.6- 4.5) and 
diabetes mellitus (OR 1.7, 95%CI 1.0-3.0) as risk factors for infections. Neutropenia at 
the previous visit was not associated with infection (univariable analysis: OR 0.9, 95%CI 
0.6-1.3).
Conclusion
This study shows that therapy with first-generation protease inhibitors was complicated 
by an infection in 31% of patients. Not neutropenia, but female sex, COPD and diabetes 
mellitus were independent risk factors for infection. These patients should be monitored 
carefully once a pegIFN regimen is initiated.
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Introduction
For many years pegylated interferon-α (pegIFN) has been the backbone of chronic 
hepatitis C (CHC) treatment. The introduction of first-generation direct acting 
antivirals (DAAs), telaprevir and boceprevir, initiated a cascade of developments of new 
generation DAAs.1 From 2014 onwards, pegIFN-free treatment options with higher cure 
rates and better tolerability have become available in many western countries.2 These 
new pegIFN-free regimens are very costly, limiting the availability in many economically 
deprived regions worldwide, where the majority of the global CHC population resides.3-6 
Guidelines still recommend telaprevir and boceprevir for use in countries where new 
generation DAAs are not available. Therefore, triple therapy still maintains its therapeutic 
value.7, 8
One of the drawbacks of triple therapy is its high rate of adverse events, which often 
can be attributed to the use of pegIFN. Neutropenia is frequently reported and mainly 
caused by bone marrow suppression.9, 10 To prevent infections, product labels and 
guidelines advise dose reductions or even discontinuation of treatment if neutrophil 
count drops below 750/μL or 500/μL respectively.7, 11 However, prior studies in CHC 
patients undergoing (peg)IFN and ribavirin (RBV) therapy did not find an association 
between treatment-induced neutropenia and infections, while dose reductions of 
pegIFN can reduce effectiveness.12-17 The situation may be different with triple therapy, 
because phase III studies found that the inclusion of boceprevir to the CHC treatment 
strategy increases the likelihood of neutropenia compared to pegIFN and RBV.18, 19 In 
addition, comparative studies found more neutropenia in boceprevir than telaprevir 
treated patients.20, 21 Real world data furthermore suggest that triple therapy substantially 
increases the risk of severe infections. However, the current evidence for this association 
is limited to CHC patients with cirrhosis.22-24 Therefore, the aims of this study were (i) 
to investigate the occurrence and risk factors for clinically relevant infections and (ii) 
the relation of on-treatment neutropenia with infections in CHC patients who received 
triple therapy with boceprevir or telaprevir.
Methods
Population and design
This nationwide, multicenter, real world cohort study included patients with a CHC 
genotype 1 infection treated with telaprevir or boceprevir and pegIFN and RBV in the 
Netherlands (2011-2015) [unpublished data]. Patients across all fibrosis stages were 
included. We retrospectively identified patients from local databases, and excluded 
patients with a co-infection with human immunodeficiency virus or hepatitis B virus. 
Treatment choice between telaprevir and boceprevir was at the discretion of the 
physician and it was administered according to national guidelines.25 We conducted 
the study in accordance with good clinical practice (GCP) guidelines, and the code of
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conduct for medical research (www.federa.org). Approval from participating centers 
was obtained following local regulations. 
Outcomes and definitions
The primary outcome of this study was occurrence of infections during treatment until 
4 weeks after cessation of treatment. Secondary outcomes were occurrence and severity 
of neutropenia, risk factors for infection, and severity of infection. In addition the time 
until occurrence of the first infection after start of treatment was assessed. Infections 
were classified as severe in case of hospitalization or intravenous antibiotics, moderate 
if oral or topical anti-infective agents were administered and mild if no treatment 
was given. Moderate and severe infections were considered clinically relevant. Based 
on the thresholds for dose reduction and treatment discontinuation of pegIFN, we 
distinguished three categories of neutropenia: severe if absolute neutrophil count (ANC) 
was below 500/μL, moderate if ANC was between 500 and 750/μL and mild if ANC was 
between 750 and 1500/μL.13, 25 We used Fib-4 > 3.25 to classify patients as cirrhosis, 
because of high performance in detecting cirrhosis and high availability of included 
biomarkers in the general population.26 History of decompensated liver disease was 
defined as a history of ascites, variceal bleeding or hepatic encephalopathy.
Data acquisition
We collected all details on demographics, disease characteristics, infectious (serious) 
adverse events, and laboratory values. Laboratory values included hematological tests, 
creatinine, aminotransferases, and indicators of liver function. In case two infections 
occurred within the same timeframe, we only included the most severe infection.
Statistical analysis
We described categorical variables as proportions and continuous variables as means 
(standard deviation, SD) or medians (interquartile range, IQR). The Kaplan-Meier 
method was used to assess time till occurrence of the first infection and the cumulative 
incidence rates of infections at 12 and 24 weeks after treatment initiation. Those time 
points were chosen as the introduction of new generation DAAs allows shortened use of 
pegIFN for 12 or 24 weeks.7 Chi-square tests were performed to compare occurrence of 
at least one clinically relevant infection between subgroups of patients with and without 
diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD) and cirrhosis. 
To identify predictors for clinically relevant infections we performed univariable and 
multivariable logistic regression analyses with correction for multiple measurements 
within a patient. Variables with a p-value ≤0.2 in univariable analysis were included in 
multivariable analysis together with age, sex, cirrhosis and DM as fixed factors (backward 
stepwise method, complete cases). ANC at the visit prior to the occurrence of infection 
was included in univariable analysis. Odds ratios (OR) with 95% confidence intervals 
(95%CI) are reported. As a sensitivity analysis, all reported infections were included.
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All analyses included the intention to treat population, and all tests were two-sided 
with a significance level of p < 0.05. The analyses were performed using SPSS (IBM SPSS 
Statistics 20) and SAS 9.3 (SAS Institute, Cary, NC, USA).
Results
Population
Our cohort study included 489 patients in total, of which 22 were excluded. Therefore 
467 patients from 45 centers in the Netherlands were analyzed (Supplementary Figure 
1). Patients were treated with telaprevir (n= 265) or boceprevir (n= 202) and pegIFN 
and RBV. Mean age was 51 years (range 19-77), 319 (68%) patients were male, and 111 
(24%) patients presented with cirrhosis. Baseline characteristics are shown in Table 1.
Table 1. Baseline characteristics
a Race: available in 360 patients (252 without infection, 108 with infection)
b Previous response: available in 454 patients (310 without infection, 144 with infection) 
c Fib-4 index: available in 438 patients (301 without infection, 137 with infection)
d Lab values >10% missings at baseline: neutrophil count, albumin
Characteristic
Age in years – mean (range) 
Male sex – n (%)
White race – n (%)a
HCV genotype – n (%)
   Genotype 1 indeterminate         
   Genotype 1a
   Genotype 1b
Treatment naive – n (%)b
Fib 4 index – median (IQR)c
Fib 4 > 3.25 – n (%)c
History of decompensated liver disease – n (%) 
Diabetes Mellitus – n (%)
Chronic Obstructive Pulmonary Disease – n (%) 
Telaprevir vs. boceprevir – n 
Laboratory valuesd
Hemoglobin g/dL – mean (SD) 
Leucocyte count per μL – mean (SD) 
Neutrophil count per μL – mean (SD) 
Platelet count x109/L – mean (SD) 
Albumin g/L – mean (SD)
Total bilirubin g/dL – median (IQR)
Overall 
(n= 467)
51 (19-77) 
319 (68) 
321 (89)
86 (18)
226 (48) 
155 (33) 
273 (60)
1.8 (1.1-3.3) 
111 (25)
24 (5)
54 (12)
37 (8)
265 vs. 202
9.1 (0.9) 
6727 (2154) 
3454 (1532) 
192 (76) 
41.4 (4.9) 
10.0 (7-14)
No infection 
(n =322)
50 (19-77) 
234 (73)
225 (89)
64 (20)
158 (49) 
100 (31) 
190 (61)
1.6 (1.1-2.9) 
67 (22)
9 (3)
30 (9)
16 (5)
186 vs. 136
9.2 (0.9) 
6827 (2152) 
3467 (1503) 
198 (78) 
41.8 (4.6) 
10 (7-14)
Infection 
(n =145)
52 (25-74) 
85 (59)
96 (91)
22 (15)
68 (47)
55 (37)
83 (58)
2.1 (1.3-4.1) 
44 (32)
15 (10) 
24 (17) 
21 (14) 
79 vs. 66
9.0 (0.9) 
6500 (2151) 
3423 (1606) 
179 (71) 
40.7 (5.5) 
10 (7-16)
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Infections
In total, 233 infections in 171 patients were reported (34 severe, 151 moderate, and 47 
mild), and thus 185 were clinically relevant occurring in 145 patients (31%). A total of 79 
of 265 telaprevir treated patients experienced 103 infections and 66 of 202 boceprevir 
treated patients experienced 82 infections. Incidence and severity of infections were 
similar for telaprevir vs. boceprevir (p=0.35, Figure 1). Main sites of infection were 
dermatological, respiratory, and gastro-intestinal (Table 2). In total, 34 severe infections 
were observed in 31 patients (21 telaprevir and 10 boceprevir treated patients). Sites 
and diagnoses of severe infections are listed in Table 3. Among patients with DM, COPD 
or cirrhosis, more infections were reported than patients without DM, COPD or cirrhosis 
(DM: 46% vs. 29%, p=0.010; COPD: 57% vs. 29%, p<0.001; cirrhosis 40% vs. 28%, p=0.024; 
Figure 2) 
Infection resulted in death in 2 patients: one patient was admitted with anemia and 
sepsis (bloodculture: Klebsiella and Staphylococcus Aureus) and died in-hospital while 
the other patient died from a mycotic endocarditis (bloodculture: Candida Parapsilosis). 
The median time to develop a clinically relevant infection was 14 weeks (IQR 6-26 
weeks). Cumulative incidence of infection within the first 12 weeks was 17.4% (95%CI 
12.9-21.9) for telaprevir treatment and 12.6% (95%CI 7.9-17.3) for boceprevir treatment 
(Figure 3). Overall, no significant differences were seen in the cumulative incidence of 
infections between telaprevir and boceprevir (p=0.712).
Figure 1. Severity of infection in telaprevir and boceprevir treated patients
The bars represent the percentage of patients who experienced a clinically relevant infection among 
the patients treated with either telaprevir or boceprevir. A total of 79 patients treated with telaprevir 
and 66 patients treated with boceprevir experienced an infection.
Neutrophil counts and infections
At baseline mean ANC was 3454/μL (SD 1532) and 21 (of 284 available measurements) 
patients had none-severe neutropenia. Only 5 (24%) of these patients developed an 
infection (1 severe). Neutrophil count dropped by an average of 2201/μL (SD 1339) 
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during treatment. A total of 310 (74%) of 419 patients with available ANC measurements 
(48 patients had no ANC tests available) experienced neutropenia during treatment. 
There were more neutropenia episodes in patients treated with boceprevir than with 
telaprevir (83% vs. 67%, p<0.001), and we detected a trend towards a higher cumulative 
incidence of severe neutropenia among patients treated with boceprevir (p=0.052, 
Figure 4). The median time to nadir neutrophil count per patient was 16 weeks (IQR 
8-24 weeks), this was similar for both DAAs.
In 127 of 185 (69%) clinically relevant infections, neutrophil count from the previous 
visit had been recorded and median neutrophil count prior to infection was 1600/μL 
(IQR 1.1-2.3). Overall, 57 times a clinically relevant infection was diagnosed (moderate 
n=50; severe n=7) in patients who had neutropenia in the preceding visit (89% mild). By 
contrast, 1456 visits with neutropenia (96%) were not followed by an infection. 
Table 2. Categories of clinically relevant infections (moderate and severe)
* Other includes: reproductive system (3), musculoskeletal (3), hepatobiliary (2), cardiac or circulatory (2), neutropenic 
fever.
Table 3. Sites and diagnoses of severe infections
Site of infection
Dermatological
Respiratory
Gastro-intestinal (incl. oral infections) 
Renal – Urinary tract
Ear Nose Throat
General
Ophtalmology 
Other*
Total
Total  Moderate  Severe
infections infections infections
45   40   5 
43   29   14 
38   36   2 
24   22   2 
10   10   0 
9   4   5
5   4   1  
11   6   5
185   151   34
Site of infection
Respiratory
General 
Dermatological
Renal – Urinary tract 
Gastro-intestinal (incl. oral infections) 
Ophtalmology
Other
No of 
infections
   14
   5 
   5
   2 
   2
   1 
   5
Diagnoses
Pneumonia (6), pneumonia and exacerbation 
chronic obstructive pulmonary disease (4), 
respiratory tract infection (3), viral pleuritis 
Sepsis, febris e causa ignota (3), fever after 
transfusion of packed cells 
Abcess, cellulitis, erysipelas, impetigo 
bacteremia, wound infection after sigmoid 
resection
Complicated urinary tract infection, urosepsis 
Tooth abscess, gastro-enteritis
Bacterial eye infection
Spontaneous Bacterial Peritonitis 
(SBP), neutropenic fever, endocarditis, 
staphylococcal sepsis after phlebitis, 
osteomyelitis
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Figure 2. Clinically relevant infections among patients with known risk factors
a)                b)
c)
The bars represent the percentage of patients who experienced a clinically relevant infection: 
2a) patients with and without diabetes mellitus (DM); 2b) patients with and without chronic 
obstructive pulmonary disease (COPD); 2c) patients with and without cirrhosis
Risk factors for infection
Results of univariable and multivariable logistic regression analysis are shown in Table 
4. Neutropenia at the previous visit was not associated with occurrence of infections 
(univariable OR 0.85, 95%CI 0.57-1.27). Furthermore moderate or severe neutropenia 
(ANC <750/μL) seemed to be predictive for infection (OR 0.45, 95%CI 0.20-0.99), however 
this was not significant in the multivariable model. The final multivariable analysis 
identified female gender (OR 1.7, 95%CI 1.2-2.5), COPD (OR 2.7, 95%CI 1.6-4.5) and 
presence of DM (OR 1.7, 95%CI 1.0-3.0) as risk factors for infections. The presence of 
cirrhosis did not reach significance (OR 1.4, 95%CI 0.9-2.1). When adding mild infections 
to the regression analysis, COPD and female gender remained risk factors, while DM lost 
significance (p= 0.11)
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Figure 3. Cumulative incidence of infections between telaprevir and boceprevir treated patients.
Kaplan-Meier curve showing the occurrence of the first clinically relevant infection during treatment 
within patients treated with either telaprevir or boceprevir. The 12-weeks and 24-weeks cumulative 
incidence rates are reported for both telaprevir and boceprevir (with 95% confidence interval).
Figure 4. Time to severe neutropenia between telaprevir and boceprevir treated patients.
Kaplan-Meier curve showing the development of severe neutropenia during treatment within 
patients treated with either telaprevir or boceprevir. The 12-weeks and 24-weeks cumulative 
incidence rates are reported for both telaprevir and boceprevir (with 95% confidence interval).
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Table 4. Logistic regression analysis with correction for multiple measurements within a patient.
OR=Odds Ratio; 95% CI= 95% Confidence Interval
Discussion
Our study demonstrates that a 24-48 week course with boceprevir or telaprevir, pegIFN 
and RBV for CHC is associated with a high incidence (31%) of clinically relevant 
infections. Within the first 12 weeks the cumulative incidence of infections was 13-17% 
depending on the type of protease inhibitor. Skin and respiratory infections were the 
most commonly seen. The infection incidence rates resemble rates of 12-26% which are 
reported in literature for pegIFN based therapy with and without a protease inhibitor, 
indicating the magnitude of this problem.12-14, 22-24, 27-29 The CUPIC cohort was the first 
cohort that signaled the high risk for severe infection with first-generation protease 
inhibitors in cirrhotic patients, and identified two important risk factors: baseline 
albumin below 35 g/L and baseline platelet count ≤ 100 x109/L.23 Of the cirrhotic 
patients in our cohort (n=111) 12 patients had both risk factors, and 5 (42%) developed 
a severe infection, comparable to the CUPIC cohort (51.4%). Presence of only one risk 
factor led to a severe infection in 22% (albumin < 35 g/L) and 8% (platelets ≤ 100 x109/L) 
of patients with cirrhosis, again resembling CUPIC data.23 Still, the combined risk factors 
were not identified as predictor for clinically relevant infections here. The independent 
factors that drove the risk for infection in our study were female sex, DM and COPD, 
but not neutropenia. The association of female sex with infections during CHC therapy 
has been reported previously and was explained by a higher incidence of urinary tract
Variable
Age
Female sex
Body mass index
Cirrhosis
Treatment experienced
Telaprevir vs. boceprevir
History of decompensated liver disease 
Diabetes mellitus
Chronic Obstructive Pulmonary Disease 
Use of corticosteroids at baseline 
Leucocyte count per μL
Neutrophil count per μL
Absolute neutrophil count < 1500 per μL 
Absolute neutrophil count < 750 per μL 
Baseline albumin, g/L
Albumin < 35 g/L
Platelet count x109/L
Platelet count < 100 x109/L
Albumin < 35g/L and platelet count 
< 100 x109/L)
Bilirubin, g/dL
Univariable 
OR (95% CI)
1.019 (0.997-1.042) 
1.728 (1.243-2.401) 
0.997 (0.933-1.064) 
1.767 (1.135-2.751) 
1.136 (0.758-1.702) 
1.144 (0.766-1.708) 
1.850 (0.838-4.082) 
1.737 (0.959-3.146) 
3.117 (1.811-5.366) 
2.312 (1.081-4.946) 
0.995 (0.903-1.096) 
1.066 (0.938-1.211) 
0.850 (0.570-1.266) 
0.448 (0.203-0.989) 
0.973 (0.925-1.024) 
1.608 (0.820-3.151) 
0.996 (0.993-0.999) 
1.619 (0.837-3.131)
3.091 (0.974-9.813)
1.001 (0.999-1.002)
p-value
0.091
0.001
0.917
0.012
0.537
0.510
0.128
0.069
<0.001
0.031
0.917
0.329
0.423
0.047
0.293
0.167
0.007
0.152
0.056 
0.388
p-value
0.006
0.116
0.047 
<0.001
  Multivariable 
  OR (95% CI)
1.722 (1.169-2.534)
1.398 (0.921-2.122)
1.734 (1.008-2.983)
2.701 (1.635-4.463)
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infections (UTIs) or vaginal infections.13, 27 Our findings are in agreement with these 
studies as 14% of clinically relevant infections were UTIs or vaginal infections (n=26) 
and 92% of these were observed in females. Another explanation might be the higher 
incidence of cirrhosis in females compared to males in our cohort (54% vs. 22%). 
Cirrhosis is established as risk factor for infection in literature, whilst our cohort only 
showed a trend for significance in multivariable analysis.30-32 The higher proportion 
of females with cirrhosis in our cohort might have influenced the regression analysis. 
Diabetes mellitus is a known risk factor for infection, but is also associated with CHC.33 
A higher infection rate in diabetic CHC patients was therefore hypothesized and can 
be explained by various factors, such as vascular insufficiency and impaired leukocyte 
function in these patients.12, 13, 34, 35 Our study implies that diabetic patients should be 
monitored for infection during CHC therapy. The only other triple therapy cohort study 
that assessed risk of infection was restricted to cirrhotics and found that respiratory 
infections were overrepresented in those on protease inhibitor therapy.22 Our cohort 
supports this finding, as respiratory infections accounted for 41% of severe infections 
and 19% of moderate infections. The identified risk factor COPD might relate to this, 
as COPD is a known risk factor for respiratory infections.36
The risk factors in our study (female sex, DM and COPD) are factors that cannot be 
influenced and are not related to the type of CHC therapy. They are furthermore identified 
by previous CHC cohorts with (peg)IFN and RBV regimes.12, 13, 36, 37 It is therefore likely 
that they remain risk factors for infection in future IFN-containing CHC regimes, thus 
these patients should be monitored carefully for infection during any pegIFN based 
regime.
Drug induced neutropenia is thought to be an important risk factor for infection. 
This stems from oncologic research as development of neutropenia following 
chemotherapy usually heralds a severe clinical situation necessitating admission and 
prompt administration of antibiotics.38 There is a wealth of literature that establishes 
that pegIFN induced neutropenia does not pose an increased risk for infections in CHC 
patients.12, 22, 39 Indeed, in our cohort neutropenia did not increase the risk of infection; it 
even seemed to be associated with a lower risk for infections. Altogether this suggests 
that neutropenia due to chemotherapy is different from that due to pegIFN. Oncology 
patients differ in factors which affect susceptibility for infection such as alteration of 
organ function caused by their underlying disease and presence of mucosal damage.40, 41 
Because these findings are absent in stable CHC patients, it is reasonable to believe that 
CHC patients receiving triple therapy are less immune- compromised than oncology 
patients and that thresholds for pegIFN dose reductions, based on the presence of 
neutropenia, may be too strict.
The advent of new generation DAAs allows to pinpoint the culprit for neutropenia in 
CHC. Neutropenia still occurs with any pegIFN containing regimen regardless of DAA 
included.42-45 IFN-free regimens do not cause neutropenia suggesting that pegIFN is 
the cause rather than CHC, DAA or RBV.43 Here, boceprevir had higher neutropenia
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rates than telaprevir. Whether this protease inhibitor interacts with PegIFN for inducing 
neutropenia or whether it is a class effect of the protease inhibitor cannot be assessed in 
this study. This finding should be interpreted with caution. Despite the higher incidence 
of neutropenia, infection rate was comparable between both drugs, confirming the lack 
of association between neutropenia and infections in CHC therapy. 
The strengths of this study are both the size of our real world cohort and its nationwide 
character. Unique to our cohort is that it includes CHC patients across all fibrosis stages 
in the Netherlands and is not limited to cirrhotic patients. Patients visited the clinic 
frequently resulting in detailed records. However, the retrospective design enhances 
the risk of reporting bias. We made an effort to minimize this risk by adhering to a strict 
definition of severity of infections and restricting our analysis to infections necessitating 
anti-infective therapy. Furthermore, telaprevir and boceprevir are first-generation DAAs 
that have lost market share in view of the advent of more effective and better tolerable 
new generation DAAs. However these drugs continue to be used in economically 
deprived countries that use pegIFN as a backbone for CHC therapy.46, 47
Conclusion
Our real world nationwide cohort study showed that the incidence of infections during 
pegIFN-based triple therapy is high, even among patients without cirrhosis. Neutropenia 
occurs frequently, but does not increase the risk for infection. Female gender, DM and 
COPD however, were risk factors for infection and are independent of type of CHC 
therapy, suggesting that these patients should be carefully monitored for infections 
once a pegIFN-based regimen is initiated.
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Abstract
Background
In many countries, treatment of chronic hepatitis C (CHC) continues to be based on 
pegylated interferon (pegIFN) and ribavirin, sometimes with addition of a protease 
inhibitor (PI). Thrombocytopenia is an important side effect of pegIFN and may lead 
to dose reductions out of fear for bleeding episodes. The primary aim of this study 
is to assess the incidence and risk factors for bleeding episodes in patients on first-
generation PI based therapy.
Methods
We established a nationwide retrospective cohort study of CHC patients who were 
treated with a first-generation PI in addition to pegIFN and ribavirin. We evaluated the 
cumulative incidence of bleeding episodes and thrombocytopenia (platelet count <150 
x109/L). Risk factors for bleeding episodes were identified through multivariable logistic 
regression analysis, adjusting for multiple measurements within a patient.
Results
This cohort contains 467 CHC patients, 319 (68%) male patients and 111 (25%) 
cirrhotics. Baseline thrombocytopenia was present in 139 (31%) patients and 379 (81%) 
patients experienced on-treatment thrombocytopenia (73 patients with platelet count 
<50 x109/L). Overall, 103 patients reported a bleeding episode which were mainly mild 
(topical or no treatment given). Cirrhosis (OR 2.2, 95%CI 1.4-3.5), platelet count below 
50 x109/L at the previous visit (OR 2.1, 95%CI 1.3-3.5) and female sex (OR 1.6, 95%CI 1.1-
2.5) were associated with a bleeding episode.
Conclusions
Risk factors for on-treatment bleeding episodes were female sex, presence of cirrhosis 
and a platelet count below 50 x109/L at the previous visit. PegIFN dose reductions during 
triple therapy should be considered thoroughly, as the majority of bleeding episodes 
were mild.
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Introduction
The development of direct-acting antivirals (DAAs) has revolutionized the treatment of 
chronic hepatitis C virus (CHC) infection. Peginterferon (pegIFN)-free and even ribavirin 
(RBV)-free regimens result in high rates of sustained virological response (SVR) while 
having excellent safety profiles.1, 2 The only factor that hampers global access to these 
drugs is pricing.3 Policy makers are forced to prioritize treatment to those patients 
who are considered to have an urgent need for successful antiviral therapy.4 In many 
countries, treatment of CHC infection still involves the combination of pegIFN and RBV, 
sometimes with the addition of a protease inhibitor (PI).5-8
Unfortunately, therapy with pegIFN and RBV is associated with many side effects, 
including haematological disorders. One of the major side effects is the development 
or aggravation of thrombocytopenia which is thought to contribute to the risk for 
bleeding episodes.9-11 Guidelines and the label advise to reduce the dose of pegIFN 
in case platelet count falls below 50 x109/L and to stop treatment when below 
25 x109/L.4,12 Therefore, onset of thrombocytopenia usually prompts pegIFN dose 
reductions curtailing its treatment efficacy for dual therapy with pegIFN and RBV.13-15 
Some studies question this dose-adaption strategy as major bleeding episodes have not 
occurred in a high frequency during pegIFN-based therapy.16-19 There are a number of 
reasons to revisit this issue. First, real-world studies have demonstrated that telaprevir or 
boceprevir based regimens come with high rates of adverse events, particularly among 
patients with cirrhosis.20-22 Moreover, a recent meta-analysis found that PI-based therapy 
amplifies the occurrence of thrombocytopenia.23 Whether triple therapy with telaprevir 
or boceprevir amplifies the risk for bleeding episodes is unknown. Therefore, the aims of 
this study were (i) to assess the incidence and risk factors for bleeding episodes during 
first-generation PI-based triple therapy, and (ii) to assess the influence of on-treatment 
thrombocytopenia on bleeding episodes.
Methods
Population and design
This nationwide cohort study includes patients with CHC genotype 1 treated between 
2011 and 2015 with first-generation PIs in the Netherlands.24 Patients were identified 
from local databases in 45 hospitals, and those co-infected with hepatitis B virus or 
human immunodeficiency virus were excluded. Due to the retrospective character of 
the study, formal approval was waived by the institute review board Arnhem-Nijmegen. 
Local regulations were followed per participating centre. The study was conducted 
following good clinical practice guidelines and the code of conduct (www.federa.org).
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Outcomes and definitions
The primary outcome of this study is the occurrence of bleeding episodes from start 
of therapy until 4 weeks after cessation of therapy. Secondary outcomes include: 
severity of bleeding episodes, occurrence and severity of thrombocytopenia, and risk 
factors for bleeding episodes (including on-treatment thrombocytopenia). We assessed 
time to the first bleeding episode and time to severe thrombocytopenia as current 
pegIFN containing regimes with DAAs allow shortened treatment durations.25 Bleeding 
episodes were defined as severe in case of death, hospital admission or transfusion of 
packed cells or thrombocytes; moderate when bleeding led to an intervention; and mild 
if topical or no treatment was required. Likewise, thrombocytopenia was categorized as 
severe if platelet count was below 50 x109/L, moderate if platelet count was between 
50 and 74 x109/L, and mild if platelet count was between 75 and 149 x109/L.16, 17, 26 
Conventional fibrosis assessment (liver biopsy or transient elastography) was missing in 
159 patients (34%), and therefore Fib-4 index > 3.25 was used to diagnose cirrhosis.27 
History of decompensated liver disease was defined as a history of ascites, hepatic 
encephalopathy, or variceal bleeding. We categorized bleeding sites by common 
terminology criteria for adverse events.28
Data acquisition
Data was collected from the patients medical records. We extracted demographic 
data, disease characteristics, bleeding episodes and laboratory values during and after 
treatment. When two bleeding episodes were reported between two visits, the most 
severe bleeding episode was included. Concomitant mediation at baseline affecting the 
risk of bleeding (vitamin K antagonists, heparin, thrombocyte aggregation inhibitors, 
vitamin K, and coagulation factors) was collected as well.
Statistical analysis
Variables were presented as mean, median or proportion depending on variable type. 
Differences between patients with and without cirrhosis, and with telaprevir vs. boceprevir 
treatment were assessed using Chi-square test. To identify risk factors for bleeding 
episodes, logistic regression analyses with correction for multiple measurements within 
one patient were performed. Age, sex, cirrhosis and variables with p ≤0.2 in univariable 
analysis were included in the multivariable analysis. Time to the first bleeding episode 
and severe thrombocytopenia were assessed using the Kaplan Meier method. Tests 
were two-sided with a significance level of p <0.05. The analyses were performed using 
SPSS (IBM SPSS Statistics 20) and SAS 9.3 (SAS Institute, Cary, NC, USA).
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Results
Population
In total, 489 CHC patients were included and 22 were excluded (Supplementary Figure 
1). Our cohort comprises 467 patients: 265 were treated with telaprevir and 202 with 
boceprevir based regimens (Table 1). It consists of 319 (68%) males and mean age was 
50.8 years (SD 9.6). The cohort included 111 (25%) patients with cirrhosis and 23 (5%) 
patients with hemophilia (9 classified as severe hemophilia with factor activity <1%).
Table 1. Baseline characteristics of patients with and without a bleeding episode
a Race: available for 360 patients; b Fib-4 score score: available for 438 patients; c Lab values >10% missings in: 
neutrophil count and albumin; d Platelet count at baseline: available for 446 patients
Bleeding episodes
A total of 130 bleeding episodes were reported in 103 (22%) patients. Of the 130 
episodes, 13 (10%) were classified as moderate and 10 (8%) as severe. Two patients, a 
63 year old male and 48 year old female, died following a hemorrhagic cerebrovascular 
accident (CVA). Both patients had cirrhosis and platelet count prior to the CVAs were 
76 x109/L and 35 x109/L, respectively. A total of 6 patients were 8 times admitted to 
the hospital due to a bleeding event (Table 2). Most frequent sites of bleeding events 
in general were gastro-intestinal (n=49), ear-nose-throat (n=48), and skin (n=21). The 
median time to the first bleeding episode was 8 weeks (IQR 4-16). 
Overall (n= 467)
51 (19-77) 
319 (68) 
321 (89)
1.8 (1.1-3.3) 
111 (25)
24 (5)
23 (5)
265 vs. 202
32 (7) 
22 (5)
9.1 (0.9)
6727 (2154)
3454 (1533)
192 (76)
139 (31)
41 (24-51)
Patients without 
bleeding (n= 364)
51 (21-77)
262 (72)
244 (90)
1.6 (1.1-2.9) 
74 (22)
16 (4)
17 (5)
200 vs. 164
25 (7) 
15 (4)
9.1 (0.9)
6770 (2190)
3508 (1513)
196 (78)
103 (30)
41 (24-51)
Patients with 
bleeding (n= 103)
51 (19-69) 
57 (55)
77 (88)
2.3 (1.3-6.8) 
37 (39)
8 (8)
6 (6)
65 vs. 38
7 (7) 
7 (7)
9.2 (0.8)
6571 (2022)
3283 (1590)
178 (67)
36 (37)
42 (27-50)
Characteristic
Age in years – mean (range)
Male sex – n (%)
White race – n (%)a
Fib 4 index – median (IQR)b
Fib 4 index > 3.25 – n (%)b 
Decompensated liver disease – n (%) 
Hemophilia – n (%)
Telaprevir vs. boceprevir – n
Baseline concomitant medication 
Use of anticoagulants – n (%) 
Use of hemostatics – n (%)
Laboratory valuesc
Hemoglobin g/dl – mean (SD)
Leucocyte count/μL – mean (SD)
Neutrophil count/μL – mean (SD)
Platelet count x109/L – mean (SD)
Thrombocytopenia at baseline 
(platelet count <150 x109/L) – n (%)d
Albumin g/L – mean (range)
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A higher proportion of patients with cirrhosis experienced at least one bleeding episode 
compared to patients without cirrhosis (33% vs. 18%, p=0.001; Figure 1). Multiple 
bleeding episodes (range 2-4) occurred in 19 patients. The total amount of bleeding 
episodes was numerically higher when telaprevir was a component of antiviral therapy, 
however non-significant (p=0.768, Figure 2). Cirrhotic patients treated with telaprevir had 
a higher cumulative incidence of bleeding episodes compared to boceprevir patients 
(p=0.029), this PI dependent difference was absent in non-cirrhotic patients (p=0.337). 
The 12-week and 24-week cumulative incidence of bleeding episodes among cirrhotic 
patients treated with telaprevir were 27.4% (95%CI 16.2-38.6) and 38.7% (95%CI 26.5-
50.9) respectively. Among the cirrhotic patients treated with boceprevir the 12-week 
and 24-week cumulative incidence of bleeding episodes were 12.2% (95%CI 3.0-21.4) 
and 18.4% (95%CI 7.6-29.2) respectively. Among cirrhotic female patients the 12-week 
and 24-week cumulative incidence of bleeding episodes were 25.0% (95%CI 13.2-
36.8) and 38.5% (95%CI 25.4-51.6) respectively. The 12-week and 24-week cumulative 
incidence of bleeding episodes among cirrhotic male patients were 16.9% (95%CI 7.3-
26.5) and 22.0% (95%CI 11.4-32.6) respectively (Figure 3).
Table 2. Sites and severity of bleeding episodes
a mainly rectal blood loss (n= 33) and gingival bleeding (n= 10)  b all epistaxis (n= 48)  c mainly hematomas (n= 20) 
d all hemoptoe (n=4)  e Severe bleeding episodes: hematemesis (3), rectal blood loss (1), epistaxis (3), hemorrhagic 
cerebrovascular accident (2), subdural hematoma (1) 
Figure 1. Occurrence of bleeding episodes according to the presence or absence of cirrhosis
The bars represent the proportion of patients who reported at least one bleeding episode according 
to the presence or absence of cirrhosis . In cirrhotic patients 37 (33%) of 111 reported a bleeding 
episode, while 59 (18%) of 327 patients without cirrhosis reported a bleeding episode. For 29 
patients cirrhotic status was missing.
Bleeding site
Gastrointestinala
Ear Nose Throatb
Skinc
Respiratoryd
Reproductive system
Central Nervous System
Renal
Total no of bleedings
Total
49
48
21
4
4
3
1
130
Mild
39
42
21
2
2
0
1
107
Moderate
6
3
0
2
2
0
0
13
Severee
4
3
0
0
0
3
0
10
no cirrhosis (n=327)     cirrhosis (n=111)
p=0.001
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Figure 2. Total amount and severity of bleeding episodes per protease inhibitor
The bars represent the number of bleeding events and the filling differentiates severity of these 
events. In total 79 (66 mild, 8 moderate, 5 severe) bleeding episodes were reported among 65 
patients treated with telaprevir and 51 (41 mild, 5 moderate, 5 severe) among 38 patients treated 
with boceprevir.
Risk factors for bleeding episodes
Multivariable regression analysis revealed three independent risk factors for on-
treatment bleeding episodes (Table 3): presence of cirrhosis (odds ratio (OR) 2.2, 95% 
confidence interval (CI) 1.4-3.5), severe thrombocytopenia at the previous visit (OR 2.1, 
95%CI 1.3-3.5) and female sex (OR 1.6, 95%CI 1.1-2.5). Hemophilia, type of PI or use of 
anticoagulant medication were not associated with the risk for bleeding episodes.
Thrombocytopenia and bleeding episodes
In our cohort, baseline thrombocytopenia was present in 139 (31%) patients (7 moderate, 
4 severe). Fifty-four (39%) of these patients developed severe thrombocytopenia in 
addition to the 4 patients who had severe thrombocytopenia at baseline. Only one 
of these 4 patients accomplished the therapy of 48 weeks, the others discontinued 
treatment early at week 3, 4 and 37 respectively, and none of them reported a bleeding 
episode. From the patients with normal or missing platelet count at baseline (n=307 and 
n=21), 240 developed thrombocytopenia. Thus, overall 379 patients (81%) experienced 
on-treatment thrombocytopenia (moderate n=80, severe n=73). This was independent 
of telaprevir or boceprevir use (Figure 3). Median drop of thrombocyte count was 81 
x109/L (IQR 56-116 x109/L), and median time to reach nadir platelet count was 12 weeks 
(IQR 8-24). Platelet count was available for 4719 (95%) visits, and laboratory results 
were consistent with thrombocytopenia in 2847 (60%) of those visits (300 visits severe 
thrombocytopenia). After 89 (3%) of the 2847 visits with thrombocytopenia, a bleeding 
episode was reported at the subsequent visit, meaning that 2758 (97%) of the visits 
were not followed by a reported bleeding event. Moreover, 24 (8%) of the 300 visits with 
severe thrombocytopenia were followed by a reported bleeding episode. In addition, 
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40 bleeding events were reported with a normal platelet count at the preceding visit. 
Median platelet count at the visit prior to a bleeding episode was 98 x109/L (IQR 56-163 
x109/L). 
Figure 3. Cumulative incidence of bleeding episodes and severe thrombocytopenia
Kaplan-Meier curves showing the occurrence of bleeding episodes (panel a and b) and severe 
thrombocytopenia (panel c and d). The dashed vertical lines represent the 12-week and 24-week 
time points. Panel a and b demonstrate the time to the first bleeding episode according to the 
cirrhotic status for the use of telaprevir or boceprevir (TVR, BOC, a) and for males and females (b). 
Panel c and d demonstrate the occurrence of severe thrombocytopenia for patients treated with 
TVR and BOC (c) and for males and females (d), based on the presence and absence of cirrhosis. The 
table below shows the 12-week and 24-week cumulative incidences of the first bleeding episode 
and severe thrombocytopenia for each subgroup (presented as % (95%CI). 
No cirrhosis
Cirrhosis
First bleeding episode        Severe thrombocytopenia
Boceprevir 
Telaprevir 
Male 
Female 
Boceprevir 
Telaprevir 
Male 
Female
12-week 
cumulative 
incidence
9.3 (4.4-14.2)
16.6 (11.3-21.9) 
11.0 (7.1-14.9)
20.0 (11.8-28.2) 
12.2 (3.0-21.4) 
27.4 (16.2-38.6) 
16.9 (7.3-26.5) 
25.0 (13.2-36.8)
24-week 
cumulative 
incidence
11.4 (6.1-16.7) 
19.3 (13.6-25.0) 
13.5 (9.2-17.8) 
22.2 (13.6-30.8) 
18.4 (7.6-29.2) 
38.7 (26.5-50.9) 
22.0 (11.4-32.6) 
38.5 (25.4-51.6)
12-week 
cumulative 
incidence
no events
1.3 (0.1-3.1)
no events
2.7 (0.0-6.4) 
20.2 (8.4-32.0) 
12.8 (3.2-22.4) 
22.4 (10.6-34.2) 
9.8 (0.8-18.8)
24-week 
cumulative 
incidence
1.0 (0.0-3.0)
3.9 (0.0-8.0)
2.2 (0.0-4.7)
2.7 (0.0-6.4) 
31.9 (17.2-46.6) 
48.3 (31.6-65.0) 
43.5 (28.2-58.8) 
34.4 (18.1-50.7)
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Table 3. Regression analysis with correction for multiple measurements within a patient.
OR: Odds Ratio; 95%CI: 95% confidence interval
Discussion
One of our key findings is that ~20% of patients experienced at least one bleeding 
episode during 24-48 weeks of triple therapy with a first-generation PI, pegIFN and 
RBV. The majority of these bleeding episodes were mild and required no or only topical 
treatment. Overall cumulative incidence of bleeding episodes was 15% (95%CI 12-19) 
at 12 weeks and 19% (95%CI 16-23) at 24 weeks of therapy. We found that the presence 
of cirrhosis, severe on-treatment thrombocytopenia at the previous visit, and female sex 
were associated with an increased risk for a bleeding event during therapy.
The proportion of patients experiencing a bleeding episode in our study (~20%) was 
higher than reported with pegIFN and RBV dual therapy (8-10%). The difference is that 
these cohorts included only patients with advanced fibrosis, while sex distribution and 
incidence of thrombocytopenia were comparable to our cohort.16, 17, 19 The addition of a 
PI in our cohort might be an explanation for the higher incidence of bleeding episodes.
Cirrhosis was an independent risk factor for bleeding episodes in our cohort with 
patients of all fibrosis stages. These results are in line with findings from (peg)IFN 
with or without RBV treated cohorts.16, 17 Previous studies attempted to explain the 
balance of bleeding risk and hypercoagulation in cirrhotic patients. It is thought that 
thrombocytopenia, defective platelet aggregation but also hemodynamic alterations, 
endothelial dysfunction, bacterial infections and renal failure contribute to bleeding 
tendency in cirrhotics.29, 30  Severe thrombocytopenia was a second predictor of bleeding
Variable
Age
Female gender
Body mass index
Hemophilia
Diabetes Mellitus
Cirrhosis
History of decompensated liver disease
Use of anticoagulants
Use of hemostatics
Treatment experienced
Telaprevir vs. boceprevir
Platelets
Platelet count < 100 x109/L at previous visit 
Platelet count < 50 x109/L at previous visit 
Baseline albumin
Albumin < 35 g/L
Albumin < 35g/L and platelet count < 100 
x109/L)
Bilirubin
Univariable 
OR (95% CI)
1.004 (0.986-1.023) 
1.987 (1.326-2.977) 
0.957 (0.739-1.240) 
1.144 (0.527-2.485) 
0.648 (0.319-1.313) 
2.909 (1.903-4.446) 
1.494 (0.704-3.167) 
1.268 (0.409-3.927) 
1.855 (0.854-4.030) 
0.720 (0.465-1.116) 
1.369 (0.860-2.178) 
0.995 (0.992-0.998) 
1.721 (0.875-3.382) 
3.486 (2.213-5.491) 
1.000 (0.999-1.001) 
2.101 (1.044-4.227)
1.673 (0.545-5.139) 
1.000 (0.999-1.001)
p-value
 0.651
 <0.001
 0.741
 0.734
 0.228
 <0.001
 0.296
 0.681
 0.119
 0.142
 0.186
 0.002
 0.116
 <0.001
 0.419
 0.038
 0.369 
 
0.788
p-value
 0.026
 
0.001
 0.005
 Multivariable
 OR (95% CI)
1.632 (1.060-2.513)
2.181 (1.356-3.508)
2.097 (1.257-3.498)
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episodes in our cohort and was experienced by 73 (16%) patients. Thrombocytopenia 
can be caused by the hepatitis C virus, liver cirrhosis and pegIFN. Suggested mechanisms 
involved are: decreased thrombopoietin activity, immune dysfunction, bone marrow 
suppression by the hepatitis C virus or pegIFN, and splenic platelet sequestration in 
case of portal hypertension.10, 31, 32 Female gender was the third identified risk factor. 
An increased incidence of bleeding episodes in females is not only observed during 
CHC therapy but is reported more frequently in literature, for example after invasive 
cardiovascular procedures.16, 33, 34 An extensive review has investigated sex differences 
and noted that bleeding time is increased in females, possibly due to sex hormone 
induced altered platelet activity.35
It is thought that pegIFN is the most likely agent to cause thrombocytopenia or 
aggravation of thrombocytopenia due to myelosuppression.10, 36 Incidence rates up to 
48% are reported in literature.19, 37, 38 Current available pegIFN free regimens support 
this hypothesis as therapy induced thrombocytopenia has not been reported by several 
landmark studies, while pegIFN containing regimens with new generation DAAs still 
report thrombocytopenia.39, 40 Dose reductions of pegIFN are recommended to prevent 
bleeding episodes, but this curtails effectiveness.13-15 Other options to improve platelet 
count are treatment with thrombopoietin receptor agonists, such as eltrombopag or 
avatrombopag, however their use is limited due to the risk of hepatic decompensation 
and tromboembolic events.41, 42
We specifically assessed a cohort treated with two different PIs added to pegIFN and 
RBV and assessed the influence of the drugs on thrombocytopenia and bleeding events. 
Whereas there was no difference in cumulative incidence of severe thrombocytopenia 
between both drugs, we found higher proportion of bleeding episodes in telaprevir 
treated cirrhotic patients. There were no differences in patient characteristics and 
particularly sex, cirrhosis and platelet counts were comparable between patients 
treated with telaprevir or boceprevir. The literature indicates that the pharmacokinetics 
of telaprevir is independent from presence of cirrhosis.43 Hence, it is possible that the 
risk for bleeding is a class effect of PIs. Future studies in cirrhotic patients with new 
generation PIs, such as simeprevir, grazoprevir or paritaprevir may provide evidence 
whether there is a synergistic effect of some PIs to pegIFN or whether the effect is PI 
specific.
Our study comes with some strengths and limitations. Strengths are the size of the 
cohort with patients across all fibrosis stages, and the high number of visits resulting in 
detailed data within a long timeframe. The nationwide character with both academic 
and regional hospitals results in a representative cohort of patients. Limitations include 
the retrospective design which can lead to reporting bias. By defining bleeding episodes 
carefully we sought to reduce this bias and probably only mild bleeding episodes were 
missed. Further, although pegIFN-free regimens are available, many countries still 
use pegIFN as backbone hence our results remain applicable to clinical practice.8, 44
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Conclusions
Bleeding episodes occurred frequently (22%) among patients in this real world CHC 
cohort who were treated with triple therapy. Female sex, the presence of cirrhosis and 
platelet count below 50 x109/L were associated with an increased risk for bleeding 
episodes, which were however mostly mild. PegIFN dose reductions during triple 
therapy should be considered thoroughly.
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Supplementary Figure 1. Study flowchart
This supplementary figure was published before (Berden, F; van Zwietering, I; Maan, R; de Knegt 
R; Kievit, W; Drenth, J; High Risk of Infection During Triple Therapy with First-Generation Protease 
Inhibitors: A Nationwide Cohort Study. J Gastrointestin Liver Dis, June 2016 Vol. 25 No 2.)
 Nationwide 47 hepatitis treatment centers
 Exclusion of centers:
 - 1 center: no treated patients
 - 1 center: tardily assessment      
   of study protocol
 Datacollection in 45 centers (8 academic)
 489 patients identified
 22 patients excluded:
 - 5 no consent
 - 6 treatment not finished at 
   time of data collection
 - 4 treatment in another center
 - 3 missing files
 - 2 peginterferon/ribavirine 
   instead of triple therapy
 - 2 HBV co-infected
 467 patients received at least one dose of  
 telaprevir (n=265) or boceprevir (n=202)
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To the editor:
The development of direct acting antivirals (DAAs) for chronic hepatitis C (HCV) 
infection was supported by many registration trials. However, trial patients appeared to 
be different from real world patients, and this puts limits on generalization. The first-
generation DAAs, while effective and safe in trials, were less effective and more toxic in 
HCV patients with advanced liver disease.1 Previously, we suggested that strict eligibility 
criteria of trials contributed to the gap between trials and practice.2 The newer DAA 
regimens are highly effective and come with a better safety profile. We hypothesize 
that eligibility criteria of DAA registration trials have become more lenient over time, 
contributing to a better generalizability.3
To assess the eligibility rate (proportion of patients fulfilling inclusion and exclusion 
criteria) over time, we checked eligibility criteria of DAA registration trials against the 
profile of a real world HCV cohort (n=177). We identified 43 registration trials of approved 
DAAs based on the labels of U.S. Food and Drug Administration (FDA) and European 
Medicines Agency (EMA), and we were able to access full eligibility criteria of 34 trials. 
Eligibility per patient was determined on the thresholds of seven criteria per trial: 
decompensated liver disease, cirrhosis, bilirubin, albumin, hemoglobin, platelet and 
neutrophil count. These factors were repeatedly identified as predictors for response in 
real world cohorts with DAA regimens, indicating that these criteria are indeed relevant 
to generalizability of outcomes.2, 4 
In Figure 1 we plotted the eligibility rate of 34 registration trials with nine DAA regimens 
against the start date of inclusion. Some points merit attention. First, the eligibility 
rate of trials has improved over time. Linear regression analysis demonstrates a positive 
association between eligibility rate and time in months (intercept=70.9; slope=0.18, 
p=0.02). Second, in some regimens (e.g. sofosbuvir/daclatasvir, blue circles in Figure 1) 
we saw that later trials had less stringent inclusion criteria than trials that commenced 
recruiting earlier. Although the exact reasons for lowering the threshold are unknown, 
we believe this might depend on factors such as progressing safety knowledge, market 
opportunities, requests from the field or authorities. Third, the circle size is decreasing 
over time, indicating that trials that started later, had fewer patients. Lastly, highest 
eligibility rates (96-99%) were seen in trials allowing decompensated cirrhotics (ALLY-
1/ASTRAL-4). Our findings are corroborated by real world cohorts that report similar 
effectiveness as registration trials.4, 5
In conclusion, the eligibility criteria of registration trials testing DAAs for HCV became 
less strict over time. This has closed the once existing gap between trials and real world. 
Registration trials should cover the complete phenotypical spectrum of a disorder to 
result in high eligibility rates. Predictors of response are related to the eligibility criteria 
affecting outcomes, thus mainly these criteria should be lenient.
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Figure 1. Eligibility rate of hepatitis C patients for DAA trials over time
This figure shows that the proportion of real world patients who are eligible for registration trials 
(y-axis) testing DAAs (colors) improved over time (x-axis). The size of the circles represents the 
number of patients per registration trial. 
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Abstract
Background
Direct-acting antivirals have improved treatment of chronic hepatitis C virus infection 
significantly. Direct-acting antivirals inhibit/induce and can also be substrates of, 
drug-metabolizing enzymes and transporters. This increases the risk for drug-drug 
interactions.
Objective
The purpose of this study was to predict drug-drug interactions with co-medication 
used by hepatitis C virus-infected patients.
Methods
We assembled a nationwide cohort of hepatitis C patients and collected cross-sectional 
data on co-medication use. We compiled a list of currently available direct-acting 
antiviral regimens and cross-checked for potential drug-drug interactions with used 
co-medication.
Results
The cohort included 461 patients of which 77% used co-medication. We identified 260 
drugs used as co-medication. Antidepressants (7.4%), proton pump inhibitors (7.1%), 
and benzodiazepines (7.1%) were most frequently used. Of the patients, 60% were 
at risk for a clinically relevant drug-drug interaction with at least one of the direct-
acting antivirals regimens. Interactions were most common with paritaprevir/ritonavir/
ombitasvir/dasabuvir and least interactions were predicted with grazoprevir/elbasvir.
Conclusion
Co-medication use is rich in frequency and diversity in chronic hepatitis C patients. 
The majority of patients are at risk for drug-drug interactions which may affect efficacy 
or toxicity of direct-acting antivirals or co-medication. The most recently introduced 
direct-acting antivirals are associated with a lower risk of drug-drug interactions.
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Introduction
Treatment of hepatitis C virus (HCV) infected patients has significantly improved with 
the introduction of direct-acting antivirals (DAAs). DAAs have the disadvantage that 
they can be involved in drug-drug interactions (DDIs) with patients’ co-medication. DDIs 
might increase the risk for toxicity or result in poorer efficacy.1, 2 The mechanism is 
twofold: DAAs can both be victim and/or perpetrator of DDIs. Drugs are victims of DDIs 
when their plasma concentration is affected by another drug. In contrast, drugs are 
perpetrators when they have the ability to influence plasma concentrations of drugs, for 
example by inhibiting or inducing metabolizing enzymes and/or drug- transporters.3, 4 
DAAs inhibit various cytochrome P450 (CYP) enzymes, responsible for drug metabolism 
(Table 1). The clinical importance of DDIs was illustrated by the interaction between 
sofosbuvir-based DAA therapy and amiodarone, resulting in severe bradycardia.5, 6 This 
report and other similar papers indicate that there is a genuine risk for relevant DDIs in 
patients treated with DAAs who use co-medication.5-11
The toxicity profiles of the currently used interferon-free DAA combinations, improved 
significantly relative to the DAAs combined with peginterferon and ribavirin. Nowadays, 
more HCV patients with complex co-morbidities and thus co-medication receive antiviral 
treatment.12 The combination of DAAs and many other drugs obviously increases the 
risk for DDIs. To date, limited data is available about the extent of co-medication use by 
HCV patients and the risk of DDIs as a consequence. Therefore, the aim of this study is to 
identify the co-medication use in a nationwide real-life HCV cohort in order to predict 
clinically relevant DDIs between co-medication and new DAA regimens.
Table 1. Overview of enzymes and drug transporters involved in the metabolism and transport of 
DAAs used for the treatment of hepatitis C.
?: Unknown if the inhibition/induction is clinically relevant. DAA: Direct Acting Antiviral, CYP: cytochrome P450, BCRP: 
breast cancer resistance protein , P-gp: P-glycoprotein , UGT: uridine diphosphate glucuronosyltransferase , OATP: 
organic anion-transporting polypeptide
Direct-acting Antiviral
Daclatasvir
Dasabuvir
Elbasvir
Grazoprevir 
Ledipasvir
Ombitasvir 
Paritaprevir/ritonavir
Simeprevir
Sofosbuvir 
Velpatasvir
Victim (= substrate of)
CYP3A4/5, P-gp
CYP2C8, CYP3A4, P-gp, BCRP 
CYP3A, P-gp
CYP3A, P-gp, OATP1B1/3 
Pg-p, BCRP
-
CYP3A4/5, P-gp, OATP1B1/3, 
BCRP
CYP3A4/5
P-gp, BCRP
P-gp, BCRP, CYP2B6, 
CYP2C8, CYP3A4
Perpetrator
Inhibitor
P-gp, OATP1B1 
UGT1A1, BCRP, P-gp
-
CYP3A (?)
P-gp, BCRP
UGT1A1
CYP3A4/5, UGT1A1, 
CYP2D6(?),OATP1B1/3, 
OATP2B1, BCRP 
CYP3A4/5, CYP1A2, P- gp, 
OATP1B1/3
-
P-gp, BCRP, OATP1B1/2, 
OATP2B1
Inducer
CYP2C19
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Methods
We performed this research in three steps: (a) we identified which co-medication were 
used by HCV-infected patients in a real-world cohort; (b) in order to predict DDIs we 
cross-checked the co-medication with DAAs in the database of the University of Liverpool 
(www.hep-druginteractions.org); and (c) we assessed the risk for DDIs per patient. For 
this type of study (retrospective) formal consent was not required. Formal evaluation 
was waived by the institutional review board Arnhem-Nijmegen. Good Clinical Practice 
guidelines and the code of conduct for the use of data in health research were followed 
(www.federa.org).
Patients and use of co-medication
Data from a nationwide, real-life cohort were used.13 This cohort included Dutch patients 
treated for an HCV genotype 1 mono-infection. Patients were identified based on local 
databases present in 45 hepatitis treatment centers in the Netherlands. Data collection 
was performed between January 2014 – July 2015. Baseline data were extracted from 
the patient’s medical record and included patient characteristics, medical history, 
HCV genotype and co-medication use prior to commencement of HCV treatment. 
Patients were excluded when data on co-medication use was missing and if patients 
had a co-infection with HIV or hepatitis B virus. In addition to prescribed medication, 
we included complementary and alternative medicine (CAM) when available in the 
medical record. Separate compounds of fixed-dose products were registered, except 
for CAMs, these were counted as one, even though they may have contained several 
chemical compounds. We did include drugs taken as part of a substance abuse disorder 
(e.g. methadone), although illicit drugs such as heroin or cocaine were not collected. 
We added Anatomical Therapeutic Chemical (ATC) codes to all co-medication reported 
in the patient’s medical record, and grouped the drugs by therapeutic/pharmacological 
subgroups.14
Predicted drug-drug interactions with DAAs
The co-medication was cross-checked with currently approved DAA regimens in Europe 
and USA through the University of Liverpool database in an effort to predict DDIs (July 
2016). The University of Liverpool database is a commonly used resource to check for 
DDIs.4, 15 For cross-checking we included approved DAA regimens effective against 
HCV genotype 1: sofosbuvir plus simeprevir, sofosbuvir plus daclatasvir, sofosbuvir plus 
ledipasvir, paritaprevir/ritonavir, ombitasvir plus dasabuvir, elbasvir plus grazoprevir, and 
sofosbuvir plus velpatasvir. Ribavirin and first-generation protease inhibitors were not 
taken into account. Ribavirin is considered not to cause any DDIs in this population as 
is not metabolized by or influencing any of the drug metabolizing enzymes and the 
included patients do not use nucleoside reverse transcriptase inhibitors (NRTIs).16 The 
first-generation DAAs are considered outdated. 
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We used four risk categories corresponding with the University of Liverpool database: 
1) No clinically significant interaction; 2) Potential interaction - may require close 
monitoring, alternation of drug dosage or timing of administration; 3) Contraindication, 
i.e. drugs should not be co-administered; 4) Unknown, as not available in the Liverpool 
database. For these unavailable drugs, the pharmacists (ES and DB) judged if there 
might be risk of a DDI. Pharmacokinetic parameters of these drugs were used (US FDA 
prescribing information and MicroMedex®) to evaluate these interactions. Overall, we 
defined Category 2 and 3 as the clinically relevant DDIs.17
Risk for drug-drug interactions per patient
To assess the number of patients at risk for a clinically relevant DDI, we counted the 
patients with at least one predicted DDI between co-medication and one of the DAA 
regimens. Further, we compared the risk for DDI between subgroups of patients: (a) 
patients aged < 65 years vs. ≥ 65 years17, and (b) in patients with vs. without cirrhosis. We 
used Fib-4 index > 3.25 to classify patients as cirrhotic.18
Analyses
Descriptive analyses were performed with frequency counts and proportions. For the 
subgroup analyses we used chi-square tests. All analyses were performed in SPSS (IBM 
SPSS Statistics 20).
Results
Patients and use of co-medication
This cohort included 467 patients; we excluded 6 patients from the analysis because 
data on co-medication was missing. There were 313 males and the mean age was 
51 years (Table 2). A total of 356 patients (77%) used co-medication at start of HCV 
therapy and 105 patients did not use any co-medication. The number of medications 
per patient ranged from 1 - 17 (median 2). Of the cohort, 12% used ≥6 medications at 
start of HCV therapy. Overall, the 356 patients had a total number of 1329 prescriptions 
(including CAMs), which comprised 260 different drugs (Figure 1). Most frequently used 
co-medication were antidepressants, proton pump inhibitors (PPIs), benzodiazepine 
derivatives, and drugs for opioid dependence (Table 3).
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Table 2. Patient characteristics
a Race: available in 352 patients; b previous response: available in 448 patients, c FIB-4 index: available in 437 patients, 
d creatinine clearance: available in 407 patients.
Table 3. Most frequently used (>2.0%) concomitant medications at start of hepatitis C treatment.
a Percentage is calculated using the total number of prescriptions in this cohort (n = 1329), ACE: Angiotensin I 
converting enzyme, ATC: Anatomical Therapeutic Chemical
Predicted drug-drug interactions with direct-acting antivirals
We used our cohort to predict DDIs between co-medication and DAA regimens. Figure 
1 presents the distribution of the DDI categories per DAA regimen for 260 different 
drugs. The combination of grazoprevir plus elbasvir and sofosbuvir plus velpatasvir had 
the lowest number of predicted DDIs in our mono-infected cohort. Grazoprevir plus 
elbasvir and sofosbuvir plus daclatasvir had no contraindicated drugs (Category 3) and 
no clinical significant interactions were predicted with 72% and 63%, respectively, of 
the concomitantly used drugs (Category 1).
Characteristic
Age, years – mean (range)
Age ≥ 65 years – n (%)
Male sex – n (%)
Caucasian – n (%)a
Treatment naive – n (%)b
Decompensated liver disease – n (%) 
FIB-4 index > 3.25 (cirrhosis) – n (%)c 
Creatinine clearance < 30 ml/min – n (%)d
Overall (n=461)
51 (19-77) 
30 (7)
313 (68) 
316 (90) 
269 (58) 
23 (5)
115 (26)
3 (1)
Drug class
Antidepressants (both tricyclic antidepressants and 
selective serontonin reuptake inhibitors (e.g. amitryptiline, 
sertraline) 
Proton pump inhibitors (e.g. omeprazole)
Benzodiazepine derivatives (e.g. diazepam, flurazepam) 
Drugs used in opioid dependence (e.g. methadone)
Selective beta-2-adrenoreceptor agonists (respiratory 
agents both systemic and inhalants e.g. salbutamol)
Antipsychotics (e.g. olanzapine, risperidon)
Vitamin D and analogues (e.g. colecalciferol) 
Thiazides (e.g. hydrochlorothiazide)
Selective beta blocking agents (e.g. metoprolol) 
ACE inhibitors (e.g. enalapril)
Glucocorticoids (respiratory sytem e.g. beclometasone) 
Biguanides (e.g. metformin)
Platelet aggregation inhibitors excl. heparin (e.g. 
acetylsalicylic acid)
Dihydropyridine derivatives (calcium channel blockers e.g. 
amlodipne)
ATC-code (4rd level)
N06AA, N06AB, N06AX
A02BC
N05BA, N05CD 
N07BC
R03AC, R03CC
N05AA, N05AB, N05AD, 
N05AF, N05AH, N05AL, 
N05AN, N05AX
A11CC
C03AA 
C07AB 
C09AA 
R03BA 
A10BA 
B01AC
C08CA
n (%)a
98 (7.4)
94 (7.1) 
94 (7.1) 
74 (5.6) 
55 (4.2)
46 (3.5)
38 (2.9) 
34 (2.6) 
32 (2.4) 
32 (2.4) 
32 (2.4) 
27 (2.0) 
26 (2.0)
26 (2.0)
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Figure 1. Overview of concomitant medication and predicted number of drug-drug interactions 
(DDIs) between the direct-acting antiviral combinations of regimens and 260 different compounds
Sofosbuvir (SOF), simeprevir (SIM), and daclatasvir (DCV) are licensed as separate compounds 
for hepatitis C virus (HCV) infected patients. These drugs are separately available in the Liverpool 
database. However, we present these regimes together, because in clinical practice these drugs 
are used in combination. DDIs with PTV/r, OBV plus DSV (paritaprevir/ritonavir, ombitasvir plus 
dasabuvir), ledipasvir (LDV) plus SOF, velpatasvir (VEL) plus SOF, and elbasvir (EBR) plus grazoprevir 
(GZR) were available per combination in the Liverpool database.
The combination of paritaprevir/ritonavir, ombitasvir plus dasabuvir had the most 
contraindications (4%), followed by simeprevir (2%), and velpatasvir (1%). Category 
2 interactions were also mainly predicted with the regimen containing paritaprevir/
ritonavir, ombitasvir plus dasabuvir (33%) and sofosbuvir plus simeprevir (26%). 
Interestingly, ~90% of these category 2 DDIs have not been studied in vivo. These potential 
interactions were predicted by the pharmacologist of the University of Liverpool database, 
based on the characteristics of the drugs. The top 5 medications which can cause 
clinically relevant DDIs with at least one of the antiviral regimens are shown in Table 4.
461 HCV patients included
105 patients (23%) did 
not use comedication
356 patients (77%) used comedication
total number of 1329 prescriptions
Assessment of risk on DDI for 6 HCV regimes
260 different drugs
EBR+GZR  VEL+SOF  DCV+SOF  LDV+SOF  SIM+SOF   PTV/r+
                        OBV+DSV
Category 1: no interaction
Category 2: potential interaction
Category 3: contraindication
Category 4: unknown whether 
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The risk of DDIs could not be assessed in 60 of the 260 different drugs (Category 4), 
because the drugs were not listed in the University of Liverpool database (July 2016). The 
top three of therapeutic subgroup (2nd ATC level) in Category 4 were antihemorrhagics 
(B02; e.g. coagulation factors), vitamins (A11; e.g. colecalciferol), and psycholeptics (N05; 
e.g. flunitrazepam) which were used by a total of 17, 33, and 13 patients, respectively.
The pharmacists (ES and DB) judged if there were potential interactions with these 
60 drugs and DAAs. We predicted that 11 drugs had a potential interaction, 30 drugs 
would not cause interactions, and for 19 drugs it is unknown if there is a potential 
interaction (for example: metabolism not known of the co-medication), data is shown 
in Table 5.
Table 4. Top five concomitant medication causing clinically relevant interactions with at least one 
of the antiviral regimens.
CAM: complementary and alternative medicine, HMG CoA: 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, DDI: 
drug-drug interaction, ATC: Anatomical Therapeutic Chemical
Risk for drug-drug interaction per patient
The majority of the patients in our cohort (60%) was at risk for a clinically relevant DDI 
with at least one of the DAA regimens: 93 patients (20%) used a drug that would be 
contraindicated (Category 3) and 184 patients (40%) had co-medication leading to a 
possible interaction (Category 2), which would require close monitoring, alternation 
of drug dosage or timing of administration. Figure 2 shows the risk of a DDI per DAA 
regimen per patient. The risk for DDIs per patient did not differ in patients aged below 
or above 65 years (60% vs. 67%, p=0.45), nor between patients without cirrhosis and 
with cirrhosis (60% vs. 64%, p= 0.50).
DDI category
DDI category 2
DDI category 3
ATC code  n
N05BA   61 
N06A   43 
A02BC   42 
R03BA   30 
C07AB   29
A02BC   52
C10AA   19 
N05A   13 
R03AC/ R03CC  12
no ATC   2
Drug class
Benzodiazepines
Antidepressants
Proton pump inhibitors (omeprazole)
Glucocorticoids respiratory system
Selective beta-blocking agents
Proton pump inhibitors (esomeprazole, pantoprazole)
HMG CoA reductase inhibitors (statins)
Antipsychotics
Selective beta-2-adrenoreceptor agonists respiratory 
system 
CAM
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Figure 2. Risk on a clinically relevant drug-drug interaction per patient (n = 461), grouped per 
direct-acting antiviral regimen
Cat: category, DDI: drug-drug interaction, SIM = simeprevir, SOF = sofosbuvir, PTV/r = paritaprevir/ritonavir, OBV = 
ombitasvir, LDV = ledipasvir, DCV = daclatasvir, DSV = dasabuvir, EBR = elbasvir, GZR = grazoprevir, VEL = velpatasvir
Discussion
In this nationwide, real-life cohort study, we show that the majority of HCV-infected 
patients is at risk for having a clinically relevant DDI with new DAAs. This can have a 
negative influence on treatment outcomes and could potentially harm the patient.1 In 
this cohort, patients with cirrhosis or ≥65 years old did not have a higher risk for a DDI 
when compared with patients <65 years old or without cirrhosis. This contrasts with 
a recently published study17 and might be explained due to low number of elderly 
patients in our cohort and the lower mean age of patients ≥65 years (68 years, standard 
deviation (SD) 3). This shows that not only the elderly are at risk for a DDI. The psycho-
active agents such as antidepressants (7.4%) and benzodiazepines (7.1%) were the 
most frequently used drugs in our cohort, as well as in the literature.3 This is relevant 
because these drugs increase the risk for DDIs: antidepressants and benzodiazepines 
are extensively metabolized through CYP enzymes, which can be inhibited by DAAs.21, 
22 This causes increased plasma concentrations of psycho-active agents increasing the 
likelihood of toxicity.
PPIs were also responsible for many clinically relevant DDIs in our cohort, both as victim 
and perpetrator.15 Omeprazole is a victim of paritaprevir/ritonavir, ombitasvir plus 
dasabuvir due to CYP2C19 induction of ritonavir, decreasing omeprazole exposure with 
40-50%.23 In contrast, PPIs are the perpetrators of a DDI with ledipasvir and velpatasvir. 
PPIs increase gastric pH, which decreases exposure to DAAs due to its insolubility at 
higher pH ranges.24, 25 The clinical relevance for DDIs between PPIs and ledipasvir is 
under debate.26, 27 For velpatasvir, the product label states that co- administration of 
omeprazole or other PPIs is not recommended, and that esomeprazole and pantoprazole 
are contraindicated.25
DDI Cat 2
DDI Cat 3
% of patients at risk for DDI
0              10             20             30             40             50
PTV/r + OBV + DSV
SIM + SOF
LDV + SOF
VEL + SOF
DCV + SOF
EBR + GZR
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Most frequently predicted DDIs were found with paritaprevir/ritonavir, ombitasvir plus 
dasabuvir, which fits with data from the published literature.11 These interactions are 
predominantly caused by ritonavir, which strongly inhibits the most important drug-
metabolizing enzyme (CYP3A4) and various other enzymes and drug-transporters are 
influenced (e.g. CYP2D6, P-glycoprotein (P-gp)).28, 29 The fewest interactions were seen 
with the newest regimens: sofosbuvir plus velpatasvir and elbasvir plus grazoprevir. 
Elbasvir and grazoprevir are substrates of P-gp and CYP3A and only strong CYP3A 
inhibitors or inducers lead to clinically relevant DDIs. Grazoprevir is also a (weak) CYP3A 
inhibitor, but no DDIs between this combination and CYP3A substrates are listed.30 
However, we recommend caution when combining elbasvir and grazoprevir with CYP3A 
substrates with a narrow therapeutic range, such as tacrolimus.31 
The contraindicated drugs count for up to 4% of the predicted interactions. This is a very 
clear signal to the physician: do not combine the co-medication with this DAA regimen. 
The dilemma is mostly present in the drugs categories in 2 and 4. In our study, ~90% of 
category 2 DDIs have not been studied, but were predicted by the University of Liverpool 
group. However, some DDIs cannot be predicted on theoretical grounds but do occur 
in clinical practice. For example, the unexpected severe bradycardia that occurred in 
nine patients who were on amiodarone treatment and received a sofosbuvir-containing 
regimen. The mechanism of this DDI and the role of sofosbuvir is still unclear.6, 32-34 
Further, 23% (n=60) of drugs used by patients from our cohort were not listed in the 
University of Liverpool database (category 4). We judged that 11 of these drugs might 
cause an enzymatic interaction with the currently used DAAs. Prescribers should be 
aware that when the drug is not mentioned in the database, it does not mean there is 
no interaction.
A strength of this study is that it is a nationwide multicenter cohort with a large number 
of patients. This cohort provides a representative overview of co-medication use in the 
Dutch HCV genotype 1 population with a treatment indication. Genotype 1 is globally 
the main genotype (60%) and we expect that the patients of the cohort reflect the 
patients who will be subjected to therapy.35, 36 Further, we provide a risk assessment for 
drugs not available in the University of Liverpool database. Limitations of our study are 
the retrospective design and that our study describes predicted DDIs and not observed 
DDIs. Finally, the research question that led to this study was not the primary objective 
of data collection.
In conclusion, co-medication use is rich in both frequency and diversity in chronic HCV 
infected patients. DDIs may result in subtherapeutic or increased drug concentrations 
of DAAs or co-medication, and can cause treatment failure or toxicity. Physicians should 
be aware that the majority of patients are at risk for clinically relevant DDIs. In that case, 
co-medication can be adjusted prior to DAA therapy or DAA treatment can be aligned 
with co-medication use.
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Abstract
Background & Aims
Direct-acting antivirals (DAA) are effective in treatment of chronic hepatitis C virus 
(HCV) infection, although results for patients infected with genotype 3 are suboptimal. 
There are several regimens available but direct comparisons have not been made and 
are unlikely to occur. We aimed to identify the most effective DAA regimen for patients 
infected with HCV genotype 3 and to assess the role of ribavirin.
Methods
We conducted a systematic search of Pubmed, Embase and Web of Science databases 
through March 2016. We performed a Bayesian network meta-analysis using a random 
effects model to indirectly compare regimens in patients with and without cirrhosis. 
We calculated mean estimated sustained virologic response (SVR) with 95% credible 
intervals (95% CrI) per regimen and effect of ribavirin as odds ratio. We focused on current 
recommended regimens and regimens under evaluation by regulatory authorities.
Results
Our search identified 2167 articles; 27 studies (comprising 3415 patients) were included. 
Among patients without cirrhosis, the greatest rates of SVR were estimated for those 
receiving sofosbuvir + velpatasvir with ribavirin (99%; 95% CrI, 98%–100%) and without 
ribavirin (97%; 95% CrI, 95%–99%), sofosbuvir + daclatasvir + ribavirin (96%; 95% CrI, 
92%–98%), and sofosbuvir + peginterferon + ribavirin (95%; 95% CrI, 91%–98%), all for 12 
weeks. Among patients with cirrhosis, the highest rates of SVR were estimated for those 
receiving sofosbuvir + velpatasvir for 24 weeks (96%; 95% CrI, 92%–99%), sofosbuvir + 
daclatasvir + ribavirin for 24 weeks (94%; 95% CrI, 87%–98%), and sofosbuvir + velpatasvir 
+ ribavirin for 12 weeks (94%; 95% CrI, 86%–98%). Ribavirin increases efficacy in patients 
with and without cirrhosis (odds ratio, 2.6–4.5).
Conclusion
An indirect comparison of DAA-based treatments, using Bayesian network meta-
analysis, found regimens containing sofosbuvir and velpatasvir to be the best option for 
patients with HCV genotype 3 infection. Our analyses indicate that ribavirin significantly 
increases rates of SVR and should be considered if tolerated.
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Introduction
Chronic hepatitis C infection (HCV) represents a chronic liver condition that may lead 
to end-stage liver disease with cirrhosis and hepatocellular carcinoma.1 The advent of 
direct-acting antiviral drugs (DAA) has completely changed the outlook of HCV. Viral 
cure has become possible with treatments that last 12-24 weeks and are devoid of side 
effects. The efficacy of DAA based therapy depends on patient related factors such as 
liver cirrhosis but also on viral genotype. Randomized clinical trials (RCTs) indicate that 
current regimens result in sustained virological response (SVR) in > 90% of patients 
with genotype 1.2, 3 However, the evidence base for DAA therapies in genotype 3 is less 
extensive than for genotype 1. Also, treatment efficacy appears to be lower in genotype 
3 patients, particularly in treatment experienced patients with cirrhosis.4
The expansion of DAAs prompted the FDA in 2013 to allow single-arm trials that 
lack formal placebo arms but instead use historical controls as a comparator.5 This 
has resulted in an uneven trial landscape with multiple trials focusing on individual 
regimens. Key agents used in HCV genotype 3 patients are sofosbuvir, combined with 
ribavirin, daclatasvir, or velpatasvir. The comparative efficacy of individual combinations 
is largely unknown, mainly because of the paucity of head-to-head trials, while that 
information is necessary to steer guideline development and clinical decision making.
Our aim was to assess the comparative efficacy of all DAA regimens for HCV genotype 
3 using a network meta-analysis and to determine whether addition of ribavirin to DAA 
improves treatment efficacy.
Methods
We conducted a systematic review and network meta-analysis according to an a priori 
written protocol. We used Preferred Reporting Items for Systematic Reviews and 
Network Meta-Analysis (PRISMA NMA) guidelines for this purpose.6
Systematic review
We performed a systematic search to identify studies in HCV genotype 3 patients 
treated with DAAs. Together with a medical librarian we designed the search strategy 
for the Pubmed, Embase and Web of Science databases, and conducted the final 
search on 15 March 2016 (Supplementary File 1). To include all available data we 
performed a manual search of abstract books of the European Association for the 
Study of the Liver (EASL) and the American Association for the Study of Liver Diseases 
(AASLD) conferences in 2015. Two researchers (FB and BA) independently screened 
articles following a dual pronged approach: screening on title and abstract and full 
text screening. Disagreements were resolved by a third researcher (WK). We included
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studies (1) with patients above 18 years with HCV genotype 3, (2) RCTs, prospective 
clinical trials and/or real life studies with at least one DAA. We excluded studies (1) 
without results specified for HCV genotype 3, (2) where no sustained virological response 
(SVR) was reported, or (3) studies involving acute hepatitis C infected patients.
Outcomes, data extraction and risk of bias assessment
The primary outcome was the mean estimated probability of SVR per studied regimen. 
SVR was defined as an undetectable HCV RNA 12 weeks after cessation of treatment. 
One author (BA) extracted study characteristics and intention-to-treat SVR data per 
regimen and entered this in a structured electronic database (Castoredc ©). A second 
researcher cross checked all entered data (FB). Two authors (FB and BA) independently 
assessed the quality of studies using the Cochrane Collaboration risk of bias tool.7 
Disagreements were resolved by a third researcher (WK).
Statistical analysis
We conducted the network meta-analysis using Bayesian Markov Chain Monte Carlo 
(MCMC) methods. We used a random effects model with non-informative priors 
comparable to the network meta-analysis model of treatment response (NMA-TR) 
of Goring.8 Direct and indirect evidence for all studied regimens were combined to 
estimate the probability of SVR per studied regimen, with a 95% equal tail Credible 
Interval (95%CrI), by means of a logistic regression model. We included the following 
fixed factors in the model: type of DAAs, ribavirin (binary), duration of therapy (12 or 
16 or 24 weeks), presence of cirrhosis as prognostic factor for efficacy, and interaction 
of ribavirin and cirrhosis. As random effect we added the study, in order to model the 
positive correlation between study arms from the same study and to reflect deviations 
from the mean effects due to specific study and patient characteristics. The additional 
effect of ribavirin was estimated by means of an odds ratio (OR). The MCMC approach 
was based on 3 chains and updated with 200,000 simulations, thinning 1 per 10 and a 
burn-in of 10,000. We checked that the MCMC procedures had reached convergence by 
visually inspecting the history trace plots and the autocorrelation plots for irregularities.
To identify the most effective regimen, we focused on a subset of regimens recommended 
in guidelines, authorized in the market or under evaluation by regulatory authorities.9-11 
We ranked these regimens according to estimated SVR rates.12 Further, we performed 
conventional meta-analyses per regimen to assess inconsistency and fit of the model. 
Heterogeneity was assessed by the estimated between-study variation τ2 of the network 
meta-analysis and by I2 of the meta-analyses per regimen.
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Sensitivity analyses
We performed four sensitivity analyses to assess the reliability and robustness of the 
model and to increase homogeneity of the population: (a) we included studies with 
a low risk of bias and studies with only a high risk of bias on blinding of participants 
as SVR is an objective outcome measure, (b) we included only regimens available in 
the market or under evaluation by regulatory authorities, (c) we excluded studies with 
patients with decompensated cirrhosis, and (d) we excluded studies with HIV/HCV co-
infected patients. Because the effect of ribavirin is expected to be lower when added 
to a regimen consisting of 2 DAAs we did an additional analysis to assess the effect 
of ribavirin when combined with 2 DAAs. Treatment status (naive or experienced) 
was not included in the model because of limited available data specified on both 
cirrhosis status and treatment status per patient. To explore the effect of this choice, 
we performed an analysis with treatment status instead of cirrhosis in the model. All 
analyses were performed in WinBUGS 1.4.3 and R version 3.0.1 (R2winbugs).13, 14 The 
WinBUGS syntax is available in Supplementary File 2.
Results
Treatment landscape
Of the 2167 identified articles, we selected 26 papers (21 full text, 5 abstracts) describing 
27 studies (16 RCTs, 6 single arm studies, and 5 observational cohorts, Figure 1).15-40 
Overall, the 27 studies included 3415 patients, consisting of 2294 (67%) treatment naive 
patients and 1088 (32%) patients with cirrhosis. Eleven combinations of DAAs were 
studied, duration of therapy varied between 8 to 24 weeks with or without addition of 
ribavirin (Table 1 and Supplementary File 3). We excluded the 8 weeks regimens from 
our NMA, because only few patients were treated with 8 weeks regimens (n=13). There 
was variation in the number of patients studied per regimen, range 7-868). We designed 
three networks to connect regimens, but the majority of regimens were connected in 
network 1 and 2 (Figure 2).
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Figure 1. Study selection flowchart
Study selection flowchart summarizing selection and identification of trials and studies. 
GT3 = genotype 3, SVR12/24= sustained virological response at 12 or 24 weeks after cessation of 
treatment, DAA = direct acting antiviral.
Systematic search:
 - Pubmed 761
 - Embase 702
 - Web of Science 1977
5 records identified 
through other sources 
(manual abstract 
search)
2167 records after 
duplicates removed
2167 abstracts 
screened
2060 records 
excluded based 
on title and 
abstract review
107 full-text 
articles assessed 
for eligibility
26 papers 
included in 
qualitative 
synthesis
27 studies 
included in 
quantitative 
synthesis 
(meta-analysis)
81 full-text articles excluded
 - Design: 5
 - Not specific results GT3: 22
 - No SVR12/24: 25
 - No DAA included in trial: 16
 - Other reasons: 13
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Figure 2. Networks of studies
 
Evidence network of all DAA-based regimens studied in chronic hepatitis C genotype 3 patients. 
Thickness of the lines represent number of studies (connecting lines) or total number of patients 
studied (box lines). Within the box the DAA combination with duration (12, 16 or 24 weeks) is visible. 
Grey marked regimes are selected for ranking. Abbreviations: SOF = sofosbuvir, VEL = velpatasvir 100 
mg, VEL(25) = velpatasvir 25 mg, RBV = ribavirin, PR = peginterferon and RBV, DCV = daclatasvir, LDV 
= ledipasvir, TPR = telaprevir, OBV = ombitasvir, PTV = paritaprevir/ritonavir, 12 = 12 weeks, 16 = 16 
weeks, 24 = 24 weeks.
Sustained virological response in non-cirrhotic patients
Twenty-two different regimens were studied in non-cirrhotic HCV genotype 3 patients 
(Figure 3a). Highest SVR rates were estimated for sofosbuvir + daclatasvir + ribavirin 
for 24 weeks (98.9%, 95%CrI 97.6-99.6), sofosbuvir + velpatasvir + ribavirin for 12 weeks 
(98.8%, 95%CrI 97.5-99.6) and sofosbuvir + daclatasvir + ribavirin for 16 weeks (98.0%, 
95%CrI 95.7-99.2).
We ranked a subset of the regimens (the clinically relevant regimens as based on 
guidelines and clinical practice, shown in Supplementary File 4 and marked grey in 
Figure 2) from 1 to 6. In this subset, the regimen sofosbuvir + velpatasvir + ribavirin for 12 
weeks had highest probability to be ranked first, sofosbuvir + velpatasvir for 12 weeks to 
be ranked second, and sofosbuvir + daclatasvir + ribavirin for 12 weeks to be ranked third 
etcetera (Supplementary File 4a). Based on the ranking we estimated the differences in 
SVR rates between treatments (Table 2). 
DCV PR 16
        (s) n= 1
       (p) n= 27
DCV PR 12
        (s) n= 1
        (p) n= 26
TPR 2 PR 22
(s) n= 1
 (p) n= 8
TPR PR 24
      (s) n= 1
      (p) n= 9
PR 24
  (s) n= 3
      (p) n= 212
SOF 12
      (s) n= 1
      (p) n= 7
SOF RBV 12
 (s) n= 6
      (p) n= 404
Placebo
        (s) n= 2
        (p) n= 104
SOF PR 12
 (s) n= 3
      (p) n= 224
SOF RBV 24
  (s) n= 7
      (p) n= 868
SOF VEL 12
 (s) n= 4
      (p) n= 371
SOF VEL RBV 12
      (s) n= 2
      (p) n= 65
SOF VEL 24
 (s) n= 1
    (p) n= 12
SOF RBV 16
(s) n= 3
     (p) n= 273
SOF DCV RBV 12 
(s) n= 5
     (p) n= 166
SOF DCV RBV 16 
(s) n= 1
   (p) n= 26
SOF VEL(25) 12
(s) n= 2
   (p) n= 79
SOF VEL(25) RBV 12
(s) n= 1
      (p) n= 53
SOF LDV RBV 12
      (s) n= 2
      (p) n= 136
SOF LDV 12
(s) n= 2
   (p) n= 32
SOF DCV 12 
(s) n= 5
     (p) n= 198
SOF DCV RBV 24
(s) n= 3
   (p) n= 25
SOF DCV 24
  (s) n= 3
     (p) n= 56
OBV PTV RBV 12
      (s) n= 1
      (p) n= 10
OBV PTV 12
(s) n= 1
   (p) n= 11
Network 1
Network 2 Network 3
Legend
Connecting lines   Box lines   
represents 1 study   < 200 patients
     200-400 patients
represents 2 studies   400-600 patients
represents 3 studies   > 600 patients
(s) : studies     subset of regimens
(p) : patients   selected for ranking
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Sofosbuvir + velpatasvir + ribavirin for 12 weeks reached higher SVR rates than all other 
recommended regimens in the subset (range 2-12% higher SVR). In contrast, sofosbuvir 
+ velpatasvir for 12 weeks, sofosbuvir + daclatasvir + ribavirin for 12 weeks and sofosbuvir 
+ peginterferon + ribavirin for 12 weeks had similar SVR rates. Sofosbuvir + ribavirin for 
24 weeks had a similar estimated SVR to sofosbuvir + daclatasvir for 12 weeks; both 
were inferior to other reported regimens.
Figure 3a. Estimated SVR rates per regimen for non-cirrhotic patients
The figure shows the mean estimated probability on Sustained Virological Response (SVR) per 
regimen with 95%CrI. The SVR rates are estimated for patients without cirrhosis. Abbreviations: SOF 
= sofosbuvir, VEL = velpatasvir, RBV = ribavirin, PR = peginterferon and RBV, DCV = daclatasvir, LDV 
= ledipasvir, TPR = telaprevir, OBV = ombitasvir, PTV = paritaprevir/ritonavir, 12 = 12 weeks, 16 = 16 
weeks, 24 = 24 weeks
Sustained virological response in cirrhotic patients
In total, 19 different regimens were studied in cirrhotic HCV genotype 3 patients. Highest 
SVR rates were estimated for: sofosbuvir + velpatasvir for 24 weeks (96.3%, 95%CrI 92.0-
98.7), sofosbuvir + daclatasvir + ribavirin for 24 weeks (94.1%, 95%CrI 86.8-98.1) and 
sofosbuvir + velpatasvir + ribavirin for 12 weeks (93.7%, 95%CrI 85.9-98.0) (Figure 3b). 
Ranking and comparison of the subset of clinically important regimens resulted in 
sofosbuvir + velpatasvir for 24 weeks to be ranked first, sofosbuvir + daclatasvir + ribavirin 
for 24 weeks to be ranked second and sofosbuvir + velpatasvir + ribavirin for 12 weeks 
to be ranked third, etcetera (Supplementary File 4b). However when we compared the 
regimens in the subset to each other, similar SVR rates were estimated for the first three 
ranked regimens (Table 3). Sofosbuvir + velpatasvir for 12 weeks resulted in 7% lower 
SVR, while sofosbuvir + peginterferon + ribavirin for 12 weeks resulted in 16% lower SVR 
than sofosbuvir + velpatasvir + ribavirin for 12 weeks. Sofosbuvir + ribavirin for 24 weeks 
was inferior to all other regimens, with 22-40% lower SVR estimates.
   Mean estimated SVR (%) with 95% credible interval
SOF + DCV + RBV 24
SOF + VEL(100mg) + RBV 12
SOF + DCV + RBV 16
SOF + DCV 24
SOF + VEL(100mg) 12
SOF + DCV + RBV 12
SOF + PR 12
SOF + VEL(25mg) + RBV 12
SOF + LDV + RBV 12
SOF + DCV 12
SOF + VEL(25mg) 12
SOF + RBV 24
SOF + LDV 12
DCV + PR 16
SOF + RBV 16
TPR + PR 24
PR 24
DCV + PR 12
SOF + RBV 12
OMB + PTV + RBV 12
SOF 12
OMB + PTV 12
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Figure 3b. Estimated SVR rates per regimen for cirrhotic patients
The figure shows the mean estimated probability on Sustained Virological Response (SVR) per 
regimen with 95% CrI. The SVR rates are estimated for patients with cirrhosis. Abbreviations: SOF = 
sofosbuvir, VEL = velpatasvir, RBV = ribavirin, PR = peginterferon and RBV, DCV = daclatasvir, LDV = 
ledipasvir, 12 = 12 weeks, 16 = 16 weeks, 24 = 24 weeks.
Effect of ribavirin
In patients without cirrhosis the OR of ribavirin was 2.6 (95%CrI 1.3-4.7), and in patients 
with cirrhosis 4.5 (95%CrI 2.5-7.7). We also performed an analysis with only studies 
including 2 DAAs +/- ribavirin. We found an OR of 6.5 (95%CrI 1.9-17.8) in patients 
without cirrhosis and OR 3.9 (95%CrI 2.0-7.0) in patients with cirrhosis. Ribavirin had 
a significant additional effect, even when used with 2 DAAs in both cirrhotic and non-
cirrhotic patients.
Fit of the model and sensitivity analyses
To assess the consistency and fit of the model we performed direct meta-analyses of 
regimens and the results were largely similar to our network meta-analysis, with the 
exception of two regimens: sofosbuvir for 12 weeks and sofosbuvir + velpatasvir for 24 
weeks. These 2 regimens were only studied once in 7 and 12 patients respectively.15, 
23 With regard to heterogeneity, the majority of meta-analyses per regimen had an 
I2 <50%, except for 3 regimens (sofosbuvir + ribavirin 12 weeks, sofosbuvir + ribavirin 
16 weeks (patients without cirrhosis), and sofosbuvir + velpatasvir(100mg) 12 weeks 
(patients with cirrhosis))(Supplementary File 5). The network meta-analysis resulted in 
an overall estimated τ2 of 0.78 (95%CrI 0.27-1.73), suggesting between-study variation 
in the SVR rates. We performed four sensitivity analyses (Supplementary File 6). For the
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first sensitivity analysis we excluded studies with a high risk of bias, except studies 
with only a high risk of bias on blinding of participants (Supplementary File 7). Overall 
estimated SVR rates were lower and 95%CrI wider; SVR for sofosbuvir + daclatasvir 
regimens dropped while sofosbuvir + velpatasvir regimens had similar SVR estimates 
as in the primary analysis. Results were consistent with the primary analysis in the 
other three sensitivity analyses. We also built a model where cirrhosis was replaced by 
treatment status (treatment naive vs. treatment experienced). Again, estimated SVR 
and ranking were largely similar to the overall results (Supplementary File 8).
Discussion
In this systematic review and network meta-analysis, we combined data from 27 
studies to establish a hierarchy of available treatment regimens for HCV genotype 3. 
The key finding is that sofosbuvir-velpatasvir regimens achieve the highest efficacy in 
HCV genotype 3: sofosbuvir + velpatasvir + ribavirin for 12 weeks in non-cirrhotics and 
sofosbuvir + velpatasvir (without ribavirin) for 24 weeks or with ribavirin for 12 weeks 
in cirrhotics, although similar estimated SVR rates can be reached with sofosbuvir 
+ daclatasvir + ribavirin for 24 weeks. In patients without cirrhosis, regimens such as 
sofosbuvir + peginterferon + ribavirin and sofosbuvir + daclatasvir + ribavirin for 12 weeks 
only had 1- 4% lower estimated SVR rates, and remain an option for treatment. The 
advantage of sofosbuvir + velpatasvir over other regimens is that ribavirin can be omitted 
in non-cirrhotics and that it shortens duration of treatment in cirrhotics.
Second, we established the added value of ribavirin (OR 2.6-4.5), regardless of the 
presence of cirrhosis. However, it is important to keep in mind that the actual effect of 
adding ribavirin on SVR rates depends on the efficacy of the backbone regimen: the 
increase in SVR due to ribavirin is highest with regimens that have a lower intrinsic 
efficacy. A recent review and current AASLD guidelines suggest that ribavirin can be 
dropped from the combination sofosbuvir + daclatasvir in non-cirrhotic genotype 3 
patients. Our data suggest that in this case SVR drops by 6%. In clinical practice, the 
effect of ribavirin has to be traded off against both the side effect profile of ribavirin 
and the expected reduction in costs related to the DAA. The authors of this review and 
guideline recommend use of ribavirin in cirrhosis which is supported by our data.9, 41
A third finding is the identification of regimens that are clearly inferior in HCV genotype 
3: sofosbuvir + daclatasvir for 12 weeks and sofosbuvir + ribavirin for 24 weeks in non-
cirrhotics. Both achieved 5-12% lower SVR rates compared to other recommended 
regimens. In cirrhotics, differences in efficacy were more visible: sofosbuvir + ribavirin for 
24 weeks was obviously inferior to other reported regimens (22-40% lower SVR rates) 
and should be considered obsolete. 
7Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection.
115
The lack of head-to-head trials is an important issue for guideline developers and 
physicians, and drives researchers to perform network meta-analyses.42 In the field 
of hepatitis C, some network meta-analyses have been performed to assess relative 
efficacy of DAAs in HCV genotype 1.3, 43, 44 Because genotype is an important predictor 
for response, these results cannot be compared with genotype 3. The technique of 
network meta-analysis is not only of value in HCV, but has merits for other disease 
entities such as alcoholic hepatitis or Crohn’s disease.45-47 Results of network meta- 
analyses support physicians and guideline developers in decision making, but can also 
identify treatments which should be compared head-to-head, in our study this could 
be the first until fourth ranked regimes.
Our study comes with strengths and limitations. We combined all available evidence 
of DAA-regimens for HCV genotype 3 with use of Bayesian statistics. Current guidelines 
do not rank therapies as formal head to head trials are lacking. Our method enables 
identification of a hierarchy of therapies for HCV genotype 3. One of the limitations 
of our study is that results are based on extensive networks with in a few cases only 
one or no study per connection. This forced us to perform an arm-based rather than a 
comparison-based network meta-analysis. This approach is supported by the literature 
for HCV, but does impede inconsistency assessment.8 However, our model produced 
similar outcomes as the conventional meta-analyses per regimen, which bolsters our 
conclusions. Further, estimated SVR rates of peginterferon and ribavirin therapy in our 
study do reflect SVR rates in the literature.48 Another limitation of our network meta-
analysis is the risk of conceptual heterogeneity, reflecting differences between trials 
which may impair comparability. We used several strategies to target heterogeneity: 1) 
we used a random effects model (by including a study effect in our model), 2) we have 
split the analyses for patients with and without cirrhosis, and 3) we performed sensitivity 
analyses to increase homogeneity, which showed similar results. Moreover SVR is an 
objective outcome which decreases the risk of heterogeneity.49 Many studies in our 
network analysis have a high risk of bias. Exclusion of these studies in our sensitivity 
analysis resulted in a similar ranking of regimens, but estimated SVR rates were lower 
and 95%CrIs were wider. In real world, SVR rates might be compromised in view of the 
lower generalizability of trials, but we do not expect that the hierarchy is affected. Lastly, 
we were not able to assess publication bias formally, as the studies per regimen ranged 
from 1-7, nevertheless we do not expect publication bias as the field of HCV evolves 
rapidly and trial results are needed for evaluation by regulatory authorities.7
Implications for clinical practice
The findings of our network meta-analysis can be used to prioritize DAA regimens 
for HCV genotype 3 patients in guidelines and clinical practice. In patients without 
cirrhosis we focused on 12 week regimens and four regimens have an estimated SVR 
rate of 95% or higher: sofosbuvir + velpatasvir + ribavirin for 12 weeks is the best option, 
directly followed by sofosbuvir + velpatasvir, sofosbuvir + daclatasvir + ribavirin and
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sofosbuvir + peginterferon + ribavirin for 12 weeks. Sofosbuvir + ribavirin for 24 weeks 
and sofosbuvir + daclatasvir for 12 weeks are inferior. In patients with cirrhosis sofosbuvir 
+ velpatasvir with ribavirin for 12 weeks or without ribavirin for 24 weeks and sofosbuvir 
+ daclatasvir + ribavirin for 24 weeks can be recommended. Sofosbuvir + velpatasvir for 
12 weeks had 7-10% lower estimated SVR rates compared to other regimes so can 
be considered as alternative instead of recommended regimen in cirrhotic patients.9 
Sofosbuvir + ribavirin for 24 weeks is inferior to newer regimens. Our study also shows 
that ribavirin significantly increases the estimated SVR rates, however the precise effect 
is dependent on the actual DAA combination. In clinical practice, choice of treatment 
may depend on several factors, such as availability and price of DAAs, tolerance of 
ribavirin, risk of adverse events or drug-drug interactions, and presence of resistance 
associated substitutions.
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NMA-TR   Network Meta-Analysis model of Treatment Response
OR   Odds Ratio
RCT   Randomized Clinical Trial
SVR   Sustained Virological Response
Velpatasvir   Velpatasvir 100mg
Velpatasvir (25mg)  Velpatasvir 25 mg
7Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection.
117
Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
Alqahtani SA, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with
and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis
of phase III ION trials. Hepatology 2015;62:25-30.
Suwanthawornkul T, Anothaisintawee T, Sobhonslidsuk A, et al. Efficacy of Second
Generation Direct-Acting Antiviral Agents for Treatment Naive Hepatitis C Genotype 1: A
Systematic Review and Network Meta-Analysis. PLoS One 2015;10:e0145953.
Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for 
the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 2016;43:1276-
92.
HHS, FDA, CDER. Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs 
for Treatment: Guidance for Industry (revision 2, draft). 2016.
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of
systematic reviews incorporating network meta-analyses of health care interventions:
checklist and explanations. Ann Intern Med 2015;162:777-84.
Higgins JPT, S. G. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0
The Cochrane Collaboration. Available from www.handbook.cochrane.org. 2011.
Goring SM, Gustafson P, Liu Y, et al. Disconnected by design: analytic approach in treatment
networks having no common comparator. Res Synth Methods 2016.
AASLD/IDSA. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and 
treating adults infected with hepatitis C virus. www.hcvguidelines.org 2016, July 6.
EASL. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199-236.
WHO. Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C
Infection. Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis 
C Infection: Updated Version. Geneva, 2016.
Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting 
results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 
2011;64:163-71.
Lunn DJ, Thomas A, Best N, et al. WinBUGS – A Bayesian modelling framework: Concepts, 
structure, and extensibility. Statistics and Computing 2000;10:325-337.
R-Development-Core-Team. R: A Language and Environment for Statistical Computing. 
Vienna, Austria : the R Foundation for Statistical Computing. 2011.
Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in Patients with 
Decompensated Cirrhosis. N Engl J Med 2015.
Dore GJ, Lawitz E, Hezode C, et al. Daclatasvir plus peginterferon and ribavirin is noninferior to 
peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 
or 3 infection. Gastroenterology 2015;148:355-366.e1.
Everson GT, Towner WJ, Davis MN, et al. Sofosbuvir With Velpatasvir in Treatment-Naive 
Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. 
Ann Intern Med 2015;163:818-26.
Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 
Infection. N Engl J Med 2015.
Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin 
reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. 
Gastroenterology 2011;141:881-889.e1.
Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients 
with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;64:1224-31.
Foster GR, Pianko S, Brown A, et al. Efficacy of Sofosbuvir Plus Ribavirin With or Without 
Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment- 
Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection. 
Gastroenterology 2015;149:1462-70.
Gane EJ, Hyland RH, An D, et al. Efficacy of Ledipasvir and Sofosbuvir, With or Without 
Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection. Gastroenterology 
2015;149:1454-1461.e1.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15. 
16.
17.
18.
19. 
20.
21.
22.
Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection.
7
118
Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide Polymerase Inhibitor Sofosbuvir plus 
Ribavirin for Hepatitis C. New England Journal of Medicine 2013;368:34-44.
Hezode C, de Ledinghen V, Fontaine H, et al. Daclatasvir plus sofosbuvir with or without 
ribavirin in genotype 3 patients from a large French multicenter compassionate use program. 
Hepatology 2015;62:314a-314a.
Jacobson IM, Gordon S, Kowdley KV, et al. Sofosbuvir for Hepatitis C Genotype 2 or 3 
in Patients without Treatment Options (vol 368, pg 1867, 2013). New England Journal of 
Medicine 2013;369:493-493.
Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C 
infection. N Engl J Med 2013;368:1878-87.
Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks 
in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 
2015;61:769-75.
Lawitz E, Sullivan G, Rodriguez-Torres M, et al. Exploratory trial of ombitasvir and ABT-450/r 
with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect 2015;70:197-205.
Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis 
C Virus Genotype 3 and Advanced Liver Disease: A Randomized Phase III Study (ALLY-3+). 
Hepatology 2016.
Lin ON, Nguyen N, Chang CY, et al. Safety and effectiveness of sofosbuvir (SOF) combined with 
ribavirin (RBV) for the treatment of genotype 2 and 3 chronic hepatitis C infection (HCV- 2 and 
HCV-3). Gastroenterology 2015:S1092.
Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in 
patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 
3 study. Lancet 2015;385:1098-106.
Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus 
sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. 
Hepatology 2015;61:1127-35.
Pianko S, Flamm SL, Shiffman ML, et al. Sofosbuvir Plus Velpatasvir Combination Therapy 
for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A 
Randomized Trial. Ann Intern Med 2015;163:809-17.
Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir, Sofosbuvir, and Ribavirin Combination 
for Hcv Patients with Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 Ally-1 Study. 
Journal of Hepatology 2015;62:S261-S262.
Shah S, Acharya SK, Mehta R, et al. Sofosbuvir plus ribavirin in the treatment of chronic HCV 
infection in India. Hepatology International 2016:S15.
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously 
treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-21.
Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with 
HIV coinfection. Jama 2014;312:353-61.
Welzel TM, Petersen J, Ferenci P, et al. Safety and efficacy of daclatasvir plus sofosbuvir with or 
without ribavirin for the treatment of chronic HCV genotype 3 infection: Interim results of a 
multicenter European compassionate use program. Hepatology 2015;62:225a-226a.
Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus Sofosbuvir for HCV in Patients 
Coinfected with HIV-1. N Engl J Med 2015;373:714-25.
Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. 
N Engl J Med 2014;370:1993-2001.
Hezode C, Bronowicki JP. Ideal oral combinations to eradicate HCV: The role of ribavirin. J 
Hepatol 2016;64:215-25.
Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and 
network meta-analysis for health-care decision making: report of the ISPOR Task Force on 
Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417- 
28.
Druyts E, Lorenzi M, Toor K, et al. Network meta-analysis of direct-acting antivirals in 
combination with peginterferon-ribavirin for previously untreated patients with hepatitis C 
genotype 1 infection. QJM 2015;108:299-306.
Kieran J, Schmitz S, O’Leary A, et al. The relative efficacy of boceprevir and telaprevir in the 
treatment of hepatitis C virus genotype 1. Clin Infect Dis 2013;56:228-35.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
7Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection.
119
Singh S, Murad MH, Chandar AK, et al. Comparative Effectiveness of Pharmacological 
Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta- analysis. 
Gastroenterology 2015;149:958-70 e12.
Singh S, Garg SK, Pardi DS, et al. Comparative efficacy of pharmacologic interventions in 
preventing relapse of Crohn’s disease after surgery: a systematic review and network meta- 
analysis. Gastroenterology 2015;148:64-76 e2; quiz e14.
Skapinakis P, Caldwell DM, Hollingworth W, et al. Pharmacological and psychotherapeutic 
interventions for management of obsessive-compulsive disorder in adults: a systematic review 
and network meta-analysis. Lancet Psychiatry 2016.
Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid 
virologic response patients in the large real-world PROPHESYS cohort confirm results from 
randomized clinical trials. Hepatology 2012;56:2039-50.
Cipriani A, Higgins JP, Geddes JR, et al. Conceptual and technical challenges in network meta- 
analysis. Ann Intern Med 2013;159:130-7.
45.
46.
47.
48.
49.
Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection.
7
120
Supplementary Files
Supplementary File 1. Search strategy
We searched 3 databases (Pubmed, Embase, Web of Science) to identify all studies 
conducted in HCV genotype 3 patients. The search strategy included the following terms or 
synonyms: (chronic) hepatitis C, genotype 3, clinical trial (cochrane sensitivity-maximizing 
search), and pragmatic trial. The year 2004 was set as a limitation because there is no data 
about DAAs prior to 2004.
We performed the first search on 7 December 2015 and repeated the search on 15 March 
2016. Search strategy with items found per date are shown below.
Pubmed
Query 7-12-2015
15-3-
2016
#4 Search ((((((((((randomized controlled trial[pt] OR controlled clinical 
trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug ther-
apy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab] NOT 
(animals[mh] NOT humans[mh]))))))) OR ((pragmatic trial[tiab]) OR 
pragmatic trial)) AND (((((((HCV-2/3) OR ((((G3[tiab] OR GT3[tiab] OR 
Genotype 3*[tiab] OR genotypes 3*[tiab] OR Genotype 2/3*[tiab] 
OR Genotypes 2/3*[tiab]))) AND ((“Hepatitis C, Chronic”[Mesh] OR 
Hepatitis c[tiab] OR HCV[tiab]))))))))) Sort by: Relevance
741 20
#3 Search ((((((HCV-2/3) OR ((((G3[tiab] OR GT3[tiab] OR Genotype 
3*[tiab] OR genotypes 3*[tiab] OR Genotype 2/3*[tiab] OR Geno-
types 2/3*[tiab]))) AND ((“Hepatitis C, Chronic”[Mesh] OR Hepatitis 
c[tiab] OR HCV[tiab])))))))) Sort by: Relevance
1357 71
#2 Search (pragmatic trial[tiab]) OR pragmatic trial Sort by: Relevance 2691 200
#1 Search (((((((randomized controlled trial[pt] OR controlled clinical 
trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug ther-
apy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab] NOT 
(animals[mh] NOT humans[mh]))))) Sort by: Relevance
1715077 61868
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Web of Science
Search Items found 
7-12-2015
Items 
found  
15-3-2016
Query
# 5 1,705 272 #3 AND #2 AND #1 
Refined by: PUBLICATION YEARS: ( 2015 OR 2006 OR 
2014 OR 2009 OR 2012 OR 2008 OR 2013 OR 2005 OR 
2011 OR 2004 OR 2010 OR 2007 ) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, ESCI Time-
span=All years
# 4 2,262 2,262 #3 AND #2 AND #1 
Indexes=SCI-EXPANDED, SSCI, A&HCI, ESCI Time-
span=All years
# 3 292,820 292,820 TOPIC: (((((((hepatitis c) OR (chronic hepatitis c) OR HCV 
OR (hepatitis C virus) OR (Hep* C) OR (hepatitis NEAR 
C))))))) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, ESCI Time-
span=All years
# 2 2,996,678 2,996,678 TOPIC: (((((((clinical trial) OR (randomi?ed clinical trial) 
OR (randomi?ed controlled trial) OR (clinical study) OR 
(clinical research) OR (controlled clinical trial) OR pla-
cebo OR random* OR randomi?ed OR (clinical NEAR/3 
trial) OR trial OR (pragmatic trial) OR (pragmatic clinical 
trial) OR (real world) OR (real life) OR (multicent* study) 
OR RCT)))))) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, ESCI Time-
span=All years
# 1 187,811 187,811 TOPIC: (((genotypes NEAR/3 3) OR (genotype NEAR/3 3) 
OR G3 OR GT3 OR (GT NEAR/3 3) OR (G NEAR/3 3) OR 
(HCV NEAR/3 3))) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, ESCI Time-
span=All years
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Embase search (both searches combined) on 15-3-2016
# Searches Results
1 exp chronic hepatitis/ 29091 
2 (hepatitis adj C).ti,ab,kw. 87682 
3 hep* c.ti,ab,kw. 88266 
4 Hepatitis c virus.ti,ab,kw. 55326 
5 hcv.ti,ab,kw. 73000 
6 1 or 2 or 3 or 4 or 5 126732 
7 genotypes 3.af. 292 
8 “genotype 2/3”.af. 495 
9 genotype 3.af. 3078 
10 “genotypes 2/3”.af. 217 
11 gt3.af. 456 
12 g3.af. 20533 
13 g?3.af. 41614 
14 7 or 8 or 9 or 10 or 11 or 12 or 13 45286 
15 “hcv-2/3”.af. 52 
16 “hcv 2/3”.af. 52 
17 “hcv2/3”.af. 7 
18 “hcv 3”.af. 281 
19 “hcv-3”.af. 281 
20 “hcv3”.af. 8 
21 exp hepatitis c virus genotype 3/ 575 
22 15 or 16 or 17 or 18 or 19 or 20 or 21 867 
23 6 and 14 3431 
24 22 or 23 3749 
25 Clinical trial/ 863634 
26 Randomized controlled trial/ 409625 
27 Randomization/ 70908 
28 Single blind procedure/ 22311 
29 Double blind procedure/ 131694 
30 Crossover procedure/ 47521 
31 Crossover procedure/ 47521 
32 Randomi?ed controlled trial$.tw. 138191 
33 Rct.tw. 20739 
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34 Placebo/ 289574 
35 Random allocation.tw. 1576 
36 Randomly allocated.tw. 25282 
37 Allocated randomly.tw. 2147 
38 (allocated adj2 random).tw. 839 
39 Single blind$.tw. 17802 
40 Double blind$.tw. 169626 
41 ((treble or triple) adj blind$).tw. 589 
42 Placebo$.tw. 240175 
43 Prospective study/ 338633 
44 pragmatic.tw. 13321 
45 “pragmatic clinical trial”.tw. 92 
46 “real world”.tw,ti,ab,kw. 28781 
47 “real life”.tw,ti,ab,kw. 16689 
48 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 1652489 
49 Case study/ 38811 
50 Case report.tw. 317843 
51 letter/ 892418 
52 49 or 50 or 51 1242044 
53 48 not 52 1612479 
54 24 and 53 702 
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Supplementary File 2. Model
 
This supplementary file shows the Winbugs code, the following components are shown:
- the full model 
- the code for probability on SVR for regime 1 and 2 as an example
- OR for ribavirin in patients with and without cirrhosis
- Difference between 2 regimes (for example regime 1 with and without ribavirin 
in non-cirrhotics, for example regime 1 and 2 in cirrhotics)
Model for Winbugs
{
 for (s in 1 : 27){
 study_effects[s] ~ dnorm(0, study_tau)
 }
 for (i in 1 : 11){
  for (t in 1: N_study_per_regime[i]){
   LP[i,t] <- a1 + a2*reg_dum2[i] + a3*reg_dum3[i] + a4*reg_
dum4[i] + a5*reg_dum5[i] + a6*reg_dum6[i] + a7*reg_dum7[i] + a8*reg_dum8[i] + 
a9*reg_dum9[i] + a10*reg_dum10[i] + a11*reg_dum11[i] + b1*dur_16[i,t] + b2*dur_24[i,t] + 
c*rbv[i,t] + d*cirr[i,t] + e*rbv[i,t]*cirr[i,t] + study_effects[studies[i,t]]
   P[i,t] <- 1/ (1+exp(-1*LP[i,t]))
   succes[i,t] ~ dbin(P[i,t], N_total[i,t])
  }
 }
a1 ~ dnorm(0, 0.01) 
a2 ~ dnorm(0, 0.01)
a3 ~ dnorm(0, 0.01)
a4 ~ dnorm(0, 0.01)
a5 ~ dnorm(0, 0.01)
a6 ~ dnorm(0, 0.01)
a7 ~ dnorm(0, 0.01)
a8 ~ dnorm(0, 0.01)
a9 ~ dnorm(0, 0.01)
a10 ~ dnorm(0, 0.01)
a11 ~ dnorm(0, 0.01)
b1 ~ dnorm(0, 0.01)
b2 ~ dnorm(0, 0.01)
c ~ dnorm(0, 0.01)
d ~ dnorm(0, 0.01)
e ~ dnorm(0, 0.01)
study_sd ~ dunif(0.01, 10)
study_tau <- 1/(study_sd*study_sd)
P1_12_WR <- 1/(1+exp(-1*a1))
P2_12_WR <- 1/(1+exp(-1*(a1+a2)))
P1_16_WR <- 1/(1+exp(-1*(a1+b1)))
P2_16_WR <- 1/(1+exp(-1*(a1+a2+b1)))
P1_12_RBV <- 1/(1+exp(-1*(a1+c)))
P2_12_RBV <- 1/(1+exp(-1*(a1+a2+c)))
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P1_16_RBV <- 1/(1+exp(-1*(a1+c+b1)))
P2_16_RBV <- 1/(1+exp(-1*(a1+a2+c+b1)))
P1_24_WR <- 1/(1+exp(-1*(a1+b2)))
P2_24_WR <- 1/(1+exp(-1*(a1+a2+b2)))
P1_24_RBV <- 1/(1+exp(-1*(a1+c+b2)))
P2_24_RBV <- 1/(1+exp(-1*(a1+a2+c+b2)))
P1_12_WRC <- 1/(1+exp(-1*(a1+d)))
P2_12_WRC <- 1/(1+exp(-1*(a1+a2+d)))
P1_16_WRC <- 1/(1+exp(-1*(a1+b1+d)))
P2_16_WRC <- 1/(1+exp(-1*(a1+a2+b1+d)))
P1_12_RBVC <- 1/(1+exp(-1*(a1+c+d)))
P2_12_RBVC <- 1/(1+exp(-1*(a1+a2+c+d)))
P1_16_RBVC <- 1/(1+exp(-1*(a1+c+b1+d)))
P2_16_RBVC <- 1/(1+exp(-1*(a1+a2+c+b1+d)))
P1_24_WRC <- 1/(1+exp(-1*(a1+b2+d)))
P2_24_WRC <- 1/(1+exp(-1*(a1+a2+b2+d)))
P1_24_RBVC <- 1/(1+exp(-1*(a1+c+b2+d)))
P2_24_RBVC <- 1/(1+exp(-1*(a1+a2+c+b2+d)))
OR_rbv <- exp(c)
OR_rbvcirr <- exp(c+e)
ZC1 <- P1_12_RBV – P1_12_WR
C1 <- P1_24_WRC – P2_24_RBVC
}
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Supplementary File 4
a)   Patients without cirrhosis
•	 Subset of regimens recommended in guidelines (EASL, AALSD, WHO) or 
under evaluation of regulatory authorities:  
Italic regimens are recommended in latest update of AASLD guideline (6 
July 2016)
1. SOF + DCV 12  
2. SOF + PR 12  
3. SOF + RBV 24
4. SOF + DCV + RBV 12 
5. SOF + VEL 12
6. SOF + VEL + RBV 12
•	 Rankograms for subset of regimens patients without cirrhosis:
1.    2. 
3.    4.  
SOF VEL RBV 12 SOF VEL 12
SOF DCV RBV 12 SOF PR 12
Rank, patients without cirrhosis Rank, patients without cirrhosis
Rank, patients without cirrhosis Rank, patients without cirrhosis
1            2           3       4 1         2     3        4         5
1       2      3       4       5       6 1       2      3       4       5       6
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5.    6.
b)   Patients with cirrhosis
•	 Subset of regimens recommended in guidelines (EASL, AALSD, WHO) or 
under evaluation of regulatory authorities: 
Italic regimens are recommended in latest update of AASLD guideline (6 
July 2016)
1. SOF + DCV + RBV 24
2. SOF + DCV 24  
3. SOF + PR 12  
4. SOF + RBV 24
5. SOF + DCV + RBV 12 
6. SOF + VEL 24
7. SOF + VEL + RBV 12
8. SOF + VEL 12
•	 Rankograms for subset of regimens in cirrhotic patients:
1.     2. 
SOF DCV 12 SOF RBV 24
SOF VEL 24 SOF DCV RBV 24
Rank, patients without cirrhosis Rank, patients without cirrhosis
Rank, patients with cirrhosis Rank, patients with cirrhosis
2         3         4         5          6 4                 5                 6
1         2         3         4         5 1         2        3        4         5
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3.     4. 
5.     6. 
 
7.      8. 
SOF VEL RBV 12 SOF DCV 24
SOF VEL 12 SOF DCV RBV 12
SOF PR 12 SOF RBV 24
Rank, patients with cirrhosis Rank, patients with cirrhosis
Rank, patients with cirrhosis Rank, patients with cirrhosis
Rank, patients with cirrhosis Rank, patients with cirrhosis
1       2      3      4      5       6 2      3     4      5     6      7     8
2       3       4       5       6       7 2      3     4      5     6      7     8
1    2     3     4     5    6     7     8 6     7       8
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Supplementary File 5. 
Meta-analyses per studied regimen in patients without cirrhosis (only regimens with >1 
study are shown).
SOF RBV 12
SOF RBV 16
SOF RBV 24
PR 24
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Placebo
SOF DCV 12 
SOF DCV RBV 12
SOF LDV RBV 12
SOF PR 12
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SOF VEL(25mg) 12
SOF VEL(100mg) 12
Meta-analyses per studied regimen in patients with cirrhosis (only regimens with >1 study 
are shown).
SOF RBV 12
SOF RBV 16
SOF RBV 24
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SOF DCV 12
SOF DCV RBV 12
SOF DCV RBV 24
SOF LDV 12
 
SOF LDV RBV 12
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SOF PR 12
SOF VEL(100mg) 12
SOF VEL(100mg) RBV 12
Supplementary File 6.
Excluded studies in sensitivity analyses:
a)  Excluding high risk of bias studies: Foster (EAP), Gane (ELECTRON), Hézode  
 (ATU), Lawitz (FISSION), Lawitz 2015, Lawitz 2015, Lin 2015, Molina (PHOTON-2),  
 Nelson (ALLY-3), Poordad (ALLY-1), Shah 2016, Sulkowski (PHOTON-1), Welzel  
 (CUP), Wyles (ALLY-2), Zeuzem (VALENCE)
b)  Excluding studies with not approved regimens: Foster 2011, Dore (AI444-031),  
 Lawitz 2015, Pianko (2015), Everson (2015)
c)  Excluding studies with decompensated liver disease patients: Curry (ASTRAL-4),  
 Foster (EAP), Lin 2015, Welzel (CUP), Hézode (ATU), Poordad (ALLY-1)
d)  Excluding studies with HIV/HCV coinfected patients: Sulkowski (PHOTON-1),  
 Molina (PHOTON-2), Wyles (ALLY-2), Welzel (CUP), Hézode (ATU), Foster (EAP)
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Sensitivity analyses patients without cirrhosis
Regimen Primary analy-
sis including all 
studies
a) Analysis 
excluding high 
risk of bias 
studies
b) Analysis 
excluding 
not approved 
regimens
c) Analysis 
excluding 
studies with 
decompensat-
ed liver disease 
patients
d) Analysis 
excluding 
studies with 
HIV/HCV 
coinfected 
patients
SOF + DCV + RBV 24 98.9 (97.6-99.6) 96.8 (88.2-99.6) 98.9 (97.5-99.7) 99.3 (98.1-99.8) 98.8 (96.4-99.8)
SOF + VEL(100mg) +  
RBV 12
98.8 (97.5-99.6) 98.8 (97.0-99.7) 98.8 (96.9-99.7) 99.4 (98.7-99.8) 99.3 (98.2-99.8)
SOF + DCV + RBV 16 98.0 (95.7-99.2) 94.7 (80.8-99.4) 98.1 (95.7-99.4) 98.4 (95.9-99.6) 97.7 (93.4-99.5)
SOF + DCV 24 97.3 (94.2-99.0) 88.6 (63.0-98.5) 97.7 (94.6-99.3) 97.8 (94.2-99.4) 95.7 (87.4-99.1)
SOF + VEL(100mg) 
12
97.2 (94.7-98.8) 95.3 (89.4-98.5) 97.5 (94.7-99.1) 98.3 (96.6-99.3) 97.4 (94.6-99.0)
SOF + DCV + RBV 12 95.6 (91.6-98.1) 91.0 (68.9-98.8) 95.3 (90.5-98.2) 95.9 (89.9-98.8) 95.0 (86.2-98.8)
SOF + PR 12 95.0 (90.6-97.8) 91.7 (80.8-97.3) 95.4 (90.9-98.1) 95.7 (92.1-98.1) 94.6 (89.3-97.9)
SOF + VEL(25mg) + 
RBV 12
94.3 (86.6-98.3) 94.7 (85.7-98.7) Excluded 96.4 (91.3-99.1) 96.0 (89.5-99.0)
SOF + LDV + RBV 12 92.6 (84.9-97.2) 88.5 (55.9-99.0) 92.1 (83.2-97.4) 89.2 (67.5-98.3) 88.1 (54.7-99.0)
SOF + DCV 12 89.9 (80.9-95.6) 73.3 (33.1-95.2) 90.5 (80.4-96.3) 88.3 (73.5-96.1) 84.3 (61.8-95.7)
SOF + VEL(25mg) 12 87.4 (73.8-95.5) 82.0 (60.7-94.1) Excluded 89.9 (79.2-96.5) 87.3 (72.2-96.0)
SOF + RBV 24 87.3 (80.5-92.4) 79.3 (62.1-90.8) 87.9 (80.3-93.5) 90.3 (85.2-94.4) 86.5 (77.6-93.1)
SOF + LDV 12 83.8 (68.7-93.5) 69.3 (22.1-95.9) 84.9 (68.6-94.6) 74.0 (36.6-94.5) 71.0 (23.7-96.5)
DCV + PR 16 81.2 (61.5-93.4) 71.5 (32.6-94.0) Excluded 82.3 (64.1-93.6) 80.3 (58.7-93.6)
SOF + RBV 16 78.8 (67.8-87.3) 68.9 (46.6-85.2) 80.8 (69.2-89.7) 80.8 (71.4-88.4) 77.4 (63.9-87.7)
TPR + PR 24 70.2 (37.6-92.4) 64.5 (24.4-93.2) Excluded 67.9 (36.2-91.0) 70.3 (35.9-93.2)
PR 24 67.6 (52.7-80.2) 56.4 (19.9-87.0) 67.9 (50.0-82.3) 65.9 (51.6-78.3) 65.6 (47.7-80.7)
DCV + PR 12 66.6 (40.4-86.6) 59.8 (20.9-89.4) Excluded 63.7 (38.2-84.2) 64.7 (36.1-86.7)
SOF + RBV 12 62.5 (48.8-74.6) 55.4 (30.6-76.4) 61.9 (45.8-76.1) 60.8 (47.5-72.4) 60.0 (42.8-75.2)
OMB + PTV + RBV 12 39.1 (7.1-81.6) Excluded Excluded 41.1 (9.8-81.0) 42.7 (6.1-88.0)
SOF 12 41.1 (22.7-60.5) 24.7 (7.3-51.1) 44.3 (21.9-67.6) 33.4 (16.5-51.8) 30.2 (13.1-51.5)
OMB + PTV 12 23.3 (2.9-63.9) Excluded Excluded 20.4 (3.0-56.0) 20.9 (1.6-66.1)
OR RBV 2.6 (1.3-4.7) 4.6 (1.9-9.3) 2.3 (1.0-4.6) 3.4 (1.6-6.6) 3.9 (1.8-7.5)
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Sensitivity analyses patients with cirrhosis
Regimen Primary anal-
ysis including 
all studies
a) Analysis 
excluding high 
risk of bias 
studies
b) Analysis 
excluding 
not approved 
regimens
c) Analysis 
excluding 
studies with 
decompensat-
ed liver disease 
patients
d) Analysis ex-
cluding studies 
with HIV/HCV 
coinfected 
patients
SOF + VEL(100mg) 24 96.3 (92.0-98.7) 93.2 (83.2-98.4) 96.7 (92.3-99.1) 98.4 (96.2-99.5) 96.2 (91.0-98.9)
SOF + DCV + RBV 24 94.1 (86.8-98.1) 87.6 (58.7-98.7) 93.6 (84.4-98.3) 96.0 (88.8-99.2) 92.8 (79.3-98.7)
SOF + VEL(100mg) + 
RBV 12
93.7 (85.9-98.0) 94.6 (85.7-98.8) 92.9 (82.0-98.4) 96.8 (92.4-99.1) 95.4 (88.8-98.8)
SOF + DCV + RBV 16 89.8 (77.9-96.6) 81.0 (44.5-97.6) 89.6 (75.8-97.0) 91.8 (78.4-98.1) 87.7 (66.9-97.4)
SOF + DCV 24 87.3 (75.8-94.7) 67.0 (26.8-94.0) 88.1 (75.7-95.5) 88.9 (73.3-96.9) 79.5 (52.7-94.6)
SOF + VEL(100mg) 12 86.8 (77.4-93.6) 82.2 (66.5-93.2) 87.4 (76.7-94.8) 91.2 (84.2-96.1) 86.2 (75.1-94.1)
SOF + DCV + RBV 12 80.1 (62.7-92.0) 71.7 (29.8-95.7) 77.4 (56.1-91.9) 81.0 (57.9-94.6) 76.5 (47.7-93.9)
SOF + PR 12 77.8 (59.6-90.5) 71.6 (43.8-90.8) 77.8 (57.4-91.5) 79.7 (62.1-91.8) 74.5 (52.7-89.9)
SOF + VEL(25mg) + 
RBV 12
75.8 (50.4-92.5) 80.2 (52.8-95.3) Excluded 83.1 (61.9-95.6) 80.1 (54.9-94.9)
SOF + LDV + RBV 12 70.3 (47.0-88.3) 67.7 (20.0-96.3) 67.4 (41.0-88.1) 63.3 (24.8-91.8) 61.5 (15.5-94.8)
SOF + DCV 12 63.3 (44.5-79.5) 43.0 (9.6-82.5) 63.2 (42.0-80.9) 59.4 (31.9-82.1) 50.1 (20.6-78.8)
SOF + VEL(25mg) 12 58.0 (34.1-79.6) 52.5 (25.6-78.2) Excluded 62.9 (39.1-83.5) 55.3 (29.3-79.6)
SOF + RBV 24 56.3 (37.6-73.8) 47.3 (22.7-73.6) 55.8 (34.2-75.9) 62.7 (43.1-79.7) 52.0 (30.9-73.0)
SOF + LDV 12 50.6 (29.3-72.1) 39.6 (5.9-84.8) 51.0 (27.9-73.9) 38.7 (9.1-76.0) 36.1 (4.7-82.2)
DCV + PR 16 46.9 (20.5-74.9) 40.5 (8.9-80.4) Excluded 47.6 (21.3-75.4) 43.0 (16.6-73.1)
SOF + RBV 16 41.6 (23.8-61.2) 34.7 (13.8-61.6) 43.0 (22.6-65.2) 43.8 (25.2-63.9) 37.2 (18.7-59.0)
DCV + PR 12 29.5 (9.8-57.9) 28.9 (5.0-68.7) Excluded 26.2 (8.7-53.0) 25.9 (7.5-54.9)
PR 24 28.9 (14.2-47.9) 25.8 (4.7-63.9) 28.0 (11.2-50.1) 26.7 (12.8-45.3) 25.1 (10.7-45.4)
SOF + RBV 12 24.5 (12.2-40.7) 23.3 (7.5-47.7) 22.9 (9.9-41.2) 22.5 (11.0-38.3) 20.8 (8.9-38.1)
OR RBV 4.5 (2.5-7.7) 6.9 (3.0-14.2) 4.4 (2.1-8.3) 6.4 (2.7-13.3) 7.8 (3.6-15.4)
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Supplementary File 7. 
a) Risk of bias across studies    b) Risk of bias per study 
These graphs shows risk of bias on 7  
components across studies (a) and per study (b).  
Risk of bias was assessed with the Cochrane  
risk of bias tool
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Curry 2015 (ASTRAL-4) + + - + + + -
Dore 2015 (AI444-031) + + ? + + + -
Everson 2015 + + - + + + -
Foster 2011 + + - + + + -
Foster 2015 (ASTRAL-3) + + - + + + -
Foster 2015 (BOSON) + + - + + + -
Foster 2016 (EAP) - - - + + + -
Gane 2013 (ELECTRON) ? ? - + ? ? -
Gane 2015 + + - + + + -
Hézode 2015 (ATU) ? - ? + - ? -
Jacobson 2013 (FUSION) + + + + + + -
Jacobson 2013 (POSITRON) + + + + + + -
Lawitz 2013 (FISSION) + + - + ? + -
Lawitz 2015 - - - + + + -
Lawitz 2015* - - - + + + -
Leroy 2016 (ALLY-3+) + + - + + + -
Lin 2015* - - - + ? + -
Molina 2015* (PHOTON-2) - - - + + + -
Nelson 2015* (ALLY-3) - - - + + + -
Pianko 2015 + + - + + + -
Poordad 2015 (ALLY-1) - - - + ? ? -
Shah 2016 + ? - + ? + -
Sulkowski 2014 (AI444040) + + - + + + -
Sulkowski 2014 (PHOTON-1) - - - + + + -
Welzel 2015 (CUP) - - - + - ? -
Wyles 2015 (ALLY-2) + ? - + + + -
Zeuzem 2014 (VALENCE) - - - + + + -
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Supplementary File 8. 
Analysis with treatment naive and treatment experienced patients
Treatment naive patients      Treatment experienced patients
Regimen Estimated SVR 
(95% CrI) 
Regimen Estimated SVR 
(95% CrI) 
SOF + DCV + RBV 24 98.3 (96.2-99.5) SOF + VEL(100mg) 24 98.1 (95.4-99.5)
SOF + VEL(100mg) + RBV 12 98.8 (97.3-99.6) SOF + DCV + RBV 24 96.9 (92.0-99.2)
SOF + DCV + RBV 16 97.2 (93.4-99.1) SOF + VEL(100mg) + RBV 12 97.8 (94.5-99.4)
SOF + DCV 24 94.2 (86.9-98.1) SOF + DCV + RBV 16 94.7 (86.5-98.6)
SOF + VEL(100mg) 12 95.8 (91.6-98.3) SOF + DCV 24 89.6 (76.5-96.7)
SOF + DCV + RBV 12 93.1 (85.7-97.5) SOF + VEL(100mg) 12 92.4 (84.7-97.1)
SOF + PR 12 94.4 (88.6-97.8) SOF + DCV + RBV 12 87.8 (72.7-96.2)
SOF + LDV + RBV 12 88.9 (75.9-96.4) SOF + PR 12 89.9 (77.8-96.7)
SOF + DCV 12 78.6 (60.5-90.9) SOF + LDV + RBV 12 81.1 (58.7-94.4)
SOF + RBV 24 86.0 (76.5-92.7) SOF + DCV 12 66.8 (42.5-85.6)
SOF + LDV 12 68.8 (44.9-86.9) SOF + RBV 24 76.6 (58.2-89.6)
DCV + PR 16 86.8 (69.9-96.0) SOF + LDV 12 55.2 (28.4-79.8)
SOF + RBV 16 77.6 (63.7-88.0) SOF + RBV 16 65.2 (43.1-83.1)
TPR + PR 24 70.0 (34.7-93.4) SOF + RBV 12 43.1 (22.7-65.3)
PR 24 63.4 (45.1-79.1) SOF + VEL(25mg) + RBV 12 90.6 (75.5-97.8)
DCV + PR 12 72.5 (46.2-90.7) SOF + VEL(25mg) 12 73.5 (48.4-90.5)
SOF + RBV 12 57. (40.7-73.4)
OMB + PTV + RBV 12 43.5 (5.4-90.2)
SOF 12 27.4 (12.8-46.1)
OMB + PTV 12 21.4 (1.4-70.0)
SOF + VEL(25mg) 12 83.3 (64.7-94.4)
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Abstract
Background
A new era for the treatment of chronic hepatitis C is about to transpire. With the 
introduction of the first-generation protease inhibitors the efficacy of hepatitis C 
treatment improved significantly. Since then, the therapeutic agenda has moved further 
forward with the recent approval of sofosbuvir and the expected approval of agents 
such as simeprevir and daclatasvir. This paper, developed parallel to the approval of 
sofosbuvir, is to serve as guidance for the therapeutic management of chronic hepatitis 
C.
Methods
We performed a formal search through Pubmed, Web of science and ClinicalTrials.gov 
to identify all clinical trials that have been conducted with EMA-approved new agents 
in hepatitis C, for this version (April 2014) we focused on sofosbuvir. For each disease 
category, the evidence was reviewed and recommendations are based on GRADE.
Results
We identified 11 clinical trials with sofosbuvir and for each disease category 
recommendations for treatment are done. Not all disease categories were studied 
extensively and therefore in some cases we were unable to provide recommendations.
Conclusion
The recent approval of sofosbuvir will most likely change the therapeutic landscape of 
chronic hepatitis C. The use of sofosbuvir containing regimens can shorten the duration 
of therapy, increase efficacy and result in less side effects, compared to standard of 
care. The efficacy relative to the standard of care needs to be weighed against increased 
costs of sofosbuvir. With future approval of other direct acting antivirals, the outcome 
of hepatitis C treatment will likely improve further and this guidance will be updated.
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Introduction
The recent approval of sofosbuvir (NS5B polymerase inhibitor) and the expected 
approval of other direct-acting antivirals (DAAs) such as simeprevir (protease inhibitor, 
PI) and daclatasvir (NS5A inhibitor) will change the therapeutic arena for chronic 
hepatitis C.1 Until 2012 the treatment of chronic hepatitis C consisted of pegylated 
interferon with ribavirin (PR) for 24 to 48 weeks.2 As of April 2012 two first-generation 
protease inhibitors, telaprevir and boceprevir, were approved for reimbursement in the 
Netherlands for patients infected with hepatitis C virus (HCV) genotype 1.3 These agents 
improved efficacy but their safety profile was poor especially in cirrhotics.3-6
In the Netherlands, the estimated hepatitis C seroprevalence is 0.1 – 0.4%, and the 
highest prevalence is seen in first-generation migrants from HCV-endemic countries.7-9 
Approximately 50% of Dutch patients are infected with genotype 1, 30% with genotype 
3 and 10% with both genotype 2 and 4.10
Sofosbuvir can be regarded as a game changer, it is an orally administered nucleotide 
polymerase inhibitor, has pangenotypic activity in vivo, a high barrier to resistance and 
an acceptable safety profile.1, 11 Approval of other drugs in different classes of DAAs may 
be expected, first of all simeprevir (during revision approved) and daclatasvir. Additional 
drugs belonging to the protease inhibitor class (asunaprevir, ABT -450/r), the NS5A class 
(ledipasvir, ombitasvir) and the non nucleoside polymerase inhibitor class (dasabuvir) 
are in later stages of clinical development.1
This paper may serve as a current guidance for the therapeutic management of chronic 
hepatitis C. This update of the earlier guideline is necessary given the wealth of new 
information that has become available since.3 As a static version will become outdated, 
we encourage to review the most current version on the websites of Netherlands 
association of hepato-gastroenterologists (NVMDL) or Netherlands association of 
internal medicine (NIV).12
Methods
We performed a formal search through the databases Pubmed, Web of Science 
and ClinicalTrials.gov to identify all relevant clinical trials performed with sofosbuvir, 
peginterferon and/or ribavirin for this version (April 2014). In addition we searched for 
future therapies and for the product characteristics provided by the FDA and EMA. 
Opinions, letters, narrative reviews, pre-clinical studies and articles in another language 
than English, Dutch or German were excluded. The search string is attached in 
Supplementary File 1. We limited the search for patients with HCV mono-infection. For 
each disease category (treatment naive, treatment experienced and cirrhotic patients) 
the evidence was reviewed by the first and second author. The treatment experienced 
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category consists of patients with a prior relapse, prior partial response or prior null 
response. Sustained virological response (SVR) is defined as an HCV RNA below the 
lower limit of quantification at 12 weeks after the end of treatment. We listed the results 
of all individual trials in tables according to disease category. The level of evidence was 
formulated based on the GRADE method with the quality of evidence and a strength 
of recommendation (Supplementary File 2).13 The recommendations in this paper 
went through a formal approval process and was vetted by individual experts and all 
members of the NVMDL and representatives of the NIV.
Results
We formulated recommendations on basis of the available evidence and information 
from the label of sofosbuvir. The recommendations are given for each disease category. 
In case no recommendation is given, treatment can be deferred or we refer to the 
earlier guideline.3 First, all currently approved agents and expected agents are listed, 
followed by recommended treatment options for the different HCV genotypes once 
sofosbuvir is approved. Recommendations are valid for all patients with an indication 
for treatment as stipulated by the earlier guideline.3
List of currently approved drugs for treating chronic HCV infection:
- Peginterferon: polyethylene glycol attached to interferon-α 
 o Peginterferon α-2a:180μg/week
 o Peginterferon α-2b:1.5μg/kg/week
- Ribavirin: nucleoside analogue, weight based dose 
  (< 75 kg 1000 mg/day and ≥ 75 kg 1200 mg/day, BID)
- Protease inhibitors (-previr):
 o Simeprevir (during revision approved, will be included in updated version)  
 o Telaprevir: 2250 mg/day, BID or TID
 o Boceprevir: 2400mg/day,TID
- Nucleotide polymerase inhibitor (-buvir): 
 o Sofosbuvir: 400mg/day, QD
List of HCV drugs in development:
This list is not exhaustive and can be expanded, we aimed to include drugs that are in 
phase III development.1
- Protease inhibitors (-previr): 
 o Asunaprevir
 o Faldaprevir
 o ABT-450/r (ritonavir-boosted)
 o MK-5172
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- NS5A inhibitors (-asvir):
 o Daclatasvir
 o Ledipasvir
 o Ombitasvir (ABT-267) 
 o MK-8742
- Non nucleoside polymerase inhibitors (-buvir): 
 o Dasabuvir (ABT-333)
Watchful waiting
Watchful waiting is a preferable strategy in patients with no urgent indication for 
treatment based on the earlier guideline, in patients where no recommendation is 
given or when the quality of evidence is low and the strength of recommendation is 
weak (Level: C2).3 There are several arguments in favor of this strategy: (A) not all patient 
groups are represented in clinical trials, therefore the evidence for recommendations 
is weak in certain disease categories, (B) with the introduction of sofosbuvir we still 
need pegylated interferon and ribavirin in many patients and (C) improved efficacy 
and reduced toxicity is expected from interferon-free combinations of DAAs likely to be 
approved in the near future.1
Recommendations by HCV genotype, disease stage and 
treatment history:
Genotype 1 treatment naive patients:
Recommendation: Sofosbuvir, peginterferon and weight-based ribavirin for 12 weeks  
    (Level: B1)
Several trials have been performed in genotype 1 treatment naive patients 
(Table 1). The recommended therapy has been studied in two trials: 
NEUTRINO and ATOMIC. The NEUTRINO trial was a single group open label 
trial that achieved 89% SVR.14 Patients without cirrhosis obtained 90% SVR 
in the ATOMIC trial. There was no additional benefit (i.e. no difference in 
SVR) of extension of treatment to 24 weeks or by extension with sofosbuvir 
monotherapy or sofosbuvir and ribavirin (n= 264).15 The dose of sofosbuvir was 
determined on basis of the PROTON study where 200 and 400 mg of sofosbuvir 
were compared. Here the SVR rate was irrespective of the dose of sofosbuvir, 
however three patients in the 200 mg group had a viral breakthrough, hence 
the selection of 400 mg.16 Only one trial was of high quality, other trials were 
open label trials of low to moderate quality.13, 16
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Genotype 1 treatment experienced patients:
Recommendation: No recommendation based on data
Genotype 1 cirrhotic patients:
Recommendation: Watchful waiting (Level: C1)
Future perspective:
The ELECTRON trial was the only trial that included treatment experienced 
genotype 1 patients, these patients received sofosbuvir with ribavirin (12 
weeks), only one of ten patients achieved SVR.17 The label recommends 
consideration of treatment with sofosbuvir, peginterferon and ribavirin for 12 
weeks or extension to 24 weeks, but in our opinion more data are needed.18
Two clinical trials included patients with cirrhosis, the NEUTRINO trial reached 
80% SVR with sofosbuvir on top of PR and 3 of 6 cirrhotic patients with 
unfavorable characteristics achieved SVR with sofosbuvir and ribavirin in a 
single centre trial.14, 19 The quality of evidence for sofosbuvir is low, the toxicity 
of previous standard of care in cirrhotic patients is high and future agents (e.g. 
simeprevir) are promising, hence watchful waiting is recommended.4
For genotype 1 patients, multiple trials are currently underway, promising 
agents are simeprevir, asunaprevir, ABT-450/r (protease inhibitors), daclatasvir, 
ledipasvir, ombitasvir (NS5A inhibitors) and dasabuvir (non nucleoside 
polymerase inhibitor). All oral treatment is expected to become possible in 
the near future for both treatment naive and treatment experienced patients.
Simeprevir and sofosbuvir with or without ribavirin were studied in the 
COSMOS trial in two cohorts, in prior null-responders with F0-2 fibrosis (cohort 
1) and in treatment naive or prior null responders with F3-4 fibrosis (cohort 
2). High SVR rates were seen in cohort 1: 91-100% and in cohort 2: 94-96%.20, 
21, 22 Therefore the combined treatment of simeprevir and sofosbuvir can 
be a reasonable option for these categories of patients in the near future. 
Simeprevir with PR has been studied in the ASPIRE, PILLAR and PROMISE 
studies and high SVR rates of 70-85% are seen in cirrhotic patients with prior 
relapse or prior partial response.23-25 Clinical trials with simeprevir have shown 
that a Q80K mutation in genotype 1a patients significantly reduces efficacy of 
the treatment.26
Sofosbuvir plus daclatasvir with or without ribavirin for 12 or 24 weeks has 
been studied in the AI444040 study, 126 treatment naive genotype 1 patients 
achieved 98% SVR. Furthermore 41 patients who failed therapy with telaprevir 
or boceprevir had 98% SVR with 24 weeks of sofosbuvir and daclatasvir with 
or without ribavirin. Cirrhotic patients were excluded.27 Currently there is a 
compassionate use program of sofosbuvir and daclatasvir with or without 
ribavirin for Child-Pugh C patients available. 
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Table 1. Trials in HCV genotype 1 patients
PR = pegylated interferon with ribavirin; QoE: Quality of Evidence (A: high, B: moderate, C:low); RBV = ribavirin; SOF = 
sofosbuvir; SVR = sustained virological response; wb = weight based;  * calculated 95% CI; ^ first cohort early-moderate 
fibrosis; second and third cohort unfavorable characteristics; # in cirrhotics: treatment naive
The combination of an NS5B polymerase inhibitor and an NS5A inhibitor are 
also studied in the LONESTAR, ION-1, ION-2 and ION-3 study. The LONESTAR 
is a single centre open label study in genotype 1 treatment naive patients 
and patients with virological failure on protease inhibitors. An SVR of 95-100% 
(n=100) with different regimens (i.e. sofosbuvir/ledipasvir with or without 
ribavirin, 8 or 12 weeks) was reached.28 In the ION-1 and ION-2 trial SVR was 
reached in 94-98% of the patients with 12 weeks of sofosbuvir/ledipasvir 
with or without ribavirin.29, 30 In the ION-3 trial treatment naive non-cirrhotic 
patients achieved 94% SVR with 8 weeks of sofosbuvir/ledipasvir.31 Phase 2a 
trials have been performed with daclatasvir and asunaprevir in combination 
with PR or the non nucleoside polymerase inhibitor BMS-791325 in prior null 
responders and treatment naive patients for 12-24 weeks. High SVR rates, 92-
100%, were achieved.32-34 Three studies (n=571, n=297 and n=473) evaluated 
multiple regimens with ABT- 450/r, dasabuvir and ombitasvir with or without 
ribavirin in different combinations and durations. High SVR rates (83%-97%) 
were seen in treatment naive and treatment experienced non-cirrhotic 
patients.35-37 The TURQUOISE-II trial studied the same regimen (with ribavirin) 
in compensated cirrhotics for 12 (n= 208) and 24 (n=172) weeks. SVR was 
achieved in respectively 92% and 96% of the patients.38
Trial         Regime (weeks)   n         SVR             SVR (95% CI)         QoE
          0    4    8    12                 24   //   48        0       50        100
Genotype 1, treatment naive
PROTON          SOF(200)+PR     PR    PR 48         90%                A
          SOF(400)+PR     PR            PR 47         91%                 A
          Placebo+PR     PR             26         58%                   A
NEUTRINO        SOF+PR                    292       89%                C
ELECTRON        SOF+RBV   25         84%                C
ATOMIC          SOF+PR     52         90%                B
          SOF+PR                  109        93%                B
          SOF+PR          SOF(+RBV)                 155        91%                B
Osinusi et al^      SOF+RBV(wb)   10         90%                C
          SOF+RBV(wb)   25         68%                C
          SOF+RBV(600)        25         48%                C
Genotype 1, treatment experienced
ELECTRON        SOF+RBV   10        10%                C       
Genotype 1, cirrhosis
NEUTRINO        SOF+PR                  54#        80%                C
Osinusi et al* ^    SOF+RBV(wb)   6#         50%                C
          SOF+RBV(600)   7#         29%                C
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Genotype 2 treatment naive patients:
Recommendation: sofosbuvir and weight-based ribavirin for 12 weeks (Level: A1)
Genotype 2 treatment experienced patients:
Recommendation: sofosbuvir and weight-based ribavirin for 12 weeks (Level: B1)
Patients with an HCV genotype 2 infection have an SVR rate of 74-83% with 
PR for 24 weeks.3, 39, 40 Multiple trials with sofosbuvir have been performed 
in treatment naive genotype 2 patients (Table 2). Two trials of high quality 
and one of low quality studied the recommended interferon-free regimen 
(POSITRON, FISSION and VALENCE) with consistent good results. The 
POSITRON trial included patients for whom interferon was not an option 
and reached 93% SVR irrespective of cirrhosis.11 In the FISSION trial SVR was 
reached in 97% of patients, while in patients treated with peginterferon and 
ribavirin (800 mg) for 24 weeks SVR was achieved in 78%.14 The results of the 
VALENCE trial are similar to FISSION and POSITRON for the recommended 
regimen.41, 42 Addition of peginterferon showed no improved SVR rates.16, 17 In 
conclusion, sofosbuvir with ribavirin for 12 weeks in genotype 2 patients was 
effective in high quality trials with implications for clinical practice because 
of an interferon free regimen with a shorter treatment duration than previous 
standard of care.3
In the FUSION trial, genotype 2 patients were treated with either 12 or 16 weeks 
of sofosbuvir and ribavirin. Patients in the 12 weeks arm received four weeks 
of placebo, they reached 86% SVR and in the 16 weeks arm this was 94%. 
For non-cirrhotic patients the FUSION trial failed to demonstrate additional 
value of extending the treatment to 16 weeks, hence the recommendation 
of 12 weeks.11 The POSITRON included 17 patients with unacceptable side 
effects in prior treatment and they achieved an SVR of 78% with sofosbuvir 
and ribavirin.11 The results of the VALENCE trial demonstrated a 90% SVR 
with the recommended regimen.18, 42 In another trial there was no additional 
value of peginterferon.43 Again this treatment has significant implications for 
clinical practice because of the high SVR rates without interferon and shorter 
treatment duration. The trials were of high and low quality with consistent 
results.11, 41, 43
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Table 2. Trials in HCV Genotype 2 patients
PR = pegylated interferon with ribavirin; QoE: Quality of Evidence (A: high, B: moderate, C:low); RBV = ribavirin; SOF 
= sofosbuvir; SVR = sustained virological response; *calculated 95% CI; $ data of genotype 2 and 3 combined; In 
cirrhotics: # treatment naive, & treatment experienced
Trial         Regime (weeks)   n         SVR             SVR (95% CI)         QoE
          0    4    8    12                 24   //   48        0       50        100
Genotype 2, treatment naive
POSITRON         SOF+RBV                  109       93%                A
          Placebo   34         0%                  A  
FISSION          SOF+RBV   70        97%                A 
          PR (RBV800)   67        78%                A
PROTON          SOF+PR   25$       92%                B   
ELECTRON        SOF+(P)R   40$       100%                B
          SOF+PR   10$       100%                 B
           SOF    10$       60%                B
VALENCE           SOF+RBV   32        97%                 C 
Genotype 2, treatment experienced
FUSION          SOF+RBV   36        86%                A
          SOF+RBV   32        94%                A
POSITRON         SOF+RBV   17$       77%                A
          Placebo    8$         0%                A
VALENCE           SOF+RBV   41        90%                C
LONESTAR-2*     SOF+PR   23        96%                 C 
Genotype 2, cirrhosis
POSITRON*        SOF+RBV   17#       94%                A
          Placebo   13$#       0%                A
FISSION             SOF+RBV   49$#      47%                A 
          PR (RBV800)   50$#      38%                A
VALENCE           SOF+RBV    2#        100%                C 
      9&        78%                C
FUSION          SOF+RBV   10&       60%                A 
          SOF+RBV    9&        78%                A
LONESTAR-2*     SOF+PR   14&       93%                C
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Genotype 2 cirrhotic patients:
Recommendation: sofosbuvir and weight-based ribavirin for 12 weeks (Level: B1)
Future perspective
Genotype 3 treatment naive patients:
Recommendation:
     o watchful waiting
     o peginterferon and ribavirin (800mg) for 24 weeks
     o sofosbuvir and weight-based ribavirin for 24 weeks
     o sofosbuvir, peginterferon and weight-based ribavirin for 12 weeks
     (Level A2)
There are four trials that evaluated sofosbuvir and ribavirin for 12 weeks 
in cirrhotic genotype 2 patients, mainly treatment naive patients were 
studied. The FISSION demonstrated an SVR of 83% (n=12), treatment with 
peginterferon and ribavirin (800 mg) for 24 weeks led to 62% SVR (n=13).14, 18 
The POSITRON trial showed an SVR of 94%. In treatment-experienced patients 
with cirrhosis an extension of duration of treatment from 12 to 16 weeks led to 
an improvement in SVR from 60% (n= 10) to 78% (n= 9) in the FUSION trial.11 
The VALENCE trial shows 82% SVR in 11 cirrhotic patients with sofosbuvir 
and ribavirin (12 weeks).18, 44 All trials included only small numbers of patients, 
but implications for clinical practice are high as treatment is warranted and 
toxicity is expected to be less than standard of care.
For genotype 2 patients the regimen of sofosbuvir with ribavirin leads to 
high SVR rates. Also, the AI444040 trial studied 26 treatment naive genotype 
2 patients, 24 (92%) achieved SVR with different regimens consisting of 
sofosbuvir and daclatasvir with or without ribavirin for 24 weeks. Cirrhotic 
patients were excluded.27
For genotype 3 patients, several options for treatment are available and the 
physician has to decide which strategy is currently better for the individual 
patient. Historically genotype 2 and genotype 3 patients achieve an SVR of 
70-80% with peginterferon and ribavirin (800 mg) for 24 weeks.3
Different trials have been performed in genotype 3 patients, all trials with 12 
weeks of sofosbuvir and ribavirin fail to show superiority in comparison with PR 
treatment (Table 3).14 The addition of peginterferon or extension of treatment 
to 24 weeks showed improved results. In the ELECTRON trial, 25 patients 
received 12 weeks of sofosbuvir and ribavirin combined with peginterferon for 
0, 4, 8 or 12 weeks, all patients achieved SVR.17 The VALENCE trial obtained 94% 
SVR in 105 patients with sofosbuvir with ribavirin for 24 weeks.18, 42 Because of 
above mentioned results peginterferon with ribavirin (800 mg) for 24 weeks 
remains an option for therapy, ribavirin should be weight-based in patients
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Genotype 3 treatment experienced patients:
Recommendation:  Watchful waiting
Alternative strategy: sofosbuvir and weight-based ribavirin for 24 weeks OR sofosbuvir, 
     peginterferon and weight-based ribavirin for 12 weeks (Level: B2)
Genotype 3 cirrhotic patients:
Recommendation:  Watchful waiting
Alternative strategy: sofosbuvir and weight-based ribavirin for 16 weeks OR sofosbuvir  
     and weight-based ribavirin for 24 weeks (Level: B2)
with baseline characteristics associated with a poor response.3 Other options 
are watchful waiting, sofosbuvir with ribavirin for 24 weeks or sofosbuvir with 
PR for 12 weeks. The choice for one of the regimens is dependent on the 
individual patient, bearing in mind the higher costs of sofosbuvir.
Results of sofosbuvir for treatment experienced genotype 3 patients are 
disappointing with high imprecision, only the VALENCE and LONESTAR-2 trials 
show acceptable results but are of low quality. The FUSION trial showed that 
extension of treatment with 4 weeks led to improvement of SVR.11 Extension 
to 24 weeks was done in the VALENCE study and an SVR of 79% was achieved, 
while for the non-cirrhotics the SVR rate was 87%.18, 42 The LONESTAR-2 trial 
showed an SVR of 83% in 24 patients treated with sofosbuvir and PR for 12 
weeks.43 In the near future more effective combinations of DAAs are expected. 
Therefore the general recommendation is watchful waiting. As an alternative 
strategy sofosbuvir with ribavirin for 24 weeks or sofosbuvir with PR for 12 
weeks may be considered.
Genotype 3 cirrhotic patients were treated with sofosbuvir in five trials with 
moderate SVR rates. The FUSION trial showed an SVR of 19% with 12 weeks 
sofosbuvir and ribavirin in treatment experienced cirrhotic patients, extension 
of treatment to 16 weeks showed an SVR of 61%. The VALENCE trial studied 
24 weeks of sofosbuvir and ribavirin in 60 cirrhotic patients, with 92% SVR in 
treatment naive patients and 62% in treatment experienced patients.18 Based 
on above results with small numbers of patients we advise watchful waiting as 
the recommended strategy since SVR rates are rather low, mainly in treatment 
experienced patients and sofosbuvir is expensive. Alternative regimens are 
sofosbuvir and ribavirin for 16 weeks or 24 weeks.
Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era
8
154
Table 3. Trials in HCV Genotype 3 patients
PR = pegylated interferon with ribavirin; QoE: Quality of Evidence (A: high, B: moderate, C:low); RBV = ribavirin; SOF 
= sofosbuvir; SVR = sustained virological response; *calculated 95% CI; $ data of genotype 2 and 3 combined; In 
cirrhotics: # treatment naive, & treatment experienced
Future perspective
Trial         Regime (weeks)   n         SVR             SVR (95% CI)         QoE
          0    4    8    12                 24   //   48        0       50        100
Genotype 3, treatment naive
POSITRON         SOF+RBV                   98         61%                A
          Placebo   37          0%                  A  
FISSION          SOF+RBV                  183        56%                A 
          PR (RBV800)                  176        63%                A
PROTON          SOF+PR   25$        92%                B   
ELECTRON        SOF+(P)R   40$       100%                B
          SOF+PR   10$       100%                 B
           SOF    10$        60%                B
VALENCE           SOF+RBV   11         27%                 C 
          SOF+RBV   105       94%                C
Genotype 3, treatment experienced
FUSION          SOF+RBV   64         30%                A
          SOF+RBV   63         62%                A
POSITRON         SOF+RBV   17$        77%                B
          Placebo    8$          0%                B
VALENCE           SOF+RBV                  145        79%                C
LONESTAR-2*     SOF+PR   24         83%                 C 
Genotype 3, cirrhosis
POSITRON*        SOF+RBV   14#        21%                A
          Placebo   13$#        0%                A
FISSION             SOF+RBV   49$#       47%                A 
          PR (RBV800)   50$#       38%                A
VALENCE           SOF+RBV   13#        92%                C 
     47&        62%                C
FUSION          SOF+RBV   26&        19%                A 
          SOF+RBV   23&        61%                A
LONESTAR-2*     SOF+PR   12&        83%                C
Daclatasvir is one of the agents that is expected to be approved in the 
near future. The COMMAND GT 2/3 study included 151 genotype 2 and 3 
patients and these patients received either 12 or 16 weeks daclatasvir with 
PR or 24 weeks placebo with PR. SVR rates were 69% (12 weeks), 67% (16 
weeks) and 59% (placebo). Treatment failure was mainly due to relapse in 
cirrhotic patients in the 12 week group.45 The combination of sofosbuvir and
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Genotype 4 treatment naive patients:
Recommendation: sofosbuvir, peginterferon and weight-based ribavirin for 12 weeks.  
    (Level: C1)
Genotype 4 treatment experienced patients:
Recommendation: No recommendation based on data
Genotype 4 cirrhotic patients:
Recommendation: No recommendation based on data
Future perspective
daclatasvir with or without ribavirin for 24 weeks does hold promise for 
treatment naive genotype 3 patients as SVR rates of 89% can be reached.27 
Treatment naive genotype 3 patients received sofosbuvir/ledipasvir with or 
without ribavirin in the ELECTRON-2 trial (12 weeks). Dual therapy reached 
64% SVR (n=25) while triple therapy reached 100% SVR (n=26).46
The recommended regimen is studied in the NEUTRINO trial, 28 patients 
were treated with sofosbuvir and PR for 12 weeks and reached 96% SVR.14 
Extension of therapy to 24 weeks did not show improved effect.15 Egyptian 
patients (n=28) received an interferon free regimen for 12 or 24 weeks and 
achieved 79% and 100% SVR respectively.47 In general, data are scarce 
(Table 4) but in view of the high SVR rates sofosbuvir based treatment is 
recommended.
There are no published data of sofosbuvir based treatment available for 
treatment experienced genotype 4 patients. The most recent data of the 
Egyptian study showed 59% SVR (n=17) with 12 weeks sofosbuvir and ribavirin 
and 87% SVR (n=15) with 24 weeks sofosbuvir and ribavirin.47, 48 The label 
recommends sofosbuvir and PR for 12 weeks, but more data are needed.
Only limited number of cirrhotic genotype 4 patients have been studied. The 
NEUTRINO trial included two cirrhotic genotype 4 patients of whom one 
achieved SVR with sofosbuvir and PR for 12 weeks.14 In the Egyptian study 
treatment naive cirrhotic patients achieved 33% (n=3) and 100% (n=3) SVR 
with 12 and 24 weeks of sofosbuvir and ribavirin. The SVR rates in treatment 
experienced patients were 50% and 100% in both groups (n=8).47
Simeprevir with PR (24 or 48 weeks) is studied in genotype 4 patients, overall 
65% of the patients reached SVR with higher SVR rates in treatment naive 
or relapse patients (83% and 86%).49 Asunaprevir with PR has been studied 
in 18 genotype 4 patients for 24 weeks and 89% reached SVR, the control
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Genotype 5, 6
Genotype 5, 6 treatment naive patients:
Recommendation:
 o Genotype 5: No recommendation based on data, consider genotype 1  
    treatment regimen as template (Level: C2)
 o Genotype 6: sofosbuvir, peginterferon and weight-based ribavirin for 12  
    weeks (Level: C2)
Genotype 5,6 treatment experienced patients:
Recommendation: No recommendation based on data, consider genotype 1     
    treatment regimen as template (Level: C2)
group consisted of 7 patients of whom 43% reached SVR with PR for 48 
weeks.50 Furthermore daclatasvir was studied in 24 treatment naive genotype 
4 patients, 67% achieved SVR with 20 mg daclatasvir and 100% achieved SVR 
with 60 mg daclatasvir with PR for 24 weeks.51 Daclatasvir with asunaprevir 
and BMS-791325 were studied in 12 patients, 11 achieved SVR and 1 patient 
is still in follow-up.52 The PEARL-I study included 86 treatment-naive genotype 
4 patients who received ABT-450/r plus ombitasvir with or without ribavirin (12 
weeks), 91-100% SVR was achieved.53 Patient numbers are limited but in view 
of the high SVR rates of future therapy, watchful waiting can be considered in 
genotype 4 patients until further data allow approval of newer DAAs.
Data from well powered clinical comparative trials for genotype 5 and 6 
patients are lacking. We think it is unlikely that such data will become available 
in the near future for the novel DAAs. Therefore we consider it acceptable to 
use treatment results for genotype 1 as a template for treatment of genotype 
5 and 6.
Only twelve treatment naive patients with genotype 5 or 6 have been treated 
in two trials (NEUTRINO and ATOMIC). In the NEUTRINO trial six genotype 
6 patients and one genotype 5 patient have been treated with 12 weeks 
sofosbuvir and PR and all patients achieved SVR.14 In the ATOMIC trial only 
five patients with genotype 6 received sofosbuvir with PR for 24 weeks, all 
achieved SVR.15 More data is needed, however considering the high SVR rates 
a sofosbuvir based treatment is recommended for genotype 6.
There are no data of sofosbuvir based treatment available for treatment 
experienced genotype 5 or 6 patients.
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Genotype 5, 6 cirrhotic patients:
Recommendation: No recommendation based on data, consider genotype 1   
    treatment regimen as template (Level: C2)
Table 4. Trials in HCV Genotype 4, 5 and 6 patients
PR = pegylated interferon with ribavirin; QoE: Quality of Evidence (A: high, B: moderate, C:low); RBV = ribavirin; SOF 
= sofosbuvir; SVR = sustained virological response; *calculated 95% CI, if 100% SVR then no CI could be calculated; 
In cirrhotics: # treatment naive, & treatment experienced
Drug-drug interactions
Many of the DAAs are substrates of CYP450 and the membrane transporter P-gp; they 
may both be the victim of drug interactions or cause these interactions with other 
agents.54, 55 Sofosbuvir has a relatively mild drug interaction profile as it is only a 
substrate of P-gp and does not interfere with CYP450 enzymes. It is necessary to check 
for interacting co-medications, including over the counter drugs (e.g. St. John’s worth), 
before starting DAA-based HCV treatment (http://www.hep-druginteractions.org).
The NEUTRINO trial included 20% cirrhotic patients but it is unknown if 
cirrhotic genotype 5 or 6 patients were included.14
Trial         Regime (weeks)  n         SVR             SVR (95% CI)         QoE
          0    4    8    12                 24   //   48        0       50        100
Genotype 4, treatment naive
NEUTRINO         SOF+PR                   28          96%                C
ATOMIC           SOF+PR                  11          82%                C
Ruane et al*        SOF+RBV                  14          79%                C
           SOF+RBV                   14         100%                C
Genotype 4, treatment experienced
Ruane et al*        SOF+RBV                  17          59%                C       
           SOF+RBV                  15          87%                C
Genotype 4, cirrhosis
NEUTRINO*        SOF+PR                   2#          50%                C
Ruane et al*        SOF+RBV   3#          33%                C
              4&          50%                C
           SOF+RBV   3#         100%                C     
     4&         100%                 C    
Genotype 5 and 6, treatment naive
NEUTRINO*        SOF+PR   7          100%                C
ATOMIC           SOF+PR   5          100%                C 
Genotype 5 and 6, treatment experienced
No available trials
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Discussion
The current guidance comes at a time that the landscape of HCV treatment undergoes 
a rapid change. There are currently four comparable guidelines, one was issued by the 
AASLD, one by EASL and the other two are guidelines from Germany.56-59 Our guidance 
differs from the AASLD and EASL guidelines and we do not offer advice on the use of 
simeprevir and daclatasvir in this version. The main difference with the other guidelines 
is that we offer the clinician the option to defer treatment in genotype 3 and some 
subgroups of patients. The main reason is that the currently published evidence, except 
for the VALENCE trial, has not proved efficacy beyond standard of care. The proportion 
of cirrhotics in the various trials is disappointingly low and recommendations cannot 
be given for this category, with the exception of genotype 2. This contrasts with clinical 
practice where cirrhotic patients have the most urgent treatment indication.3
For genotypes 5 and 6 the current evidence is poor. The AASLD, EASL and German 
guidances recommend sofosbuvir triple therapy for genotype 5 and 6. The consensus 
in the Hepatology committee was that the evidence for sofosbuvir was acceptable 
for genotype 6 naive patients, while we recommend standard of care or considering 
the genotype 1 regimen as template for other disease categories in genotype 5 and 
6. At odds with other guidances we do not recommend sofosbuvir based treatment 
for genotype 1 and 4 treatment experienced patients given the lack of evidence. This 
guidance only includes recommendations for HCV monoinfected patients. Sofosbuvir 
and other DAAs are also studied in HIV/HCV patients, this will be updated in a new 
version of this guidance.
The rapid pace of development of drugs to treat HCV infection introduces not only great 
expectations but also uncertainty about the optimal timing to initiate therapy.60 The 
key question here is which patients can benefit from the DAAs that are available now. 
Sofosbuvir is a first-generation polymerase inhibitor that is in the vanguard of a wave 
of drugs that have the potential to cure HCV. With the approval by EMA, sofosbuvir will 
be released on the Dutch market soon. As medication is an important costdriver, the 
added efficacy of sofosbuvir relative to standard of care should be weighed carefully.61 
As the pipeline with new antiviral drugs is full and new releases can be expected in 
2014 and 2015, this paper serves as a dynamic document and will be continually edited 
and updated.12
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Summary box of recommendations for HCV monoinfected patients:
Dosing for currently recommended agents:
- Sofosbuvir  400 mg once daily oral; there are no data in patients with 
   renal impairment available (eGFR < 30 ml/min/1.73m2)
- Peginterferon α-2a  180μg/week subcutaneous
  Peginterferon α-2b 1,5 μg/kg/week subcutaneous
- Ribavirin  weight based: < 75 kg 1000 mg/day, ≥ 75 kg 1200 mg/day,  
   BID
 Geno
 type
  1
  2
  3
  4
  5,6
Patient group
Treatment naive
Treatment experienced 
Cirrhotic
Treatment naive 
Treatment experienced 
Cirrhotic
Treatment naive
Treatment experienced
Cirrhotic
Treatment naive 
Treatment experienced 
Cirrhotic
Treatment naive
Treatment experienced 
Cirrhotic
Recommendation
Sofosbuvir, peginterferon and ribavirin for 12 
weeks 
No recommendation based on data
Watchful waiting
Sofosbuvir and ribavirin for 12 weeks 
Sofosbuvir and ribavirin for 12 weeks
Sofosbuvir and ribavirin for 12 weeks
Physician opinion to determine the strategy, 
options: 
  - Watchful waiting
  - Peginterferon and ribavirin (800 mg) for 24 
    weeks 
  - Sofosbuvir and ribavirin for 24 weeks
  - Sofosbuvir, peginterferon and ribavirin for  
    12 weeks 
Watchful waiting
Alternative strategy: Sofosbuvir and ribavirin 
for 24 weeks OR Sofosbuvir, peginterferon 
and ribavirin for 12 weeks 
Watchful waiting
Alternative strategy: Sofosbuvir and ribavirin 
for 16 weeks OR Sofosbuvir and ribavirin for 
24 weeks
Sofosbuvir, peginterferon and ribavirin for 12 
weeks 
No recommendation based on data
No recommendation based on data
Genotype 5: No recommendation based on 
data, consider genotype 1 treatment regimen 
as template 
Genotype 6: Sofosbuvir, peginterferon and 
ribavirin for 12 weeks
No recommendation based on data, consider 
genotype 1 treatment regimen as template 
No recommendation based on data, consider 
genotype 1 treatment regimen as template
Future perspective
Daclatasvir, simeprevir, 
ledipasvir, asunaprevir, 
ABT- 450/r, dasabuvir, 
ombitasvir
Daclatasvir
Daclatasvir, ledipasvir
Simeprevir, 
daclatasvir, 
asunaprevir, ABT- 
450/r, ombitasvir
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Supplementary Files
Supplementary File 1. Search
An initial search was conducted on 25-Feb-2014 with the term: ‘2-((5-(2,4-dioxo-3,4-
dihydro-2H-pyr imidin-1-yl ) -4-f luoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)
phenoxyphosphorylamino) propionic acid isopropyl ester [Supplementary Concept]’ as a Mesh term. 
Furthermore we included ‘sofosbuvir OR GS-7977 OR PSI 7977 OR PSI7977 OR PSI-7977 OR Sovaldi’ 
in our search. In total 98 articles were found in Pubmed. All were scanned on title and abstract 
for inclusion. New results of the search were added until 8-Apr-14. For the future perspectives we 
searched the agents in phase III of clinical trials, including simeprevir (as Mesh combined with 
‘simeprevir OR TMC 435350 OR TMC435350 OR TMC-435350 OR Olysio OR TMC 435 OR TMC435 
OR TMC-435’, with the limit of clinical trials). We did the same for daclatasvir, ledipasvir, asunaprevir 
and the ABT formulations in Pubmed. Clinicaltrials.gov was used to get more information about the 
unpublished trials. Prior to submission, the abstracts of the International Liver Congres 2014 (49th 
annual meeting of the European Association for the Study of the Liver) were scanned and relevant 
studies were included in the future perspectives of the different genotypes.
Supplementary File 2. Evidence grading (adapted from the GRADE system)
Level Evidence quality Strenght of recommendation
A1 High  Strong
B1 Moderate  Strong
C1 Low  Strong
A2 High  Weak
B2 Moderate  Weak
C2 Low  Weak
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The main aim of this thesis was to improve translation of results from clinical trials with 
direct acting antivirals (DAAs) in chronic hepatitis C to clinical practice. In 2012, the first 
signs of a development paradox in first-generation DAAs for chronic hepatitis C virus 
(HCV) became apparent. HCV patients treated in real world conditions had unexpected 
high rates of serious adverse events (SAEs) compared to those included in registration 
trials.1 These trials were the basis for approval of these agents by regulatory authorities 
and should have given us a comprehensive picture of safety and efficacy of these agents. 
This was clearly not the case, and this motivated us to study the reasons for this paradox 
in Dutch HCV patients. We initiated a nationwide retrospective registry of all patients 
treated with the first-generation DAAs, telaprevir or boceprevir (n=467). We studied the 
generalizability of trials as a first step in translation of evidence from trials to practice. 
Further, we interpreted evidence from trials by conducting a network meta-analysis and 
by developing a guidance for HCV treatment in the Netherlands.
Generalizability of trials to clinical practice
In chapter 2 we demonstrated that generalizability of trials with first-generation DAAs 
was poor. Almost half of patients who were treated in clinical practice would have 
been excluded from registration trials. Excluded patients had significantly more SAEs 
when exposed to first-generation DAAs than eligible patients (27% vs. 11%, p<0.001). 
DAAs were less effective in excluded patients in case very strict exclusion criteria 
were applied. In contrast, the real world patients who were eligible for the trials had 
comparable results as obtained from registration trials. Thus, the results of trials were 
only generalizable to patients who completely fulfilled the eligibility criteria.2
We studied three problems that might arise as a result of limited generalizability: 
chapter 3 and chapter 4 are about adverse events and chapter 6 about drug-drug 
interactions (DDIs). In the pegylated interferon era, research was focused on the risk of 
infections and bleeding episodes related to bone marrow toxicity of peginterferon.3-6 
In chapter 3 we found that 31% of patients treated with peginterferon, ribavirin and 
telaprevir or boceprevir developed an infection during therapy and 7% was categorized 
as severe.7 This is in line with infection rates found with dual (peginterferon and ribavirin) 
therapy but are higher than those reported in the registration trials of telaprevir and 
boceprevir (severe infections 1-3%).8-12 The CUPIC cohort was the first to describe the 
increased risk of infections in clinical practice with protease inhibitors. Patients with 
an albumin <35g/dL and a platelet count ≤100 x109/L had the highest risk, which is 
similar to findings from our study.13 Both albumin and platelet count were identified in 
chapter 2 as important exclusion criteria affecting generalizability, so the exclusion of 
these patients from the registration trials probably was key to the lower infection rates. 
In the subsequent study (chapter 4) we showed that 22% of patients experienced a 
bleeding episode, but majority (>80%) of bleedings were mild and did not necessitate 
intervention. The incidence of bleedings in our cohort was higher than reported in 
other dual therapy cohorts, possibly related to the protease inhibitor.5, 14  In contrast, 
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the registration trials did not report bleeding episodes, suggesting that the prevalence 
was <10%. However, as the majority of bleeding episodes were mild, lack of generalizability 
did not seem to be a problem here.
Another interesting topic is the risk for DDIs. None of the registration trials of telaprevir 
and boceprevir gave a risk assessment or indicated relevance of DDIs. An extensive 
review highlighted this issue and summarized the DDIs with > 60 frequently used co-
medications in HCV.15 In addition, we found in chapter 2 that concomitant medication 
was the most important reason for exclusion from trials in clinical practice. Not only 
the first-generation DAAs carry a risk for DDIs. In chapter 6 we predicted the risk 
on DDIs of concomitant medication and new generation DAAs with the help of the 
Liverpool database (www.hep-druginteractions.org). We found that 60% of all patients 
were at risk for a relevant DDI with one of the DAA regimens. Our results are in line 
with other cohorts and support the involvement of a pharmacist when initiating 
HCV treatment.16, 17 DDIs are clinically important because they can lead to decreased 
effectiveness or increased toxicity of both DAA and the concomitant drug. It is essential 
that pharmaceutical companies clearly describe this limitation of generalizability not 
only in the label, but also in the papers.
In chapter 2 we identified criteria which affected effectiveness and safety, i.e. hepatic 
decompensation and co-morbidity such as cardiac disease and anemia. It turned out 
that these criteria were similar to important predictors of response in large real world 
cohorts with new generation DAAs: history of (decompensated) cirrhosis, platelet count, 
total bilirubin, serum albumin, and hemoglobin.18 Unfortunately, criteria concerning 
co-morbidity and co-medication are often poorly justified in drug intervention studies.19 
By improving justification of criteria, generalizability will likely increase as well. With 
this in mind we were interested in the generalizability of the new generation DAAs. In 
chapter 5 we showed that the patients in registration trials resemble real world patients 
more and more over time, indicating that the gap between trials and practice is closing. 
This probably results in an increased generalizability, which is indeed corroborated 
by the comparable effectiveness and safety results from large real world cohorts.18, 20 
Although, to assess the eligibility rate of a trial, the full set of eligibility criteria should be 
readily available. Unfortunately this is often not the case.21 We were able to find 34 of 43 
protocols (79%) in chapter 5, mainly because journals required to publish the protocols. 
However, even some landmark trials, for example the COSMOS trial, did not reveal the 
complete eligibility criteria.22 In addition, the global trial register (ClinicalTrials.gov) 
often does not report the full set of eligibility criteria as well.23 In our experience, mainly 
criteria on co-morbidity, co-medication and laboratory values are lacking, while these 
criteria are equally important.
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Interpretation of evidence in clinical practice
For interpretation of evidence in clinical practice is good generalization necessary, 
but also comparative effectiveness data to identify which treatment option is best 
for the patient. In the field of HCV only few head-to-head comparisons have been 
performed and often the comparative arm was not standard of care.24 Physicians 
and guideline developers need comparative effectiveness data to justify choices and 
prioritize treatments, and this information is often lacking. Yet, there are some ways to 
interpret data in case no comparative effectiveness studies are executed, for example 
by performing a network meta-analysis.25, 26 In chapter 7 we adopted a network meta-
analysis and identified that sofosbuvir/velpatasvir regimens achieved highest SVR rates 
in HCV genotype 3 patients. In addition we found that ribavirin significantly boosts 
SVR rates in all patients (OR 2.6-4.5).27 This methodology can be applied in other fields. 
However, it should not discourage pharmaceutical companies or researchers to design 
comparative effectiveness trials.
The rapid changing therapeutic landscape in HCV led to the need of a guidance in the 
Netherlands.28 Chapter 8 is the first version of this Dutch guidance for treatment of 
HCV patients, developed after the approval of sofosbuvir.29 After the publication there 
was an initiative to collaborate with several associations within the Netherlands for 
the guidance (NIV, NVHB, NVMDL, NVH and NVZA). Collectively we aimed to guide 
physicians practically regarding indication and therapy for HCV patients and strived 
for a uniform and high quality treatment (www.hcvrichtsnoer.nl). Instead of grading all 
the published papers ourselves we summarized recommendations from international 
guidelines, applied this to the Dutch situation, and updated the website already six 
times in 2015-2016 after important new data or DAA approval.30-33
Reflection
With this thesis we aimed to improve translation of trials to clinical practice in HCV. 
The difficulty was the rapidly changing therapeutic field from availability of (solely) 
peginterferon and ribavirin until 2012 to a comprehensive set of interferon-free DAA 
combinations in 2016. One of the strengths of this thesis is that we were able to set 
up a nationwide registry with data of patients treated with first-generation DAAs 
from 47 hospitals. Unfortunately, collection of data was time-consuming which led to 
publication of our study at the time that first-generation DAAs were not prescribed 
anymore in the Netherlands. The retrospective character of the registry was another 
limitation, although, we think this does not lead to relevant bias as HCV is a straight 
forward disease with standardized therapy regimens, outpatient visits and an objective 
outcome measure (SVR: HCV RNA negativity 12 or 24 weeks after treatment). In 
addition, there were already several competing large prospective registries worldwide 
(e.g. TRIO, HCV-TARGET, Veterans Affairs) which study classic research questions about 
effectiveness and safety of DAAs in real world patients. 
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By focusing on generalizability issues we identified an important niche in HCV 
research. We discovered general principles, relevant for the development of new DAAs. 
Furthermore, despite the fact that telaprevir and boceprevir are not prescribed in the 
Netherlands anymore, we believe the research is still relevant for countries prescribing 
interferon based therapy.
Another strength of this thesis is that we used a relative new technique to interpret data 
from trials to practice. By using the network meta-analysis we could establish the most 
optimal regimen, but also the role of ribavirin in HCV. This was important because it was 
not properly studied in trials and could not be assessed in registries (confounding by 
(contra)indication). We do encourage researchers to use this methodology, as it provides 
relevant data for guideline developers. Concerning our guidance, it is unique that it is 
supported by hepatologists, infectiologists, and pharmacists in the field. We believe it 
has contributed to a uniform and high quality therapy in the Netherlands. Of course, 
this guidance is no formal guideline and not all evidence was assessed by ourselves, 
which is a limitation. At this time, this was the most feasible manner to produce an 
up-to-date guidance. We would advise the Dutch guidance group to write a formal 
evidence-based guideline once the key developments in field have happened.
Future directions
Ideally, registration trials (phase 3 trials) should be perfectly generalizable to the real 
world, i.e. registration trials should include all subgroups of patients with mild to severe 
disease (probably in separate studies), with various co-morbidities and concomitant 
medications. Results obtained in these trials should be directly translatable to practice. 
We have shown that generalizability in HCV was hampered because of use of strict 
inclusion and exclusion criteria. However, this issue is not unique to HCV but is also seen 
in psoriasis, rheumatoid arthritis and inflammatory bowel disease.34-36 Justification of 
each exclusion criterion is essential to limit the selection bias.19
We do acknowledge that the outlined ideal situation is costly, time-consuming and 
often not feasible. However there are some ways to deal with the current shortcomings 
(visualized in Figure 1).37 One option is to execute a pragmatic trial just before of after 
registration. In this trial there are no restrictions regarding inclusion or exclusion, but 
patients are randomized between the intervention and standard of care.38 Further, we 
urge pharmaceutical companies to include specific subgroups of patients with severe 
disease in an early stage of research to assess the risks of therapy. Another option for 
these patients is a compassionate use or early access program, launched for adaptive 
licensing of drugs. Unfortunately, these programs are frequently unavailable.39
The responsibility to conduct trials properly lies with pharmaceutical companies and 
regulatory authorities. However, physicians can also contribute in clinical practice, for 
example by collecting data prospectively in well-designed registries. Especially when
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drugs are very expensive, as is the case in HCV. There are some good examples such as 
the DREAM-registry (Dutch REumatoid Arthritis Monitoring) and the HIV-Monitoring 
database. It is paramount to develop an HCV-registry in the Netherlands. The data can 
be used to assess outcomes of treatment, behavior of physicians, but also long term 
effects of drugs. In addition, data from a registry could be used for the concept ‘pay-for-
performance’, an arrangement where the payer gets reimbursed by the pharmaceutical 
company if the drug was not effective. Also data from registries can be combined with 
other data sources (evidence synthesis) to estimate treatment effects, identify clinically 
relevant predictors etcetera, for example by using Bayesian statistics.40 Of note, data from 
a registry has the disadvantage of confounding by (contra)indication which emphasizes 
the importance of well-conducted (pragmatic) trials.41
In the case of HCV all of the above described options are possible to improve care. The 
ultimate goal is to eradicate HCV. To achieve this it is important that patients, including 
those who are unaware of the infection, are traced, treated and registered. Also, drugs 
should be cheaper and available worldwide. In the Netherlands we have the luxury to 
be able to prescribe drugs to all infected patients, in contrast to other countries where 
drugs are only reimbursed for patients with the highest need or not reimbursed at all.
Figure 1. Schematic visualization of population included in clinical trials and clinical practice
This figure shows which part of the population is included in various ways to collect data: 1 (phase 
1 trial), 2 (phase 2 trial), 3 (phase 3 trial), 4, (phase 4 data), CUP (Compassionate Use Program), 
pragmatic trial, and a registry. The size represents the size of the trial or database. Light grey 
represents trials before registration and dark grey after registration; it is clear that not the whole 
disease spectrum is included in phase 1-2-3 research.
Registry
Mild disease
Moderate disease
Severe disease
Healthy volunteers
2
3 4
1
Pragmatic trialCUP
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General conclusions
Generalization of data from registration trials to the clinical practice was limited for first-
generation DAAs. Exclusion criteria related to predictors affected outcomes significantly 
and should be properly justified in future trials. Fortunately, trial patients do resemble 
real world patients more and more, especially when trials include subgroups of patients 
with severe disease (decompensated cirrhosis). A registry with real world data is 
paramount to assess (longterm) outcomes of HCV therapy. Further, data from both trials 
and registries can be combined by network meta-analysis for translation to practice 
and guidelines when comparative effectiveness data is lacking. However, conducting 
a pragmatic trial is a better option, in this way the quality of evidence improves which 
aids guideline developers in recommending therapy to physicians.
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Summary
Hepatitis C 
Patients with a chronic hepatitis C virus (HCV) infection have contracted the hepatitis 
C virus and failed to spontaneously eradicate the virus. This RNA-virus can only be 
transmitted through blood-blood contact. Worldwide, there are about 130-150 million 
patients infected. There are seven different HCV genotypes identified, of which genotype 
1 and 3 are most prevalent. Majority of HCV patients do not develop symptoms at 
infection, and only 20-25% of patients can clear the virus spontaneously. In case the 
virus is not cleared after 6 months, patients are classified as chronically infected. In 
this stage the liver is infected for months or years which can lead to scarring of the 
liver (fibrosis) and eventually cirrhosis (end-stage fibrosis). Progression to fibrosis and 
cirrhosis should be prevented as it can lead to development of hepatic decompensation 
and/or hepatocellular carcinoma.
Treatment of hepatitis C
Treatment has the goal to eradicate HCV. The surrogate marker for eradication is a 
sustained virological response (SVR), defined as HCV-RNA negativity 3-6 months 
after cessation of treatment. Until 2012 the treatment consisted of a combination of 
pegylated interferon (pegIFN) and ribavirin (RBV), but cure rates were disappointing (45-
80%) and toxicity was high. Since 2012, the first direct-acting antivirals (DAAs) became 
available on the market in 3 classes: NS3/4A protease inhibitors, NS5A inhibitors and 
NS5B polymerase inhibitors. These new agents are combined and achieve high SVR 
rates (>90%) for patients with an HCV genotype 1, 2, or 4 infection. However, it is still a 
challenge to cure patients with HCV genotype 3.
Approval and registration of new drugs
In general, many trials have to be conducted to get approval of regulatory authorities 
for a drug. These trials are divided in three phases: phase 1, phase 2 and phase 3 trials. 
The latter are conducted to register the drug and are also called registration trials. 
These trials should be generalizable to clinical practice and should include a relevant 
comparator drug to apply the results to clinical practice. Both issues were not optimal 
in registration trials with DAAs for HCV. 
This thesis focuses on the translation of HCV registration trials to clinical practice in two 
steps: 1) the generalization of trials conducted in patients with chronic hepatitis C and 
2) the interpretation of evidence in clinical practice.
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Generalizability of trials to clinical practice
In chapter 2 we set up a nationwide retrospective registry of 467 Dutch HCV genotype 
1 patients who were treated with telaprevir or boceprevir combined with pegIFN and 
RBV. We demonstrated that 47% of patients who were treated in clinical practice 
would have been excluded from registration trials with these first-generation DAAs. 
These patients had significantly more serious adverse events (SAEs) than patients 
who would have been included in the trials (27% vs. 11%, p<0.001). Effectiveness was 
reduced in case very strict eligibility criteria were applied. The real world patients 
who were eligible for the trials had comparable results as obtained from registration 
trials, indicating that results of trials are only generalizable to patients who fulfill 
the eligibility criteria. In our study we identified the eligibility criteria which affected 
effectiveness and safety, i.e. signs or history of hepatic decompensation (including low 
platelet count, low serum albumin and high bilirubin) and co-morbidity such as cardiac 
disease, malignancy, anemia and neutropenia. These criteria were similar to important 
predictors of response in a large real world cohort treated with new generation DAAs: 
history of (decompensated) cirrhosis, platelet count, total bilirubin, serum albumin, 
and hemoglobin. This suggests that the results of our study remain relevant in the 
new generation DAA era. Unfortunately, exclusion criteria are often not fully available in 
published papers. Even the global trial register (ClinicalTrials.gov) does not report full 
eligibility criteria. In our experience, mainly criteria on co-morbidity, co-medication and 
laboratory values are lacking. This hampers careful judgment of generalization of trials. 
Patients underrepresented in trials, but who receive treatment in clinical practice, can 
be exposed to suboptimal effectiveness or unforeseen harm.
In chapter 3 and chapter 4 we focused on two specific adverse events (infections 
and bleeding episodes) occurring in the cohort treated with first-generation protease 
inhibitors. These adverse events were already topic of research with pegIFN and RBV 
therapy, because bonemarrow suppression caused by pegIFN would increase the 
risk to develop infections and bleeding episodes. In chapter 3 we found that 31% of 
467 treated patients developed a clinically relevant infection during therapy and 7% 
was severe. The rates resemble infection rates found with dual therapy (pegIFN and 
RBV), but were higher than reported in the registration trials. We identified female 
sex, diabetes mellitus and chronic obstructive pulmonary syndrome as predictors for 
infection. Neutropenia was not associated with development of infections, indicating 
that advised dose reductions of pegIFN for neutropenia might be too strict, which can 
lead to reduced effectiveness. It is important to monitor the patients with risk factors 
carefully, rather than reduce the dose of pegIFN. In chapter 4 we showed that 22% of 
patients treated with first-generation protease inhibitors developed a bleeding episode, 
but majority (>80%) of bleedings were mild and needed no intervention. We found ten 
severe bleedings: hematemesis (3), severe epistaxis (3), hemorrhagic cerebrovascular 
accident (2), rectal blood loss and a subdural hematoma. 
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The incidence of bleeding episodes in our cohort was higher than reported in other dual 
therapy cohorts, possibly induced by the protease inhibitor. Predictors for bleedings in 
our cohort were similar to risk factors with dual therapy: severe thrombocytopenia (<50 
x109/L), female sex and cirrhosis. Still, as the majority of bleeding episodes were mild, 
the problem is often not clinically relevant.
The HCV therapies developed rapidly over time. In the past years several trials studied 
DAA regimens and current regimens are interferon-free. PegIFN had specific contra-
indications and severe side effects which could limit inclusion of patients in trials, 
therefore we expected that eligibility criteria became less strict over time. In chapter 5 
we stated that the patients in registration trials resemble real world patients more and 
more over time. We studied this by calculating the proportion of patients from a clinical 
practice HCV cohort (n=177) who would be eligible for the registration trials (eligibility 
rate) of new DAA regimens. We found a linear association with start date of trials: the 
eligibility rate increased from on average 75% in 2008 to 89% in 2014. This probably 
resulted in an increased generalizability, which is supported by the comparable 
effectiveness and safety results from current large real world cohorts. 
One might think that all problems with DAAs are resolved now, however in chapter 2 
we found that concomitant medication was the most important reason for exclusion 
from trials. The rational here is that DAAs inhibit/induce and can be substrates of drug-
metabolizing enzymes and drug transporters. In chapter 6 we predicted the risk on 
drug-drug interactions (DDIs) of concomitant medication and DAAs based on the 
Liverpool database (www.hep-druginteractions.org). We found that 77% of patients 
used concomitant medication and that 60% of all patients were at risk for a relevant 
DDI with one of the DAA regimens. DDIs are clinically important because they can lead 
to decreased effectiveness or increased toxicity of both the DAA and the concomitant 
drug. Antidepressants, protonpump inhibitors and benzodiazepine derivates were most 
frequently used, but also carry the risk of a DDI with a DAA. The newest generation 
DAA regimens (grazoprevir/elbasvir and sofosbuvir/velpatasvir) had the lowest DDI-
potential while paritaprevir/ritonavir, ombitasvir and dasabuvir carried the highest risk. 
In total, 23% of concomitant medications (n=60) was not available in the database. 
We predicted that 11 of 60 drugs were at risk for potential DDIs when combined with 
DAAs. Our results are in line with other cohorts and encourage the involvement of a 
pharmacist when initiating HCV treatment. 
Interpretation of evidence in clinical practice
Eventually all data obtained in phase 1, 2 and 3 trials are used for regulatory approval and 
for implementation in clinical practice. This stresses the importance of generalizability 
of trials. While the generalizability of DAA trials seemed to improve over time, the full 
interpretation of data is not optimal yet. One of the issues is comparative effectiveness. 
Only few head-to-head comparisons of DAAs were executed and the comparative 
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arm(s) usually lacked standard of care. Yet, there are some ways to interpret the data, 
for example by performing a network meta-analysis. A network meta-analysis is able to 
compare more than 2 treatments by combining direct and indirect evidence. Bayesian 
statistics can be used to estimate the treatment effect of each therapy. In chapter 7 
we identified that sofosbuvir/velpatasvir was the best DAA regimen for HCV genotype 
3 patients with this method. We chose genotype 3 as efficacy of DAAs was suboptimal. 
Further, we found that ribavirin significantly increased SVR rates in all patients (odds 
ratio 2.6-4.5). These findings can aid guideline developers to prioritize treatment and 
physicians in their choice of therapy.
The Dutch guideline published in 2013 was outdated in 2014, hence an update was 
needed. Chapter 8 is the first version of a Dutch guidance, developed after the approval 
of sofosbuvir. The speed of DAA development forced us to write a guidance instead of 
a formal guideline. We systematically reviewed all available evidence of sofosbuvir and 
formulated recommendations based on the GRADE method. After the publication, five 
Dutch associations collaborated for the future versions of the guidance: Netherlands 
Association of Internal Medicine (NIV), Dutch Association of HIV-treating physicians 
(NVHB), Netherlands Association of Hepato-gastroenterologists (NVMDL), Netherlands 
Association of Hepatology (NVH) and the Netherlands Association of Hospital 
Pharmacists (NVZA). The aim was to provide practical therapeutic guidance to physicians 
and to achieve high quality treatment in the Netherlands (www.hcvrichtsnoer.nl). We 
summarized recommendations from international guidelines and applied this to the 
Dutch situation. We updated the website regularly after important new data or DAA 
approval.
Conclusions and future directions
We have shown that strict eligibility criteria of HCV registration trials limited 
generalization of results, which led to unforeseen harm in clinical practice patients. 
We have identified general principles for improving generalizability: 1) justifying all 
eligibility criteria is needed with special attention for exclusion criteria related to 
predictors of response, this should stretch the eligibility rate to >95% and improve 
generalizability; 2) the full set of eligibility criteria of each trial should be available to 
adequately assess the generalizability of the trial; 3) we identified subgroups which 
should be studied prior to registration of a DAA to prevent unexpected harm in clinical 
practice (patients with hepatic decompensation and comorbidity such as anemia, 
malignancy and cardiac disease); and 4) we showed the need of involving a pharmacist 
in starting HCV treatment as the risk of DDIs is high and not appropriately mentioned 
in the publications of HCV trials. Fortunately, trial patients resemble clinical practice 
patients more and more. However, the introduction of pragmatic trials, trials with a 
relevant comparator, more accessible compassionate use programs and inclusion of 
patients with the highest need for therapy in an early phase of drug development could 
improve generalizability in the HCV field. In addition, a registry of treated HCV patients is
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necessary to assess outcomes and long term effects of drugs. Data of above mentioned 
improvements can be synthesized to assess true treatment effects for clinical practice 
and can be used for guidelines. An example of this evidence synthesis is our network 
meta-analysis. Currently, our HCV guidance is still in use, however once the key 
developments have happened, it is time to write a formal guideline based on original 
data. 
10
Summary
183
Samenvatting
10
184
Samenvatting
Hepatitis C
Mensen met hepatitis C hebben een ontsteking van de lever die veroorzaakt wordt door 
het hepatitis C virus. Dit virus wordt verspreid door bloed-bloed contact, bijvoorbeeld 
via besmette bloedtransfusies of bloedproducten (vóór 1992) of via het delen van 
naalden bij drugsgebruik. Daarnaast komt de ziekte vaker voor bij hivpositieve 
mannen die seks hebben met mannen en bij mensen afkomstig uit landen waar 
hepatitis C frequent aanwezig is. Wereldwijd zijn ongeveer 130-150 miljoen mensen 
geïnfecteerd, in Nederland zijn er ongeveer 19.200 patiënten met hepatitis C. Er zijn 
zeven verschillende genetische samenstellingen van het virus bekend, dit noemen we 
genotypen. Genotype 1 en 3 komen het vaakst voor. Besmetting met het hepatitis C 
virus geeft in het algemeen weinig tot geen klachten, de ziekte is dus vaak ongemerkt 
aanwezig. Bij ongeveer een kwart van de mensen kan het eigen immuunsysteem het 
virus klaren, bij 75% van de mensen blijft het virus echter langer dan 6 maanden in 
het lichaam, waarna we het een chronische hepatitis C infectie noemen. Als de lever 
gedurende jaren ontstoken is kan er littekenweefsel (fibrose) en zelfs verschrompeling 
(cirrose) van de lever ontstaan. Dit moet voorkomen worden, omdat in dit stadium de 
functie van de lever achteruit kan gaan. In dat geval kunnen er complicaties optreden, 
zoals decompensatie ofwel ontregeling van de levercirrose met bloed braken, vocht 
vasthouden en ernstige verwardheid tot gevolg. Daarnaast kan ook een hepatocellulair 
carcinoom (leverkanker) ontstaan.
Behandeling van hepatitis C
Behandeling heeft het doel het hepatitis C virus permanent te verwijderen uit het 
lichaam. Hiervoor gebruiken we de maat SVR (Sustained Virological Response, ofwel 
blijvende virale respons). SVR is gedefinieerd als afwezigheid van het virus in het 
bloed, 3-6 maanden na het staken van de behandeling. Tot 2012 hadden we maar één 
type behandeling voor alle genotypen: peginterferon en ribavirine. Deze behandeling 
duurde lang (24-48 weken), had ernstige bijwerkingen en genezingspercentages waren 
matig (45-80%). In 2012 was er een doorbraak, de eerste direct-werkende antivirale 
middelen (DAAs, Direct Acting Antivirals) werden op de Nederlandse markt beschikbaar. 
Inmiddels zijn er in totaal 3 typen DAAs die direct op het virus aangrijpen: NS3/4A 
protease remmers, NS5A remmers en NS5B polymerase remmers. Deze middelen 
kunnen met elkaar gecombineerd worden en met de behandeling behalen we hoge 
genezingspercentages (>90%) voor patiënten met hepatitis C genotype 1, 2 en 4. 
Patiënten met genotype 3 blijken lastiger te genezen.
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Goedkeuring en registratie van nieuwe geneesmiddelen
Meerdere onderzoeken moeten uitgevoerd worden voordat goedkeuring van een 
geneesmiddel kan worden verkregen via autoriteiten als Food and Drug Administration 
(FDA) en European Medicines Agency (EMA). Deze onderzoeken zijn in 3 fasen te 
verdelen: fase 1, fase 2 en fase 3. De laatste fase wordt met name uitgevoerd voor 
registratie en toegang tot de markt en worden ook wel registratie studies of registratie 
trials genoemd. De resultaten van deze studies moeten generaliseerbaar zijn naar de 
klinische praktijk, zodat artsen goed kunnen inschatten wat de beste therapie voor de 
individuele patiënt is. De generaliseerbaarheid van de eerste studies met DAAs voor 
hepatitis C bleek matig te zijn. Daarnaast zouden de nieuwe geneesmiddelen in deze 
studies vergeleken moeten worden met een relevante andere therapie (bij voorkeur de 
standaard therapie) zodat artsen meteen weten welke behandeling het beste werkt.
Dit proefschrift heeft als doel de vertaling van hepatitis C registratiestudies naar de 
klinische praktijk te verbeteren. We hebben hiervoor twee stappen onderzocht: 1) de 
generaliseerbaarheid van studies bij patiënten met hepatitis C, en 2) de interpretatie 
van data in de klinische praktijk. 
Generaliseerbaarheid van studies naar de klinische prakrijk
Voor hoofdstuk 2 hebben we een landelijke database opgezet van 467 hepatitis 
C patiënten met genotype 1, die behandeld zijn met telaprevir of boceprevir 
gecombineerd met peginterferon en ribavirine. We hebben de gegevens middels 
statusonderzoek verzameld in 45 ziekenhuizen. Met dit onderzoek toonden we aan 
dat bijna de helft (47%) van de patiënten die in de Nederlandse praktijk behandeld 
zijn op basis van de in- en exclusiecriteria uitgesloten zouden worden van de 
registratiestudies met deze middelen. De uitgesloten patiënten hadden duidelijk meer 
ernstige bijwerkingen (leidend tot ziekenhuisopname, blijvende beperking of zelfs 
overlijden) dan de patiënten die wel voldeden aan alle criteria (27% vs. 11%, p<0.001). 
Als we de meest strikte in- en exclusiecriteria hanteerden was ook de effectiviteit 
van behandeling lager in de groep met uitgesloten patiënten. De patiënten die wel 
voldeden aan alle in- en exclusiecriteria van de registratiestudies hadden vergelijkbare 
resultaten met de studiepatiënten. Resultaten van registratiestudies blijken dus alleen 
generaliseerbaar naar patiënten die voldoen aan alle criteria. We hebben ook gekeken 
naar de exclusiecriteria die het meeste invloed hadden op effectiviteit en bijwerkingen. 
Dit bleken zowel een voorgeschiedenis van decompensatie van levercirrose (inclusief 
bijpassende bloedwaarden zoals trombocytopenie, laag albumine en hoog bilirubine) 
als bepaalde co-morbiditeit (zoals een hartziekte, maligniteit, anemie en neutropenie) 
te zijn. Deze criteria zijn vergelijkbaar met belangrijke voorspellers van effectiviteit in 
huidige grote klinische praktijk cohorten: voorgeschiedenis van (gedecompenseerde) 
levercirrose, trombocyten, bilirubine, albumine en hemoglobine. Dit suggereert dat 
de resultaten van onze studie ook relevant zijn in het huidige nieuwe-generatie-
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DAA tijdperk. Helaas is het zo dat de volledige set aan in- en exclusiecriteria vaak 
niet beschikbaar is in de gepubliceerde artikelen. Zelfs het wereldwijde trial register 
(ClinicalTrials.gov) geeft niet alle criteria weer. Met name criteria gerelateerd aan 
co-morbiditeit, co-medicatie en bloedwaarden ontbreken. Hierdoor is zorgvuldige 
beoordeling van generaliseerbaarheid van studies lastig. Patiënten die onvoldoende 
geïncludeerd worden in trials maar die wel in de klinische praktijk behandeld worden, 
hebben kans op suboptimale effectiviteit of onverwachte bijwerkingen.
In hoofdstuk 3 en hoofdstuk 4 hebben we twee specifieke bijwerkingen (infecties en 
bloedingen) onderzocht in het cohort van patiënten die behandeld zijn met telaprevir 
of boceprevir. Deze bijwerkingen zijn al eerder onderzocht bij de combinatietherapie 
met peginterferon en ribavirine omdat beenmergsuppressie door peginterferon het 
risico op deze bijwerkingen zou verhogen. In hoofdstuk 3 vonden we dat 31% van 
de 467 behandelde patiënten een klinisch relevante infectie ontwikkelde tijdens 
therapie en 7% van de infecties was ernstig. Deze resultaten kwamen overeen met 
de infectie percentages bij peginterferon en ribavirine therapie, maar waren hoger 
dan de infectie percentages in de registratiestudies van telaprevir en boceprevir. We 
identificeerden de volgende risicofactoren voor infectie: vrouwelijk geslacht, diabetes 
mellitus en chronisch obstructief longlijden (COPD). Neutropenie was geen risicofactor 
voor infectie, dus geadviseerde dosisreducties van peginterferon zijn waarschijnlijk 
niet nodig en kunnen leiden tot verminderde effectiviteit. In hoofdstuk 4 vonden 
we dat 22% van de patiënten die behandeld zijn met telaprevir of boceprevir een 
bloeding ontwikkelden. Echter, het grootste deel (>80%) van de bloedingen was mild 
qua ernst en behoefde geen behandeling. We vonden 10 ernstige bloedingen: bloed 
braken (3), ernstige neusbloeding (3), bloedig cerebrovasculair accident (CVA, 2), 
rectaal bloedverlies en een subduraal hematoom. Het percentage patiënten met een 
bloeding was hoger dan in onderzoek met peginterferon en ribavirine, mogelijk wordt 
dit veroorzaakt door telaprevir of boceprevir. Risicofactoren voor een bloeding bleken: 
ernstige trombocytopenie (bloedplaatjes <50 x109/L), vrouwelijk geslacht en levercirrose. 
Echter, omdat de meerderheid van de bloedingen mild was, is dit probleem vaak niet 
klinisch relevant.
De ontwikkeling van de nieuwe generatie hepatitis C medicatie ging snel: in de 
afgelopen jaren zijn er veel studies naar nieuwe middelen gedaan en de huidige 
behandeling behoeft geen peginterferon meer. Peginterferon had specifieke contra-
indicaties en ernstige bijwerkingen, wat invloed gehad kan hebben op de inclusie van 
patiënten in trials. We verwachtten daarom dat de in- en exclusiecriteria van trials steeds 
minder streng zouden zijn geworden in de tijd. In hoofdstuk 5 concludeerden we dat 
patiënten in de registratiestudies steeds meer lijken op de patiënten uit de klinische 
praktijk. We onderzochten dit door te berekenen hoeveel patiënten uit een klinisch 
praktijk cohort (n=177) voldeden aan de in- en exclusiecriteria van registratiestudies 
van de nieuwe DAA regimes. We vonden een lineaire associatie met de startdatum 
van de studies: gemiddeld voldeed 75% van de patiënten in 2008 en 89% in 2014 
aan de in- en exclusiecriteria. Waarschijnlijk heeft dit geresulteerd in een betere 
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generaliseerbaarheid. Dit zien we ook in de vergelijkbare resultaten van huidige grote 
klinische praktijkcohorten en registratiestudies .
Ondanks dit goede nieuws zijn nog niet alle problemen rondom DAAs opgelost. In 
hoofdstuk 2 zagen we dat gebruik van co-medicatie de belangrijkste reden voor exclusie 
uit een registratiestudie was. De achterliggende gedachte is dat DAAs invloed kunnen 
hebben op geneesmiddeltransporters en enzymen, maar ook beïnvloed kunnen worden 
door co-medicatie. In hoofdstuk 6 hebben we het risico op geneesmiddel-geneesmiddel 
interacties tussen DAAs en co-medicatie onderzocht op basis van de Liverpool database 
(www.hep-druginteractions.org). We zagen dat 77% van de patiënten co-medicatie 
gebruikte en dat 60% van de patiënten risico had op een relevante geneesmiddel-
geneesmiddel interactie met één van de DAA combinaties. Deze interacties zijn van 
belang in de klinische praktijk omdat ze kunnen leiden tot verminderde effectiviteit 
of meer bijwerkingen van zowel de DAA als de co-medicatie. Antidepressiva, 
protonpompremmers en benzodiazepine derivaten werden het meest gebruikt, maar 
hebben ook het risico op een interactie met DAAs. De nieuwste generatie DAA regimes 
(grazoprevir/elbasvir and sofosbuvir/velpatasvir) bleken het laagste risico op interacties 
te hebben, terwijl de combinatie paritaprevir/ritonavir, ombitasvir en dasabuvir het 
hoogste risico gaf. Opvallend was dat 23% van de gebruikte co-medicatie (n=60) niet 
in de database beschikbaar was. Wij voorspelden dat 11 van de 60 medicijnen wel in 
staat waren een interactie te hebben met een DAA. Onze resultaten kwamen overeen 
met andere onderzoeken en moedigen aan tot het consulteren van een apotheker bij 
het starten van hepatitis C therapie.
Interpretatie van data in de klinische praktijk
Uiteindelijk worden alle data, verkregen in fase 1, 2 en 3 onderzoek, zowel gebruikt om 
goedkeuring van de autoriteiten te krijgen als voor implementatie van de therapie in de 
klinische praktijk. Dit benadrukt het belang van generaliseerbaarheid van trials. Terwijl de 
generaliseerbaarheid in de loop van de tijd leek te verbeteren, was volledige interpretatie 
van data nog niet optimaal. Als arts wil je graag weten of het ene geneesmiddel beter 
is dan het andere geneesmiddel. Echter, er zijn slechts enkele studies geweest die 
verschillende DAA regimes direct met elkaar vergeleken en in die gevallen was de 
vergelijkende arm vaak niet de standaardbehandeling. Toch zijn er manieren om deze 
data te interpreteren, bijvoorbeeld door het uitvoeren van een netwerk meta-analyse. 
Een netwerk meta-analyse kan meer dan 2 regimes met elkaar vergelijken door directe 
en indirecte data met elkaar te combineren. Bayesiaanse statistiek kan dan ingezet 
worden om de effectiviteit van de behandelingen afzonderlijk te schatten. In hoofdstuk 
7 vonden wij middels deze methode dat sofosbuvir/velpatasvir het beste DAA regime 
is voor patiënten met hepatitis C genotype 3. We hebben voor hepatitis C genotype 3 
gekozen omdat dit genotype het lastigst te genezen is. Daarnaast vonden we dat de 
toevoeging van ribavirine de effectiviteit significant verbeterde bij alle patiënten (odds 
ratio 2.6-4.5). Deze bevindingen kunnen makers van richtlijnen helpen om regimes te 
prioriteren en tevens kunnen ze de arts helpen een keuze voor therapie te maken.
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Aangezien de Nederlandse richtlijn, gepubliceerd in 2013, al achterhaald was in 2014, 
was een update nodig. Hoofdstuk 8 is de eerste versie van een Nederlands richtsnoer 
voor de behandeling van hepatitis C, ontwikkeld na de goedkeuring van sofosbuvir. De 
snelheid van ontwikkelingen in het hepatitis C veld zorgde ervoor dat het niet haalbaar 
was een volledige richtlijn te schrijven. We voerden een systematisch review uit om alle 
beschikbare data te achterhalen en formuleerden aanbevelingen op basis van de GRADE 
methode. Na publicatie ontstond er een samenwerking tussen vijf beroepsverenigingen 
voor toekomstige versies van het richtsnoer: Nederlandse Internisten Vereniging (NIV), 
Nederlandse Vereniging van HIV Behandelaren (NVHB), Nederlandse Vereniging van 
Maag-Darm-Leverartsen (NVMDL), Nederlandse Vereniging voor Hepatologie (NVH) en 
Nederlandse Vereniging van Ziekenhuis Apothekers (NVZA). Het doel van dit richtsnoer 
is tweeledig: het bieden van een praktische leidraad aan artsen en het bevorderen 
van uniforme en hoge kwaliteit behandeling in Nederland (www.hcvrichtsnoer.nl). We 
bestudeerden aanbevelingen in internationale richtlijnen en pasten deze toe op de 
Nederlandse situatie. Na belangrijke nieuwe data of goedkeuring van een DAA hebben 
we de aanbevelingen aangepast.
Conclusies en toekomstperspectief
Ons onderzoek heeft aangetoond dat strenge in- en exclusiecriteria van hepatitis C 
registratiestudies leidden tot beperkte generaliseerbaarheid van de resultaten. Hierdoor 
zagen we onverwacht veel ernstige bijwerkingen bij patiënten in de klinische praktijk. 
We hebben een aantal algemene principes geïdentificeerd om generaliseerbaarheid 
te verbeteren: 1) alle in- en exclusiecriteria moeten zorgvuldig verantwoord worden, 
met aandacht voor criteria die gerelateerd zijn aan voorspellers voor effectiviteit of 
bijwerkingen; 2) de volledige set aan in- en exclusiecriteria van elke trial zou beschikbaar 
moeten zijn om adequaat de generaliseerbaarheid van een trial te onderzoeken; 3) 
we hebben subgroepen geïdentificeerd die bestudeerd zouden moeten worden 
voordat een DAA goedgekeurd wordt, om zo schade in de klinische praktijk te 
voorkomen (patiënten met gedecompenseerde levercirrose en co-morbiditeit zoals 
bloedarmoede, maligniteiten of hartziekten); en 4) we toonden aan dat het betrekken 
van een apotheker van belang is bij het opstarten van therapie, omdat het risico op 
geneesmiddel-geneesmiddel interacties hoog is en de gepubliceerde artikelen hier 
onvoldoende aandacht aan schenken.
Gelukkig lijken de trial patiënten steeds meer op de patiënten uit de klinische praktijk. 
Echter, de introductie van pragmatische trials, studies met een relevante vergelijkende 
arm, meer toegankelijke ‘compassionate use’ programma’s en inclusie van patiënten 
die de therapie het hardst nodig hebben in een vroege fase van medicatie ontwikkeling, 
zouden de generaliseerbaarheid van hepatitis C studies kunnen verbeteren. Verder 
is een goed patiëntregister van de behandelde patiënten in Nederland nodig om 
uitkomsten en lange termijn effecten van de medicatie te onderzoeken. Al deze data 
kunnen gebruikt worden om het werkelijke effect van medicatie in te schatten voor 
de klinische praktijk en voor richtlijnen. Een voorbeeld hiervan is onze netwerk meta-
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analyse. Op dit moment wordt het richtsnoer nog voortdurend aangepast. Zodra de 
belangrijkste ontwikkelingen achter de rug zijn is het echter tijd voor een Nederlandse 
richtlijn, gebaseerd op originele data van de studies.
&
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DankwoorD
Lange tijd heb ik gedacht dat het mij nooit zou lukken om te promoveren. Nu ik dit 
dankwoord mag schrijven is het toch zover: ik mag mijn proefschrift gaan verdedigen. 
Natuurlijk heb ik dit proefschrift niet alleen geschreven. Juist samenwerking en samen 
discussiëren maakt onderzoek beter en vooral ook leuker. Graag wil ik iedereen bedanken 
die hieraan bijgedragen heeft, zowel in wetenschappelijke als persoonlijke zin. 
Prof. dr. J.P.H. Drenth, beste Joost, veel dank voor jouw begeleiding in de afgelopen jaren. Ik 
weet nog hoe ik begon als trial-arts en langzaam de wereld van de farmaceutisch gedreven 
onderzoeken leerde kennen. Dank voor het vertrouwen wat ik toen van je gekregen heb om 
dit traject voort te zetten in een promotie traject. Na een lange tijd van dataverzameling 
kon het schrijven beginnen. Dank voor je geduld en de supersnelle feedback. De ‘Floor 7’ 
zal ik niet meer vergeten. Daarnaast mocht ik van jou solliciteren voor de Radboud Da Vinci 
Challenge, dit heeft me een boost en veel vertrouwen gegeven. Ik vond onze samenwerking 
erg plezierig en kijk uit naar de volgende fase, de opleiding tot MDL-arts.
Dr. W. Kievit, beste Wietske, zonder jou was dit proefschrift nooit klaar gekomen vrees ik, 
veel dank voor je hulp. Ik heb genoten van onze wekelijkse gesprekken waarin ik alle vragen 
aan je kon stellen. We hebben interessante wetenschappelijke discussies gehad, maar ook 
persoonlijke gesprekken, o.a. in het kader van de Da Vinci Challenge. Jouw invloed is in 
het hele proefschrift zichtbaar, je altijd kritische blik en vermogen om snel te schakelen is 
indrukwekkend. Jouw ideeën en enthousiasme over onderzoek werken aanstekelijk. Ik had 
me geen betere copromotor en begeleider kunnen wensen. Ik hoop dat we nog regelmatig 
kleine restaurantjes in Nijmegen blijven uitproberen.
Leden van de manuscriptcommissie, prof. dr. R. van Crevel, prof. dr. G.A.P.J.M. Rongen 
en prof. dr. H.J. Metselaar. Dank dat jullie de tijd hebben genomen om dit proefschrift 
te bestuderen. Leden van de corona, dank dat jullie vandaag tijd vrij maken voor mijn 
verdediging. Beste em. prof. Stuyt, beste Paul, speciaal dat jij vandaag de plaatsvervangend 
rector bent, dank daarvoor.
Artsen, verpleegkundigen en patiënten van de hepatitis behandelcentra, hartelijk dank 
voor de fijne samenwerking. Samenwerking is essentieel voor goed onderzoek. Mijn dank 
gaat ook uit naar alle co-auteurs en studenten die een bijdrage hebben geleverd aan dit 
proefschrift. Ik heb veel geleerd van jullie feedback en hulp bij moeilijke statististiek.
Leden van de richtsnoercommissie, dank voor de prettige samenwerking in de afgelopen 
jaren. Jullie kritische houding en vertrouwen heeft geleid tot een mooi en zinvol Nederlands 
richtsnoer. In het bijzonder dank ik graag dr. J.E. Arends en drs. M. van Tilborg, beste Joop 
en Marjolein, we waren een goed team samen! 
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MDL onderzoekersgroep, bedankt voor de fijne tijd. Wat een leuke groep mensen en 
toekomstige MDL collega’s zijn jullie! Kritisch, gezellig en altijd in voor een borrel. Ik ben 
trots op de ontwikkelingen die we als groep hebben doorgemaakt en op het ontwikkelplan 
wat we voor onszelf hebben opgezet. De groep collega’s en oud-collega’s is te groot om 
iedereen persoonlijk te bedanken, een aantal collega’s wil ik speciaal noemen. Hedwig, 
bijna onze hele onderzoeksperiode hebben we samen gedeeld. Mooi om te zien hoe 
enthousiast, snel en hard jij kunt werken, én dit kunt combineren met je drukke sociale 
leven. Ik hoop dat we elkaar in Den Bosch ook vaak buiten het werk blijven zien. Myrte, 
behalve dat we een kritische onderzoeksblik delen en vaak vergelijkbare feedback geven, 
delen we ook de hobby beachvolleybal. Ik heb genoten van onze trainingen samen en de 
tijd dat we elkaar buiten het werk zagen. Jammer dat we niet in hetzelfde ziekenhuis onze 
vooropleiding doen, maar hopelijk zien we elkaar in de tussentijd nog vaak op het zand of 
gewoon voor een drankje. Angelique, ondanks dat je er een tijdje uit bent geweest voor je 
opleiding voelt het alsof we continu hebben samengewerkt. Heerlijk hoe goed jij dingen 
kunt relativeren! Hopelijk kunnen we over een tijdje nogmaals samenwerken. Karina, jouw 
open blik en oprechte waardering zijn mooi om te zien, dank voor je positieve feedback 
als ik weer even in een dipje zat. Lauranne, dank voor alle voorbeelden en tips die je me 
gegeven hebt. Isabelle, veel tijd hebben we samen op een kamer doorgebracht. Knap hoe 
jij jouw promotie vormgeeft, dank voor je gezelligheid. Natuurlijk dank ik graag alle andere 
onderzoekers voor de fijne tijd samen: Titus, Marten, Jos, Mark, Mark, Simon, Loes, Yannick, 
Anna, Xavier, Dorian, René, Bram, Liyanne, Lisa, Vera, Kelly, Judith, Edgar, Evelyn, Govert, 
Yasmijn, Tom, Wybrich, en Mieke.
Elise, onze verschillende karakters qua onderzoek maakten ons een goed team! We hebben 
echt een leuke tijd samen gehad, zowel op de apotheek, als bij de MDL, als op congressen. 
Ondanks dat je in Zwolle zit hoop ik dat we elkaar nog blijven zien. Zet ‘m op met de 
laatste loodjes van jouw proefschrift!
Beste mede-‘Radboud Da Vinci Challengers’, Ellen en Talenboard, dank voor de reis die we 
samen hebben mogen afleggen. Wat was dit speciaal en één van de hoogtepunten van 
mijn promotietijd. Ik heb ervaringen voor het leven opgedaan en hoop dat de wijnavondjes 
erin blijven. Ik ben voor!
Beste MDL-artsen, AIOS, verpleegkundigen, research unit, MDL lab, secretaresses, dietisten 
en Ricky, bedankt voor de fijne tijd! Ik heb veel van jullie geleerd en vond het niet erg dat 
de (nieuwe) koffiemachine een minuutje over een grote koffie deed, mooi momentje om 
even te kletsen. Tot over een paar jaar! 
Beste Jessica, dank voor de inspiraties die je me de afgelopen jaren geboden hebt. Door 
jou is mijn blik breder gericht en heb ik veel geleerd wat niet geheel in woorden te vatten 
is. Jouw uitnodiging om bij het Hotspots team te komen overviel me even, maar heeft me 
veel gebracht. Ik wil dan ook alle leden van het hotspotsteam en aanvragers van hotspots 
danken voor de inspirerende ideeën. Jessica, de term miss Radboud misstaat je niet. 
Jammer dat je onze afdeling hebt verlaten, maar veel succes en plezier op je nieuwe plek.
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Judith en Jody, 5 dagen per week van Eindhoven naar Nijmegen rijden is niks aan in je 
eentje. Dank voor jullie gezelschap en leuke gesprekken in de auto.
Een goede werk-privé balans is mijns inziens essentieel voor goed functioneren op de 
werkvloer. Ik wil graag alle vrienden en vriendinnen bedanken voor de leuke dingen die we 
gedaan hebben de afgelopen jaren. Het was een goede afleiding tijdens het onderzoek.
Lieve Yvonne, Maud, Evelien, Laura, Susan, Fien, Eef, Janine, Liesbeth en Karlijn, ik waardeer 
onze weekendjes en uitjes enorm. We kennen elkaar al zo lang, het is fijn om mezelf te 
kunnen zijn bij jullie. Lieve Maud, jou wil ik speciaal bedanken dat je mijn paranimf wilt 
zijn. Je hebt de speciale gave dat iedereen zich fijn voelt bij jou, ik ben blij dat je aan mijn 
zijde staat vandaag.
Lieve Romy, Stephie, Manon en Maartje, we kennen elkaar al sinds de studie en zijn ieder 
onze eigen weg ingeslagen. Romy en Manon, ik ben blij dat ik eindelijk jullie voorbeeld 
mag volgen, dank voor jullie support op de momenten dat ik dacht dat het niet ging 
lukken. Lieve Romy, ik ben vereerd dat je mijn paranimf wilt zijn, je bent altijd enorm 
geïnteresseerd ondanks dat je het zelf zo druk hebt. Ik heb veel aan je tips en steun gehad 
de afgelopen jaren.
Lieve volleybalmaatjes, speciaal Maud, Jannie, Inge, Petri, Hanneke en Juliette, graag 
wil ik jullie bedanken voor de leuke tijd bij de leukste sporten die er zijn, volleybal en 
beachvolleybal.  Volleybal is voor mij een soort parallel voor werk geweest, alles wat ik 
heb geleerd qua teamwork, ambitie en gedrevenheid kon ik tijdens mijn promotietraject 
toepassen. Maar tijdens het (beach)volleybal kon ik ook alles even vergeten en vooral veel 
plezier hebben met jullie! Merci!
Lieve pap, mam, Kris, Britt en Jans, bedankt voor de interesse en steun de afgelopen jaren. 
Ondanks dat het af en toe lastig was uit te leggen waar mijn onderzoek over ging of ‘hoe 
de dingen er aan toe gaan’ bleven jullie geïnteresseerd. Ik vind het ook heel speciaal dat 
de afronding van dit proefschrift een familieproject is geworden. Jans, jouw gevoel voor 
taal is bijzonder, daar moet je iets mee doen, dank voor je feedback op de samenvatting; 
Britt, veel dank voor het mooie design van het proefschrift en je hulp om InDesign te leren 
kennen, en Kris bedankt dat je de cover hebt ontworpen op basis van de schilderijen van 
mam. Ik ben er heel blij mee! En pap en mam, fijn dat jullie altijd klaar staan om mee te 
denken!
En tot slot, lieve Tom, meer nog dan iedereen heb je alle ups-en-downs van mijn promotietijd 
en, bijna analoog, van mijn humeur gezien. Ik heb veel respect voor het geduld dat je met 
me hebt gehad als ik weer eens ging werken in de weekenden of avonden. Zelfs op onze 
reis had je al het geduld van de wereld als ik een dagje ging werken. Tijdens onze reis 
hebben we ontdekt dat we elkaar echt aanvullen en dat we op één lijn zitten qua dingen 
waar we van genieten. Natuur en avontuur is ons ding, en relaxen is niet onze sterkste kant. 
Ik kijk er naar uit om samen nieuwe avonturen aan te gaan!
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CurriCulum vitae
Floor Berden werd geboren op 16 januari 1986 te 
Horst-America (Limburg). In 2004 behaalde zij haar 
VWO-diploma aan het Dendron College te Horst. 
Aansluitend startte zij met de studie geneeskunde 
aan de Radboud Universiteit Nijmegen. Tijdens 
de studie ging Floor tweemaal naar Afrika voor de 
wetenschappelijke stage te Ghana (2008) en het 
senior coschap te Tanzania (2010). Zij behaalde 
in 2011 haar artsexamen. Daarna startte zij als 
ANIOS (arts niet in opleiding tot specialist) Interne 
Geneeskunde in het Canisius Wilhelmina Ziekenhuis 
te Nijmegen. 
Eind 2012 startte Floor als trial-arts op de afdeling Maag-, Darm-, en Leverziekten 
van het Radboud universitair medisch centrum. Zij voerde meerdere farmaceutisch 
gedreven fase 2 en fase 3 trials uit met nieuwe geneesmiddelen voor hepatitis C, 
primaire biliaire cholangitis, primaire scleroserende cholangitis en inflammatoire 
darmziekten. Daarnaast behandelde Floor patiënten met hepatitis C op de polikliniek. 
Floor had de ambitie te promoveren en maakte met prof. dr. Drenth en dr. Kievit 
een onderzoeksplan, gebaseerd op de ervaringen met de farmaceutische trials en 
polikliniek. De resultaten hiervan staan beschreven in dit proefschrift. Naast het 
onderzoek zette Floor zich in voor het ontwikkelplan op de afdeling Maag-, Darm-, 
en Leverziekten ter bevordering van persoonlijke en professionele ontwikkeling van 
de arts-onderzoekers. Daarnaast werd zij geselecteerd voor de Radboud Da Vinci 
Challenge en was zij lid van het Radboudumc Hotspots team. Sinds mei 2017 is Floor 
in opleiding tot Maag-, Darm-, en Leverarts (opleider. mw. dr. M. van Kouwen). Zij is 
per 1 mei 2017 gestart met de vooropleiding Interne Geneeskunde in het Jeroen 
Bosch Ziekenhuis te ’s Hertogenbosch (opleider mw. dr. W. Smit). 
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riHS pHD portfolio
Name PhD candidate: Floor A.C. Berden
Department: Gastroenterology and Hepatology
Graduate School: Radboud Institute for Health 
Sciences
PhD period: 01-11-2013 – 31-12-2016
Promotor: Prof. dr. J.P.H. Drenth
Copromotor: Dr. W. Kievit
Year(s) ECTS
TRAINING ACTIVITIES
a) Courses & Workshops
- Introduction day Radboudumc
- BROK course
- Ultrasonography of the liver course
- Fibroscan course
- Young Investigators Meeting, United European  
Gastroenterology
- Biometrics Course
- Scientific Integrity Course
- Summerschool, United European Gastroenterology
2013
2013
2013
2013
2014
2014
2015
2016
0.5
1.75
0.4
0.2
1.75
3.75
1.0
1.75
b) Seminars & lectures
- IGMD PhD retreat: poster presentation
- PhD retreat department of gastroenterology and  
hepatology
2013
2015, 2016
0.75
1.5
c) Symposia & congresses
- Nederlandse Vereniging voor Gastroenterology 
(NVGE) congress: attendence and one oral presenta-
tion
- European Association for the Study of the Liver 
(EASL) congress:  attendence
- United European Gastroenterology Week: attendance 
and 3 poster presentations
- Dr. Falk symposium: attendence
- National Hepatitis Day: attendence
- National Hepatitis Symposium: attendance and oral 
presentation (debate)
2013, 2016
2013, 
2014, 2015
2015, 2016
2013
2014, 2016
2014
0.75
3.0
3.0
0.5
0.25
0.5
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d) Other
- Weekly journal club and research meeting of  
department
- Two-monthly regional education gastroenterology 
and hepatology
- Radboud Da Vinci Challenge
- Development plan PhD-students Gastroenterology 
and Hepatology: development and maintenance; 
focus on feedback training, peer-to-peer consultation 
(intervisie) and writing-weekend 
- Member of hepatitis C  guidance committee 
- Member of Radboud Hotspots team
2013-2016
2013-2016
2016
2014-2016
2015-2016
2014-2016
12.0
2.0
4.25
5.0
1.0
1.0
TEACHING ACTIVITIES
e) Lecturing
- Multidisciplinary Symposium for hemophilia
- Viral Hepatitis Prevention Board Meeting
- Nursing congress, presentation hepatic diseases and 
workshop non-alcoholic fatty liver disease
- Diner Pensant, regional education Utrecht
- National hepatitis day for patients
- Presentation in Gelderse Vallei, Ede
- Presentation at RAMS summerschool Radboud  
University
- Education for pharmacologists
2013
2013
2014
2014
2014
2015
2015
2016
0.1
0.1
0.2
0.1
0.1
0.1
0.1
0.1
f) Supervision of internships / other
- Supervision of two  medical students (3 months 
each)
- Supervision of two biomedical students (bachelor  
student 3 months and master student 6 months)
- Supervision of one medical student assistant (4 
months)
2014-2015
2015-2016
2016
2.0
3.0
1.0
TOTAL 53.5

